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Abstract and key words 
ABSTRACT 
The developments of immunoassay methods for the early stage diagnosis of 
tuberculosis (TB) are described. These went through two different routes, one 
through flow injection analysis (FIA), and the other using 
immunochromatography methodology. The design of a simple long-
wavelength fluorescence detector to serve the above purposes has also been 
described. 
The FIA immunoassay methods involve immobilising antibodies on to beads, 
either directly or through protein A based solid phases. The beads are then 
packed into a micro-column reactor for incorporation into the FIA system. In 
this case reactor-bound molecules are eluted from the system by a change of 
pH, thus limiting the available fluorophores to those that are reasonably 
fluorescent in acid solution. Sandwich (reagent excess) assays have been 
investigated. A couple of long wavelength (600-800) fluorophores have been 
studied. The bead injection option has also been investigated. 
The immunochromatographic method uses a lateral flow system and a 
sandwich (two-site) immunometric assay. Capture antibodies are immobilised 
on a coated membrane matrix at a pre-determined position and the antigen is 
analysed after binding to a fluorescence-labelled antibody. Both fluorescent 
latex preparations and conventional fluorescent labels have been used and 
compared. The strips are simply immersed in a small volume of sample to 
start the analysis. The chromatographic step is rapid and extremely simple. 
The fluorescence detector is fitted with a motor-driven sample holder to allow 
the length of the immunochromatographic strip to be scanned. The detector 
utilises a diode laser light source, optical filters in the emission beam and a 
miniaturised photomultiplier. It can be easily modified for the FIA, and can 
readily be adapted to operate from batteries, so is suitable for field use. 
Key words: Immunoassay, FIA, Fluorescence, Immunochromatography 
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Research aims and scope of work 
RESEARCH AIMS 
The objective of this investigation was to develop immunoassay methods for 
early stage diagnosis of tuberculosis and build a portable laser long 
wavelength fluorimeter to serve this purpose. The system should be capable 
for use by non trained personnel and field use. 
SCOPE OF WORK 
The work presented in this thesis reports the investigations that were carried 
out to achieve the above aims. Chapter 1 provides an overview of the subject 
areas that are pertinent to the investigation, while Chapter 2 describes the 
materials, instrumentation, and general procedures that have been adopted 
for use during the practical work. The development of the portable laser long 
wavelength fluorimeter is briefly described in this chapter. 
Chapter 3 deals with the investigation of immuno-sandwich assay in the 
format of beads injection. Chapter 4 describes the investigation of the 
immuno-sandwich assay in flow injection analysis with a micro reactor. 
Chapter 5 describes the preliminary experiment of the immunochro-
matography method using standard human albumin as the antigen, while 
Chapter 6 describes the immunochromatography assay development for the 
real analyte for diagnosis of tuberculosis. 
Finally, Chapter 7 provides a discussion on the practical work that has been 
carried out and the conclusions that can be derived. Ideas on further 
extensions of the work are presented and future directions are also discussed. 
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Chapter 1 - Introduction 
INTRODUCTION 
Immunoassay is one of the most widely used analytical techniques for the 
detection and quantification of bio molecules through an increasingly diverse 
range of devices. The last two decades have seen the development and 
refinement of many new immunoassay reagents and systems. The major 
trend has been away from liquid-phase assays involving radio isotopic labels, 
towards fast homogeneous or solid-phase assay that enables an 
immunoassay to be performed at the point-of-care and towards precise and 
reliable non isotopic, automated or semi-automated laboratory assay, often 
with detection limits measured in the range of pico to attomoles. 
Immunoassays are now used routinely for the recognition of small molecules, 
such as drugs, through peptides, to large macromolecules and whole cells. 
The analytical goals for all materials can be resolved down to the sensitivity 
and specificity of the assay, whilst the operational requirements increasingly 
focus on the speed of response and the mode of delivery. 
Immunoassay exploits the unique specificity of an antibody binding to an 
antigen in order to selectively recognise and determine analytes that are 
either antibodies or antigens. High selectivity can then be obtained, because 
other interfering compounds in the sample will not be recognised in an 
immunoassay. Ultimately, all developments in immunoassay stem from the 
report of the first immunoassay by Yalow and Berson in 1959 [1]. Their 
immunoassay was for insulin, employed a radiolabelled form of the hormone, 
and was able to detect 10 - 40 pg of insulin. Such radioimmunoassays (RIA) 
were rapidly transformed into routine quantitative methods for many analytes 
and because they provided superior sensitivity, greater specificity and higher 
throughput than traditional methods of analysis, they gained rapid and 
widespread acceptance among clinical chemists. Challenges in immunoassay 
today include the design of assays with improved specificity and the detection 
of lower concentrations of analyte, whilst also providing the facility on the one 
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1 INTRODUCTION 
Immunoassay is one of the most widely used analytical techniques for the 
detection and quantification of bio molecules through an increasingly diverse 
range of devices. The last two decades have seen the development and 
refinement of many new immunoassay reagents and systems. The major 
trend has been away from liquid-phase assays involving radio isotopic labels, 
towards fast homogeneous or solid-phase assay that enables an 
immunoassay to be performed at the point-of-care and towards precise and 
reliable non isotopic, automated or semi-automated laboratory assay, often 
with detection limits measured in the range of pico to attomoles. 
Immunoassays are now used routinely for the recognition of small molecules, 
such as drugs, through peptides, to large macromolecules and whole cells. 
The analytical goals for all materials can be resolved down to the sensitivity 
and specificity of the assay, whilst the operational requirements increasingly 
focus on the speed of response and the mode of delivery. 
Immunoassay exploits the unique specificity of an antibody binding to an 
antigen in order to selectively recognise and determine analytes that are 
either antibodies or antigens. High selectivity can then be obtained, because 
other interfering compounds in the sample will not be recognised in an 
immunoassay. Ultimately, all developments in immunoassay stem from the 
report of the first immunoassay by Yalow and Berson in 1959 [1]. Their 
immunoassay was for insulin, employed a radiolabelled form of the hormone, 
and was able to detect 10 - 40 pg of insulin. Such radioimmunoassays (RIA) 
were rapidly transformed into routine quantitative methods for many analytes 
and because they provided superior sensitivity, greater specificity and higher 
throughput than traditional methods of analysis, they gained rapid and 
widespread acceptance among clinical chemists. Challenges in immunoassay 
today include the design of assays with improved specificity and the detection 
of lower concentrations of analyte, whilst also providing the facility on the one 
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hand to study large numbers of samples, and on the other to apply 
immunoassay at the point of care [2]. 
Five major trends [3] in the development of immunoassay technology since 
the 1960s are: 1) the move away from radioisotope labels to nonisotopic 
labels (e.g. luciferase, photoprotein, phosphor, electro-chemiluminescent 
labels); 2) the development of ultra sensitive immunoassays 
(chemiluminescent substrates for enzyme labels, immuno-peR); 3) 
automation of immunoassays; 4) simultaneous multianalyte immunoassays; 
and 5) assay simplification and development of immunoassays for point-of-
care testing (e.g. immunochromatography). 
1.1 Structure of immunoglobulins 
Immunoglobulins are glycoprotein molecules composed of four polypeptide 
chains linked covalently by disulphide bonds (Figure 1.1). The four 
polypeptides consist of two pairs of identical chains of relative molecular mass 
of about 25,000 and 50,000 and are designated as light and heavy chains 
respectively. The light (L) chains have about 220 amino acid residues, and the 
heavy (H) chains have about 450-600 amino acid residues. In addition to the 
inter chain disulphide bonds, each polypeptide contains a number of intra 
chain disulphide bonds which divide up the polypeptide chain into a series of 
domains. In addition, immunoglobulins possess an area known as the hinge 
region that allows for flexibility of the chains in relation to one another. 
Sequence analysis of Hand L chains and X-ray crystallography shows that 
each chain consists of homologous segments of about 110 amino acids that 
form independently folded domains, Hand L chains all contain a variable and 
a constant region, which are encoded by separate gene segments [4]. 
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Figure 1.1. Basic structure of an immunoglobulin (lgG) molecule 
Five major sub-classes (isotypes) of human immunoglobulin have been 
recognized. The differences between the classes lie in the heavy chains, 
which vary considerably in the amino acid sequence. The heavy chains of 
immunoglobulins are designated as y, 11, U, () or E and when two identical 
heavy chains are combined in an immunoglobulin, the molecule is designated 
as being either IgG, IgM, IgA, IgO or IgE respectively. The heavy chains can 
be further subdivided into several subtypes. There are four subtypes of IgG 
(Y1, Y2, Y3. Y4), two of IgA (U1, U2) and two of IgM (111, 112)' The light chains do not 
show such variation and only two main types are demonstrable, known as the 
kappa (K) and the lambda (A) chains (Table 1.1) [5]. 
1.1.1 The role of antibodies 
IgG comprises some 80% of the total immunoglobulin [6] in healthy human 
plasma and because it is relatively small it is capable of crossing membranes 
and diffusing into the extravascular body spaces. It can cross the placental 
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membrane, so maternal IgG provides the major immune defence during the 
first few weeks of life until the infant's own immune mechanism becomes 
effective. IgG molecules have a molecular weight of 150,000 daltons. 
IgM is a large molecule composed of five units, each one similar in structure 
to an IgG molecule (Figure 1.2). It contains an additional polypeptide, the J-
chain (relative molecular mass RMM about 15,000), which appears to be 
important in the secretion of the molecule from the cell. IgM has a molecular 
weight of about 900,000 daltons. IgM is an effective agglutinating and 
precipitating agent and, although optionally capable of binding ten antigen 
molecules, it is usually only pentavalent. It does not cross membranes easily 
and is largely restricted to the bloodstream. 
IgE is known as a cytophilic immunoglobulin because of its ability to bind to 
cells, which may account for its low concentration in body fluids. The 
molecular weight of IgE is 190,000 daltons. When IgE reacts with an antigen it 
causes degranulation of the mast cell to which it is bound, with the release of 
vasoactive amines such as histamine. This process may well be helpful in 
initiating an inflammatory response but in allergic individuals the reaction is 
excessive and leads to a hypersensitive or over reactive state. 
IgA is associated mainly with seromucous secretions such as saliva, tears, 
nasal fluids, etc., and is secreted as a dimer with both a J chain and a 
secretor piece (RMM 70,000), the latter (which is not present in plasma IgA) 
apparently to prevent damage to the molecule by proteolytic enzymes. Its 
major role appears to be the protection of mucous membranes and its 
presence in blood, mainly as the monomer, may be as a result of absorption 
of the degraded dimer. Monomeric IgA molecules have a molecular weight of 
150,000 daltons. 
IgD is difficult to investigate because of the low concentration of this protein in 
serum, average of 30 IJg/ml, and because of the tendency of IgD to aggregate 
and fragment during isolation. 
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Figure 1.2. Structure of IgM 
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1.2 Production and purification of the antibodies 
Antibody formation results from contact of the antigen with antigen-sensitive 
cells of the immune system. It occurs either under natural conditions during 
the developments of the individuals, or after an artificial antigen 
administration, i.e. vaccination and immunization. In human being, vaccination 
is mainly performed to induce protection against infectious disease, whereas 
immunization of animals, besides conferring protection, is primarily used to 
obtain antibodies for experimental purpose (immune sera, antisera). 
In the immune system, a single Iymphocyte produces a single type of antibody 
molecule. In a typical immune response to an antigen, e.g. a foreign protein, 
many B-Iymphocytes produce many different antibody molecules directed to 
different parts of the antigen (epitope) and with a range of binding constant. 
Such an antibody population is called polyclonal. Monoclonal antibodies, on 
the other hand, are specific for one epitope and are produced by cell fusion 
techniques. 
1.2.1 Polyclonal antibodies 
During immunization of an experimental animal, polyclonal antibodies are 
formed, because every antigen has more than one epitope group. The 
antisera produced have the disadvantage of containing a mixture of 
antibodies with different affinities and specificities. This heterogeneity is 
responsible for differences in the quality of sera prepared in various 
laboratories that may give rise to conflicting experimental results. These 
drawbacks of polyclonal antibodies emphasize the advantages of monoclonal 
antibodies, if the latter are available. 
1.2.2 Monoclonal antibodies 
Monoclonal antibodies are produced by clones of cells all derived from a 
single Iymphocyte. Any Iymphocyte can probably produce only a single 
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immunoglobulin and hence the antibody produced by a clone of identical cells 
is very restricted in the antigens to which it will bind, making it a very specific 
reagent. 
The production of monoclonal antibodies starts with the immunization of an 
animal (usually a mouse) in the traditional manner. However, instead of 
allowing the immune system of the mouse to generate antibodies, 
Iymphocytes are separated from the spleen of the mouse and fused in vitro 
with myeloma cancer cells growing in cell culture. A fusogen, usually 
polyethylene glycol (PEG), is used and the resulting fused cell is known as a 
hybridoma. The cell suspension is diluted and distributed among a large 
number of sub-cultures in order to achieve single-cell distribution. The original 
cancer cell has the ability to synthesize immunoglobulin non-specifically but 
when fused with the Iymphocyte stimulated by the injected antigen produces 
only the immunoglobulin for which the Iymphocyte has the genetic information. 
The hybridoma cells are initially grown in a medium that will not maintain the 
growth of the cancer cells, these therefore die, as do non-fused Iymphocytes, 
leaving only the fused cells. As the hybridoma cells grow, the supernatant fluid 
is tested for the presence of antibodies using a suitable assay system, usually 
an enzyme immunoassay. Those cultures producing the desired antibody are 
further cloned and either grown in bulk or as a tumour in an animal and the 
monoclonal antibodies harvested. This process is shown schematically in 
Figure 1.3 [7]. 
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Figure 1.3. Production of monoclonal antibodies from mouse [71. 
1.3 Chemistry of the antigen-antibody reaction 
An immunoassay is a quantitative technique that depends on the reaction 
between the molecules of interest, the antigen, and a complementary 
molecule, the antibody [5]. Antigens are macromolecular substances of 
natural or artificial (synthetic) origin, recognized by the immune system as 
foreign (non-self). After administration to a suitable (competent) organism, the 
antigens stimulate formation of antibodies, and activity of regulatory and 
eftectory T-cells, i.e. they induce an immune response. The antigen and its 
antibody may form specific complex when present together in a mixture. The 
bonding between an antibody and antigen involves non-covalent interaction 
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and its stability depends upon the complementary shape of the antigen and 
the binding site of the antibody. Because of the relative weakness of the 
forces that hold antibody and antigen together, these combinations are 
reversible and the complex will dissociate, dependent upon the strength of 
binding: 
Ag + Ab Ag Ab (11 ) 
where ka and kd are the respective rate constants for association and 
dissociation of the bound complex. The strength of the binding of an antibody 
to an antigen is referred to as its affinity and is defined by the affinity 
equilibrium constant Ka/f, where 
[AgAb] 
Kaff = ka / kd = ----[Ag] [Ab] 
(1.2) 
Where [Ab] and [Ag] is the concentration of the unbound or free antibody and 
unbound antigen, respectively, and [Ag:Ab] is the concentration of antigen-
antibody complex. K./f, also referred to as the affinity constant of equilibrium, 
is defined in reciprocal molar concentration, M-1 or litres per mole ( I/mol). The 
larger the K./f, the greater the affinity of the antibody for the antigen [8]. 
Thus, a high affinity antibody forms a strong bond with its antigenic epitope, 
the resulting Ag:Ab complex in such a case has a low tendency to dissociate, 
i.e. the binding reaction or its equilibrium is shifted towards the right side in the 
above equation. Therefore, the higher the affinity of the antibody, the greater 
will be the antigen amount bound to the antibody at equilibrium. In other 
words, for a constant amount of antibody in the reaction, fewer antigens is 
required for a high affinity antibody to bind 50% of the antigen than is required 
for 50% binding by a low affinity antibody. 
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The antigen can be a small molecule (hapten) such as drugs (M.Wt. <1000), 
or it can be a large protein such as albumin (M.Wt. 66,000 Da). A hapten, 
however, is usually too small to initiate an immune response but may do so 
when attached to a larger molecule such as albumin. The epitope of the 
antigen binds to the paratope of the antibody. An antigen may contain several 
epitopes, each capable of binding one antibody molecule. 
Large antigens have many antigenic epitopes and, as a result, serum taken 
from an animal that has been immunized against such an antigen will contain 
many different antibodies against the different antigenic epitopes. It is possible 
that another antigen may share some similar antigenic epitopes with the 
original antigen so that some of the antibodies in an antiserum will bind to 
both antigens. Such an antiserum is said to show cross-reactivity between the 
two antigens, and thus lacks perfect specificity. Antisera used for analytical 
purpose should be specific and it is essential that every antiserum is 
thoroughly tested prior to its use. 
1.4 Quantitation of antigen-antibody reactions 
The law of mass action (equation 1.1 and 1.2 described earlier) provides a 
useful framework to base a theoretical appreciation of the thermodynamic 
principles underlying immunoassay techniques. However, several 
assumptions need to be made in understanding such models [8]. Some of 
these include the following: 
1. The antibody is homogeneous, and has a single binding site that 
recognises only one epitope of the antigen with the same affinity, 
2. The antigen should also be homogeneous, consisting of only one chemical 
species, and possessing only one epitope for binding, 
3. The antigen-antibody binding should be uniform and without any positive 
or negative allosteric effect, i.e. the binding of one antibody-binding site 
should not influence the binding of the other site, 
4. The reaction must be at equilibrium, 
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5. The separation of the bound from free antigen must be complete, and 
6. No non-specific binding should occur in the assay system. 
Thus, in equation (1.1.) described earlier, if [AbJr represents the total 
concentration of antibody in the system, then the concentration of unbound or 
free antibody [Ab) becomes: 
[Ab) = [AbJr - [Ag:Ab) (1.3) 
Further, if the terms Band F are used to denote the [Ag:Ab) complex and free 
[Ag) antigen, respectively, then equation (1.2) can be rewritten as 
Kaff= BI {([AbJr - B) • F} (1.4) 
And rearranging 
B/F = Kaff • ([Ab Jr - B) (1.5) 
Or, 
B/F =Kaff • [AbJr - Kaff • B (1.6) 
Equation (1.6) indicates a linear relationship between the ratio of B/F and the 
concentration of bound antibody. The graphical representation of this is known 
as a Scatchard plot [8). If any two of the three unknowns are known in this 
equation, the third one can be calculated. Two useful parameters may be 
derived from the Scatchard plot: the affinity constant Kaff from the slope of the 
line, and the total concentration of antibody binding sites (AbT) from the 
intercept on the x-axis, because as B/F approaches zero, B equals the total 
antibody-binding sites. An example of a typical Scatchard plot is shown in 
Figure 1.4 [9). The intercept on the x-axis is equal to the maxim un 
concentration of bound antibody Bmax; the slope is equal to -Kaff. 
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Bound ligand 
Figure 1.4. Scatchard plot ofthe ideal slope if reactants combine homogeneously. 
1.5 Immunoassay 
Since immunoassay was introduced in 1960s by Yalow and Berson[1]. it has 
been used in almost all areas of analytical biochemistry. Immunoassays can 
be classified according to a range of criteria including sample type, nature of 
analyte, assay conditions etc.[10). The majority of approaches have been 
described for the quantification of antigens, although most are equally 
applicable to the analysis of antibodies. The three major criteria for 
classification that have the greatest influence on the performance expected of 
an assay with regard to precision and sensitivity are: 1) the use of limited or 
excess reagent fonmat; 2) the use of a homogeneous or heterogeneous 
format and 3) the use of a label or unlabelled assay format and the choice of 
label. The accuracy of an assay will primarily, but not solely, depend on the 
characteristics of the complementary molecule (Le. antibody in the case of an 
assay for antigen). The influences of factors other than the antibodies are 
listed in Table 1.2. 
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Table 1.2. Factors that influence the design and performance of an immunoassay 
Sample 
Nature of antigen Size 
Polarity 
Matrix Viscosity 
Presence of binding Protein 
Presence of unusual antibodies 
Presence of cross-reacting species (e.g. metabolite) 
Interference with label 
Reagent Immunoassay buffer pH, ionic strength 
Polymer enhancers 
Detergents 
Preservatives 
Reaction environment Temperature 
Mixing 
Sequence and speed of addition of reagents 
1.5.1 Limited reagent or excess reagent in immunoassay 
As described earlier in Section 1.3, the basic principle of an immunoassay is a 
reversible reaction between an antigen (Ag) and its antibody (Ab). The antigen 
combines with the antibody to form the Ag:Ab complex at a rate constant k •. 
At equilibrium, the complex dissociates with a rate constant kd to form free Ag 
and Ab. 
Based on this principle, immunoassay may be broadly divided into two 
classes[8] as follows: 
1) Excess reagent assay (also known as non-competitive or immunometric) 
methods in which, as in most classical methods of chemical analysis, the 
primary reagents are in excess: 
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Antigen + antibody ~ antigen:antibody complex + residual antibody 
2) Limited reagent assay (also ~nown as competitive immunoassay), so 
called because they make use of limited amounts of antibody: 
antigen + antibody ~ antigen:antibody complex + residual antigen. 
1.5.1.1 Excess reagent assay 
The excess reagent assays (synonymous with two-site immunometric reagent 
assays, labelled antibody assays, immunometric assays, noncompetitive 
immunoassays and "sandwich" immunoassays) rely on labelling of the 
antibody reagent and utilize a stoichiometric excess of reagent antibody over 
analyte. These assays utilize direct measurement of antibody binding sites 
occupied by analyte antigen. The sample is first incubated with the "capture" 
antibody, which reacts with the first epitope of the analyte and binds it to the 
solid phase. The solid phase is then washed to remove unreacted 
components and further incubated with a labelled detector antibody that binds 
to the antibody-antigen complex. Unreacted excess detector antibody is then 
removed by washing (Figure 1.5). The signal in the solid phase, i.e., enzyme 
activity in enzyme immunoassay, fluorescence in fluoroimmunoassay, etc., is 
directly proportional to the concentration of the analyte. 
In the excess reagent assays, if both capture and detector antibody reactions 
proceed to completion, then the dose-response curve would approximate a 
straight line. Many assays approach this ideal, particularly at low 
concentrations, and some have sufficient linearity to enable calibration of the 
standard curve (see an example of calibration graph in Figure 1.6.) [9]. 
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Figure 1.5. Schematic of two site immunometric assay ('sandwich' assay) 
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Figure 1,6. An example of sandwich immunoassay calibration curve 
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Excess reagent assays with a radiolabeled antibody are' called IRMAs. This 
type of assay that has antibody or antigen coated onto a solid phase is also 
known as enzyme-linked immunosorbent assays (ELlSA) where enzyme 
labels used for detection. 
1.5.1.2 Limited reagent assay 
Limited reagent assays are based on labelling of the analyte and a limited 
antibody concentration, If the equilibrium constant Ksff and antibody 
concentration are known, then it is possible to derive the bound/free (B/F) 
ratio, and hence, the percentage bound for any given concentration of 
antigen. Conversely, if the percentage bound is measured, then the antigen 
concentration of an unknown solution can be estimated. In fact, this principle 
formed the basis for the first type of immunoassay described by Yalow and 
Berson (1959) (1) for the assay of insulin in human serum. The schematic of a 
limited reagent assay is shown in Figure 1.7. 
-< C> 'rf \C> / , -<C> C> 
-< + C> + ~ 
-<C> + C> C> 
'rf /:3 -< / , 'rf C> C> / , ~C> 
Antibody Antigen in Labelled Separation of antibody·bound and free fraction e.g. 
sample antigen by precipitation of antibody, centrifugation and 
(tracer) decantation of free (retian or using column 
Figure 1.7. Schematic of limited reagent (competitive) immunoassay 
Limited reagent assays require a method of separating the bound antigen 
from the free, and a means of determining the relative quantities of antigen in 
each. Commercially, a variety of separation and detection systems have been 
employed in this assay design. In practice, neither Ksff nor the antibody 
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concentration is known with sufficient certainty to enable accurate predictions 
to be made of the concentration of unknown antigen, therefore, samples of 
known antigen concentration are included as standards. A calibration curve is 
then drawn of percentage of activity in the bound fraction/total activity (often at 
equilibrium, but kinetic assays are also feasible [11]) against the antigen 
concentration in the standards. The concentration of antigen in unknown 
samples may then be interpolated from the calibration curve. In the limited 
reagent assays, the specific activity of the bound labelled analyte fraction is 
inversely proportional to the concentration of the free analyte in the sample 
(see Figure 1.4). 
1.5.1.3 Comparison of excess and limited reagent assays 
The characteristics of excess reagent and limited reagent immunoassays are 
listed in Table 1.3 [8). They are discussed here mainly using enzyme 
immunoassay as examples. 
The major advantages of excess reagent assays over limited reagent assays 
are the specificity of the assays, more sensitive than limited reagent assays, 
with the theoretical sensitivity approaching detection of one antigen molecule, 
and less influenced by environmental substances such as salt and urea, 
which may modulate the kinetics of antigen-antibody reactions 
18 
Chapter 1 - Introduction 
Table 1.3 Characteristics of excess reagent and limited reagent immunoassays 
Excess reagent immunoassays 
• Maximal sensitivity is attained as amount of labelled/detector antibody 
approaches infinity 
• Theoretical sensitivity of assay is one molecule of analyte 
• Cross-reactive antigens will be equipotent with excess antibody 
• Antigen-antibody reaction is less influenced by substances such as salt 
and urea 
• Assay time is relatively rapid with labelled antibody procedures 
Limited reagent immunoassays 
• This saturation assay is regulated by the equilibrium constant of the 
reaction between analyte and antibody 
• Sensitivity of the assays is dependent on the affinity constant of the 
antibody 
• Maximal theoretical sensitivity is 1x1 0-14 M 
• Cross-reactive antigen will demonstrate a relative potency dependent on 
the rate of the equilibrium constants of the analyte and the cross-reactive 
antigen 
• Assay reaction is slow, because equilibrium must be reached 
1.5.2 Heterogeneous and homogeneous immunoassays 
Another criterion for the classification of immunoassays is based on the 
differentiation of the bound from free labelled antibody/antigen. This can be 
achieved either by separating bound from free using a means of removing the 
antibody (heterogeneous assay), or modulation of the signal of the label when 
antigen is bound to antibody (homogeneous assay). The various 
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heterogeneous and homogeneous immunoassays can be further 
characterized as either competitive or noncompetitive assays depending on 
whether the unlabeled antigen and the antigen linked to an enzyme or 
attached to a solid phase compete for a limited number of antibody binding 
sites, or whether the antigen or antibody to be measured is allowed to react 
alone with an excess of immune reactant. 
1.5.2.1 Heterogeneous assays 
Heterogeneous immunoassays can be formatted in many different ways [8]. 
Their sensitivity is primarily determined by antibody affinity or binding 
constant, type of label and detection system employed for the label, type of 
format used, and manipulation of reagents in a given format to achieve 
desired sensitivity. Limit of detection in EIA format ranging from 1 Ilmol (10-6 
M) to 1 attomol (10-18 M) has been reported in the literature [10]. Competitive 
hetegeneous EIAs can detect picogram quantities of hormones and drugs [12-
14]. 
There are many ways of separating bound from free label. These can briefly 
be described in terms of adsorption of free label, precipitation of antibody, 
coupling of antibody to a solid phase and chromatographic techniques. In 
each case, the performance is governed by the completeness of the 
separation, the efficiency of the washing to remove any unbound label and the 
level of non-specific binding. 
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Table 1.4. Techniques used to separate the bound and free fractions in immunoassays 
Principle Example 
Adsorption of free fraction Dextran-coated charcoal 
Precipitation of bound fraction Ethanol, ammonium sulphate, PEG 
Solid phase Use of second antibody directed against the 
primary antibody species. 
Using antibodies coupled to plastic tubes, 
beads, micro-titre plates. 
Using antibodies coupled to magnetic particles. 
Specific binding Use of other specific binding properties 
protein A, Protein G 
1.5.2.2 Homogeneous assays 
The need to separate free from bound label in a heterogeneous immunoassay 
constitutes another analytical step (two more steps if washing), which can 
influence method precision. Furthermore, it has been proved to be a challenge 
to the automation of immunoassays and is probably one of the main stimuli for 
the rapid development of homogeneous immunoassays over the past three 
decades. 
Homogeneous immunoassays are mainly competitive enzyme immunoassays 
(EIAs). The basic principle of homogeneous EIA involves a competitive 
binding mechanism and the differences between different homogeneous 
assay techniques lies in the way in which the reactants are labelled, the 
molecular recognition is used to either inhibit or enhance the enzymatic 
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activity. These assays require no separation step and hence simplified assay 
protocols can be developed. In addition, all homogeneous EIAs are based on 
measurement of enzyme activity in the kinetic mode of detection to eliminate 
endogenous sample interference and to reduce background noise. 
1.5.2.3 Comparison of heterogeneous and homogeneous assays 
Which technique is chosen in a particulate case depends on the analyte, its 
size, the required detection sensitivity and the dynamic range, the availability 
of antibodies, labels, and instruments. The simplicity of the technology is also 
a strong driving force, especially in commercialised technologies, and has led 
to the exploitation of rapid homogeneous assays for applications which do not 
require the highest possible sensitivities. When higher sensitivities and wider 
dynamic ranges are required, heterogeneous assays are generally chosen 
[15]. The relative merits and drawbacks of homogeneous and heterogeneous 
assays are summarized in Table 1.5. 
Table 1.5. Comparison between homogeneous and heterogeneous assays 
Homogeneous Heterogeneous 
Simple to perform More complicated assay performance 
Easy to automate Mechanization difficult 
Robust procedure Performance may contain critical 
Limited sensitivity steps 
Limited dynamic range Higher sensitivities 
Small antigens Wide dynamic range 
Sensitive to interference derived for General applicability 
samples Less prone to matrix difference 
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1.5.3 The non-specific binding (NSB) problem 
Non specific binding of conjugate antibody to the capture antibody is a big 
problem for immunoassay. 
In order to maximize assay precision and sensitivity, an ideal separation 
technique must ensure complete separation of the free and bound fractions 
with relatively simple and foolproof manipulations. The techniques should be 
accomplished rapidly, preferably without expensive equipment. Furthermore, 
an ideal separation method should be unaffected by the constituents of the 
sample (whole blood, plasma, serum, urine, saliva, cerebrospinal fluid, faeces, 
milk, etc.), be generally applicable to a wide variety of analytes, and be 
amenable to automation [8]. The efficiency of a separation technique can be 
defined as the completeness with which the bound and free forms are 
separated. In theory, a perfect separation system should completely divide the 
two components of the assay (i.e., be 100% efficient). However, in practice, 
this is seldom achieved. An incomplete separation often causes 
'misclassification errors', thereby resulting in assay bias and imprecision. 
Non-specific binding (NSB) is the binding of a label or labelled conjugate 
during solid-phase immunoassay by non immune-specific means. This 
phenomenon can lead to high background signals or false positive results 
[16]. In competitive EIAs, such binding adds a level of background noise that 
can reduce precision, particularly at high concentrations, and it can be 
minimised by using solid-phase or second antibody separation. In contrast, 
the separation in immunometric sandwich assays has a direct effect on assay 
sensitivity, i.e. the precision at very low and zero concentrations of the 
analytes. The separation in such assay designs can be greatly improved by 
repeatedly washing off the unbound, residual labelled antibody from the solid 
phase with wash solution [8]. 
NSB can be minimised by blocking, a process in solid-phase immunoassay, 
usually involving use of a protein solution or detergent, designed to prevent 
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non-specific interactions of the analytes or detection system with the solid-
phase or other components of the system [16]. 
Blocking buffers are used to reduce non-specific binding. Because there is no 
universal blocking buffer for all immunoassays, different blocking buffers must 
be tested for each immunoassay. Optimising a blocking buffer requires 
monitoring both background (negative control) and signal strength (positive 
control) to compare blockers. The blocker that produces the highest signal-to-
noise ratio should be chosen. 
1.6 Methods of detection in immunoassay 
Quantification of the antigen-antibody reaction can be achieved using a 
variety of instrumentation or simply by visual assessment (semi-quantitative, 
screening). The choice of immunoassay format (limited/excess reagent), label, 
and instrumentation can all influence the characteristics of the assay with 
respect to detection limits, precision and analytical range [17]. A summary of 
the choices of labels and instrumentation used are listed in Table 1.6 and 
Table 1.7 [10,17]. 
Table 1.6. Choice of labels in immunoassays 
Label Substance 
Enzyme Alkaline phosphatase, Horseradish peroxidase, etc. 
Fluorescent Fluorescein, Cy5, Alexa Fluor series, Bodipy, etc. 
Ligand Avidin, Biotin derivative, etc. 
Chemiluminescent Acridinium ester, Isoluminol derivatives, etc. 
Particle Latex, stained bacteria, etc. 
Radioisotope 57CO, 1251, 14C, 3H etc. 
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Table 1.7. Methods of detection used in immunoassays 
Colorimetry 
Fluorimetry 
Phosphorescence 
Chemiluminescence 
Turbidimetry 
Nephelometry 
Photon correlation 
Photothermal 
Isotope counting 
Neutron activation 
Atomic absorption 
Solid scintillation counting 
Sensors 
Potentiometric 
Amperometric 
Piezoelectric 
Surface Plasmon Resonance 
Ellipsometry 
Total internal reflection 
Visual assessment 
The most commonly used immunoassay detection techniques are radio, 
enzyme, electrochemical, fluorescence, and chemiluminescence labelling. 
1.6.1 Radioimmunoassay 
The first labels used in radioimmunoassays [1] were 131 1 and 1251 which were 
used to label protein and polypeptide hormones. Other radioisotopes, such as 
57CO, 3H and 14C have also been used. The use of radioisotopes has a 
number of advantages: 
1. Radioisotopes are totally impervious to normal environmental changes, 
which may partly account for the widespread opinion that RIA methods are 
inherently stable, with low between-assay variability, hence their continued 
popularity in large scale clinical analytical services [10]. 
2. The small size of the labels means minimal disruption to the biological 
properties of the molecules they are attached to. 
3. High sensitivity and selectivity, the limit of detection is usually in the range 
of femto mol/well. 
4. Wide applicability: radioimmunoassays have been developed for a wide 
range of compounds, including protein, steroid and peptide [5]. 
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Radioimmunoassays do, however, suffer from several disadvantages: 
1. Radioisotopically labelled antigens do have limited stability. Whereas 1251_ 
labelled compounds have short shelf lives, mainly due to the half-life of the 
isotope (60 days), antigens labelled with 3H or 14C are often chemically 
unstable and also need replacing at the interval of 6-13 months 
2. The cost of the reagents is high because of the relatively short shelf lives, 
and the cost of specialised radioactivity counting instruments is high. 
3. Although biological samples do not interfere with radioactivity 
measurements, the signal cannot be modified and therefore a separation 
stage is needed. 
1.6.2 Enzyme immunoassay 
In 1971 enzymes were first introduced as an alternative to radioisotopes in 
immunoassay [18], and they have since become a versatile and popular class 
of labelling substance for non isotopic immunoassays. Enzyme immunoassays 
(EIA) have been the subject of quite a large number of books, symposium 
volumes and reviews [8, 10, 19-22]. 
Enzymes are biological catalysts; by lowering activation energy they 
accelerate chemical reactions without themselves being changed in the 
process. Enzymes are high molecular mass proteins or glycoproteins and the 
part of the enzyme that interacts with substrates is called the active site. Like 
all true catalysts, enzymes do not affect the state of equilibrium of a reaction; 
they just permit equilibrium to be attained much more rapidly. 
The activities of some enzymes are very impressive. Each molecule of the 
exceptionally fast enzyme catalase can break down >107 molecules of H20 2 
per second. Enzymes are also specific, anyone enzyme catalyses only one 
type of reaction with structural and stereo specific selectivity for every 
substrate [23]. 
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Enzyme immunoassays have the following advantages: 
• High sensitivity by the amplification effect of enzyme. 
• No radiation hazards occur during labelling or disposal of waste. 
• Inexpensive equipment and relatively cheaper reagents that can have 
long shelf life. 
• Multiple simultaneous assays can be developed. 
• Rapid, simple EIA adaptable to automation can be developed. 
• Homogeneous EIA can be developed for haptens and proteins. 
Enzyme has, however, important disadvantages that limit its developments: 
• Measurement of enzyme activity can be more complex than 
measurement of the activity of some types of radioisotopes. 
• Enzyme activity can be affected by plasma constituents. 
• Many of homogeneous assays at the present time have the sensitivity 
of 10·g M and are not as sensitive as RIA. 
• Homogeneous EIAs for large protein molecules have been developed 
but require complex immunochemical reagents due to their relative 
fragility and large size. 
1.6.3 Fluoroimmunoassay 
Fluorescent labels were used in immunological staining system before the 
advent of radioimmunoassays, and semi quantitative immunofluorescence is 
still routinely used as microscopic technology. Reports by O'Oonnell et al 
[24], Soini [25] et aI., Hemmila [26], Bright [27], and Gosling [10] outline the 
usefulness of fluorophores as labels in immunoassay. 
In general, the detection limits for fluorescence immunoassay methods can be 
high because of background fluorescence of the biological sample at the 
lower wavelength (e.g., proteins fluoresce at 335 nm) and quenching 
problems. However, the use of long-wavelength or near infrared fluorophores 
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that fluoresce in the near-infrared region (600-1000 nm) has proven to reduce 
the background interference problem (Miller [28)1993, [29)1995), and provide 
a route to assays with excellent sensitivity. Fluorimeters are becoming an 
integrated part of respective immunoassays. Relatively few of today's 
fluorimetric immunoassays are measured with research fluorimeter; rather, 
fluorimeters developed for that particular type of assay and label are used. 
With the commercial availability of laser diode, the development of portable 
long wavelength fluorimeter for field fluoroimmunoassay detection is rapidly 
growing. 
The most profound trend of immunoassay development during the late 1980s 
and early 1990s, perhaps even now, is the automation [15) and point of care 
immunoassays. In automated instruments the fluorescence detector is an 
integral part of the whole system. While in point of care devices, portable laser 
long wavelength fluorimeter, like the one developed in this project, can be 
used to detect for otherwise rather dim coloured immunochromatographic 
strips at lower detection limit. 
Development of quantitative fluorimetric immunological technologies has 
proceeded in two ways: the quantitation and standardisation of 
immunofluorescence and the development of simple homogeneous methods. 
Although two of the current fluorimetric techniques, time-resolved 
fluoroimmunoassays and enzyme immunoassays with fluorimetric detection, 
have resulted in sensitivities adequate to make alternative to 
radioimmunoassay [15), straightforward heterogeneous immunoassays are 
discussed here as they are applied in this project. 
There are numerous sources of information on the theory of fluorescence and 
its applications [27, 30, 31) so these will not be discussed in great detail here. 
An excellent paper covers the basic principles of fluorescence spectroscopy 
[32). Reviews covering new developments in the theory and practice of 
molecular luminescence for chemical analysis are published every two years 
[33-35). 
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1.6.3.1 Theory of fluorescence 
The sequence of events that occur in fluorescence are shown in Figure 1.8 
and is as follows: 
• A quantum of light is absorbed by a molecule promoting it to an excited 
electronic level (a). 
• Rapid radiationless relaxation (internal conversion) takes the molecule to 
the thermally relaxed S1 level (b). 
• The molecule retains this energy for a certain period of time (around 10.5 to 
10-8 seconds), generally designated as the lifetime (,). The average lifetime 
of an excited triplet state may range from 10-4 to several seconds, 
compared with an average lifetime of 10-5 to 10-8 seconds for an excited 
singlet state. 
• The excess energy is dissipated through radiationless de-excitation (c, d, 
and e) caused predominantly through vibrational and rotational modes and 
collisions with solvent molecules, or by photon emission (f, g). When this 
photon emission is from a singlet electronic state, it is referred to as 
fluorescence (t). Conversely, when the emission is from a triplet state, 
phosphorescence is the result (g). 
• The difference between the excitation wavelength and emission 
wavelength is termed Stokes' shift. As the excitation and emission 
wavelength are shifted to longer wavelength, the Stoke's shift tends to 
become smaller, as will be seen in Table 1.8 below. 
• The quantum yield (0) or quantum efficiency, for fluorescence or 
phosphorescence is the ratio of the number of molecules that luminesce to 
the total number of excited molecules. For highly fluorescent molecules 
such as fluorescein, the quantum efficiency under some conditions 
approaches unity. Chemical species that do not fluoresce appreciably have 
efficiencies that approach zero. 
• The extinction coefficient is the energy captures efficiency (E), and usually 
ranges from 10,000 - 250,000 cm-1 M-1. 
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Assuming that the Beer-Lambert law is obeyed 
A = Log lO [10 Iltl= cbc 
It = 10 10 ·Ebe 
and all non-transmitted light is absorbed, i.e. light scattering is neglected, so: 
la = lo-It = 10 (1 - 10 .Ebe) 
Take the quantum yield (0) and the instrument factor (K) into account, the 
fluorescence intensity F is 
F = 0 k 10 ( 1 - 10 .Ebe) 
= 0 k 10 ( 2.3 cbc _ (2.3sbc)2 ..... ) 
2! 
For a very dilute solution where A< 0.05, only first term is significant, so the 
above equation reduces to 
F = 2.3 0 k 10 cbc 
If 0 k 10, c, and b remains constant, the relationship between the fluorescent 
signal and dye concentration should be linear for a dilute solution 
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Figure 1.8. Jablonski diagram showing absorption and emission processes of 
fluorescence and phosphorescence. 
(So = ground singlet state, 5, and 5, = first and second singlet levels respectively, T, 
and T, = first and second triplet levels respectively) 
1.6.3.2 Advantages of fluorescence techniques 
When compared with conventional absorbance-based techniques, 
fluorescence technique is several orders of magnitude more sensitive. 
Increase in sensitivity arises because the emitted radiation is measured 
directly and could be increased by increasing the incident power. Moreover, 
as fluorescence is measured at right angles to the incident beam, it is 
considered a zero background technique. Absorbance however, is a measure 
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of the difference between incident and transmitted intensities i.e. signals are 
measured as a small change in a large background. By using a high powered 
source, e.g., Xenon, Hg arc lamp, or laser, and a sensitive detector, as low as 
0.001 Ilg mr1 concentration can be easily detected, about 2-3 orders of 
magnitude better than absorption techniques. 
Selectivity in fluorescence-based techniques is also much higher than in 
absorbance-based approaches. All molecules absorb photons. However, 
only a few fluoresce and fewer still phosphoresce at ambient temperatures. 
Thus the rarity of luminescent materials makes fluorescence an attractive 
technique for the resolution of trace fluorescent components in complex 
mixtures. In addition, the ability to employ both excitation and emission 
wavelengths as selectivity parameters gives fluorescence increased 
selectivity. 
The ease of handling fluorophores compared with the expense and difficulties 
of handling and disposing of radioactive material makes fluorescence an 
attractive alternative to radioactivity in immunoassays. 
1.6.3.3 Long wavelength fluorescence 
Fluorescence spectrometry has been accepted for many years as a major 
technique for trace analysis, but in real samples the sensitivity of fluorescence 
is not as high as that seen in pure solutions that contain the same 
fluorophores. This is because of baCkground-scattered light and fluorescence 
signals from endogenous sample components. This problem is particularly 
prevalent in biological samples where high levels of proteins and other natural 
polymers cause intense light scattering, which commonly contain fluorophores 
whose spectra overlap those of the target fluorophores. Substances found in 
blood plasma, for example, proteins and amino acids, exhibit fluorescence 
emission at 350 nm, and protein-bound bilirubin shows emission at 520 nm. 
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Background fluorescence originating from endogenous fluorescent species 
and from Raman and Rayleigh scattering can greatly limit the potential 
sensitivity of the analysis. However, long wavelength fluorescence detection 
in the region 600 -1000 nm has proven to reduce interference [36]. Scatter is 
a property of the solvent or particulate matter in the sample. Some photons 
are uniformly scattered without change in frequency due to collisions with the 
solvent molecules. The emitted light has the same wavelength as the exciting 
light since the absorbed and emitted photons are of the same energy. This 
scattering is termed Rayleigh scattering and occurs at all wavelengths. Its 
intensity, however, varies in proportion to A. -4, so its effect can be minimised by 
working at longer wavelengths [37]. Raman scattering is a source of 
interference that occurs in aqueous solutions, which are typically used for 
biological samples. Raman scatter always occurs at a constant wavenumber 
difference from the incident light [38]. With longer excitation wavelengths, the 
Raman band decreases in intensity, and becomes further displaced from the 
Rayleigh scatter band [28]. Therefore at longer excitation wavelengths both 
Rayleigh and Raman scatter are much reduced. 
Photochemical theory predicts a sharp diminution in the quantum yields of 
fluorophores as their emission wavelengths increase [39]. In practice the long 
wavelength region boasts a few fairly intense f1uorophores, with almost all 
other molecules being effectively non-fluorescent. Thus, fluorophores with 
moderate molar absorptivities and quantum yields can give excellent limits of 
detection because of the low background signals. 
The development of semiconductor-based detectors, photodiodes, and 
inexpensive long wavelength laser diodes and LEDs at long wavelength (e.g., 
635 nm, 650 nm, 670 nm, etc) has allowed the reduction of detector noise and 
an enhancement of the fluorescence signal. There is therefore the 
opportunity for simple, robust but sensitive instruments based on solid-state 
light sources and photodiode detectors and cheap and effective fibre optics. 
Both the simplicity and sensitivity of long wavelength fluorescence thus make 
it an obvious choice as a detection method. Further discussions of the 
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advantages of long wavelength fluorescence and its applications can be found 
in references [28, 29]. 
1.6.3.4 Fluorescent labels 
A variety of fluorescent labels have been used in this study, and the structure 
of each f1uorophore is discussed below. The energy capture efficiency of a 
fluorescent dye is expressed as the extinction coefficient, E, and usually 
ranges from 10 000 - 250 000 cm-l M-l . The emission efficiency is expressed 
as the quantum yield (0), and usually ranges from_0.05 - 1.0. Quantum yield 
NCS 
HO o OH 
Aex = 494nm, Aem = 520 nm, MW = 389.4 
Aex = 649 nm, Aem = 670 nm, MW = 975.15 
Figure 1.9. Structures of FITC isomer I, and clMs bisfunctional dye. 
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is strongly influenced by the local environment and so is not usually reported 
as a 'constant' like the extinction coefficient. The best fluorophores will have 
both a high extinction coefficient and high quantum yield. 
Alexa Fluor 647 (Aex=650nm, Aem=668nm), the structure of which is 
proprietary, has a succinimidyl ester moiety that reacts efficiently with primary 
amines of proteins to form stable dye-protein conjugate. Alexa Fluor 647 is 
claimed by the manufacturer (Molecular Probes) to be, unlike Cy™5 dye 
(Amersham), resistant to quenching at high degree of SUbstitution. 
Table 1.8. Properties of FITC Isomer I, Cy ™S bisfunctional dye, and Alexa Fluor 647 
dye. 
Alexa Fluor 647 Cy™5 FITC 
Extinction coefficient (M"cm") 239,000 250,000 73,000 
Excitation wavelength (nm) 650 649 494 
Emission wavelength (nm) 668 670 520 
Stokes shift (nm) 18 21 26 
Fluorescence quantum yield >0.28 0.9 
Sensitivity to buffer pH Insensitive Insensitive pH sensitive (pK. 
6.4),alkaline buffer 
1.7 Flow injection analysis (FIA) 
Flow analysis was the result of the high demand of automation for chemical 
analysis. In 1957, Skeggs [40] described an automated system for the 
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colorimetric determination of urea in whole blood and serum. This system 
relied on continuously flowing streams of reagents and diluents with each 
sample separated or segmented by air bubbles. The first continuous flow 
injection analysis system which did not make use of air segmentation was 
reported by Ruzicka and Hansen in 1975 and was dubbed by the authors as 
flow injection analysis, FIA [41]. They subsequently demonstrated that the 
use of unsegmented flow did not result in cross-contamination of sequentially 
injected samples and that it was possible to reproducibly control sample and 
reagent injection volumes, mixing of sample and reagent, and reaction time 
[42] and these attributes have been substantiated over the years [43]. 
The wide success of flow-injection analysis is due to (1) its extremely high 
flexibility in adapting most chemical and biochemical reaction procedures; (2) 
its compatibility with virtually any detection methods; (3) its reliability in low 
volume, rapid experiment and (4) its high precision when it is automated. 
However, FIA has its limitation. Generally FIA is capable of only single analyte 
detection, although there are attempts to dual analyte formats by statistical 
analysis and reagent control. 
1.7.1 Theory of flow injection analysis 
Theory, applications, and developments of FIA are covered by many papers 
[44-49] and books [42, 501. The technique of FIA depends on four primary 
factors: unsegmented flow, sample injection. reproducible timing, and 
controllable sample dispersion. A basic flow-injection system consists of a 
multi-channel pump, an injection valve. a reactor and a detector (Figure 1.10). 
The reagent is normally a part of the carrier stream, so the injected sample 
zone can be merged with it. The resulting reaction product forms a 
concentration gradient corresponding to the concentration of analyte 
throughout the entire sample zone length. Typical flow rates are around 1 ml 
min-1 and typical sample volumes are around 25 Ill. 
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Pump Injection Micro Detector 
valve column 
Carrer 
Stream 
Figure 1.10. A simple flow injection system. 
When the sample is first injected, it forms a well-defined sample plug in the 
stream. As the sample is swept downstream through the narrow bore tubing, 
the plug disperses into, and thus mixes with, the carrier stream under laminar 
flow conditions to form a gradient. The magnitude of this dispersion is 
dependent upon the operating parameters applied to the system, including 
sample volume, tubing bore size, tubing length, flow rate, the molecular 
diffusion coefficient of the species concerned, and possibly coil diameter. By 
changing these parameters, the dispersion can be easily manipulated to suit 
the requirement of a particular analytical procedure so that an optimum 
response is obtained at minimum time and reagent expense. 
For the purpose of FIA, the dispersion (D) is defined as the ratio of 
concentrations before and after the dispersion process has taken place in the 
element of fluid that yields the analytical readout. The dispersion or dilution of 
a sample in an FIA system is given by the following equation: 
D=~ 
Cmax 
where 0 is the dispersion coefficient at the peak maximum produced by the 
ratio between Co, the concentration of a pure dye, and Cmax, the concentration 
of that same injected dye as it passes through the detector. 
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Based on FIA, a number of alternative modes of FIA have been developed, 
illustrating the versatility of this technique. These include stopped flow 
injection [51], sequential injection (SI) [52, 53] and bead injection (BI) [54-63] 
analysis developed by Ruzicka and co-workers. In contrast to the modest 
beginning of FIA's continuous flow system; the advanced SI and BI modes 
use microfluidic systems performing precisely orchestrated forward and 
reversed-stopped flow sequences tailored to the needs of the assay. The 
heart of the SI and BI system is the sample-processing unit, which is designed 
to minimize the volume of the sample path from injector to detector by 
integrating the flow-through detector into a monolithic structure mounted atop 
a six-position valve, resulting in the "Iab-on-valve" concept [64]. 
1.7.2 Affinity chromatography 
Affinity chromatography is a type of adsorption chromatography in which the 
molecule to be purified is specifically and reversibly adsorbed by a 
complementary binding ligand immobilized on to an insoluble support matrix. 
The immobilized ligand retains its specific binding affinity for the substance of 
interest. After washing away the non-interacting material, the desired material 
is eluted by adjusting the elution conditions, e.g. by changing the pH or ionic 
strength. In heterogeneous flow injection immunoassays, affinity 
chromatography is used in the form of a solid phase reactor to separate 
antibody-analyte complexes from unbound analyte. Immobilized protein A [65-
67], protein G [68], or thiophilic gels (T-gels) [69] are commonly used in the 
affinity chromatography of antibodies. The application of affinity 
chromatography in flow-injection immunoassay is discussed below. 
1.7.3 Flow injection immunoassay (FilA) 
With the movement toward automation in immunoassays, more and more 
research is being done with continuous flow systems. This format is 
inherently easier to operate than formats using tubes, microtiter plates or 
other similar reaction vessels and it can lead to very rapid results and very 
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sensitive detection. Many works have been done and many reviews [48, 70-
72] have been published on this subject. 
Flow-injection analysis has found many applications in the life sciences. Its 
application to immunoassays is a logical one. Although microtiter plate 
technology has been automated, in particular using robotics, the resulting 
system is complex and slow due to the many steps robotic arms must make to 
check their position. Many assays are still performed manually and in a batch 
mode, which is time-consuming and repetitive, giving rises to errors. Assays 
require the sequential addition of sample, reagents, and in some cases wash 
steps, and the FIA configuration is well suited to these tasks. A complication 
of FIA is that because the movement of sample and reagents is generally 
dynamic and not static, the system is usually not at equilibrium when the final 
measurement is made [71]. 
1.7.3.1 Flow injection immunoassay formats 
Both homogeneous and heterogeneous formats have been employed in FilA. 
They are discussed here using fluorescence as labels. The major 
characteristic of a homogeneous immunoassay is the modulation of the 
specific signal either by enhancement or quenching when the labelled 
reactant binds to its partner (e.g. an antibody where a labelled antigen is 
used). In particular, homogeneous FIAs are assays in which the antibody-
binding reaction significantly alters the fluorescence properties of the label so 
that it is possible to monitor the extent of the binding reaction at any time from 
the homogeneous reaction mixture. So far, the most serious limitation to the 
widespread application of the homogeneous FilA technology has been an 
inferior sensitivity compared to the equivalent separation methodology due to 
the interference associated with the untreated biological material. In addition 
homogeneous assays are extremely vulnerable to matrix variation [73]. 
In spite of these difficulties, several types of homogeneous immunoassay 
using fluorescence detection have been developed and successfully 
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exploited. The vast majority of these procedures are competitive and have 
been developed for the measurement of low molecular mass analytes and 
haptens. The limitations on assay sensitivity imposed by a competitive design, 
together with the need to pre treat or dilute the sample to avoid matrix effects 
has led to assays that can rarely detect analytes in less than nanomolecular 
concentration. 
The basic types of homogeneous fluorescence technology can be categorised 
as follows: (1) fluorescence polarisation immunoassays; (2) release 
f1uoroimmunoassays; (3) fluorescence modulation immunoassays, which 
includes both enhancement and quenching phenomena; and (4) fluorescence 
energy transfer immunoassays. These have been extensively reviewed by 
Wood and Barnard [73] (1997). 
Heterogeneous FIIAs can be divided into two types: competitive binding 
assays (Figure 1.7) and sandwich assays (Figure 1.5) (represented with 
fluorescence labels). 
In the competitive binding FilA format (Figure 1.7), competition will take place 
only if the number of available antibody (Ab) binding sites is less than the sum 
of the labelled and the unlabelled antigen (Ag) molecules. If the Ab is 
immobilized on particles, then the number of binding sites can be controlled 
by controlling the number of particles introduced into the zone. If a packed 
bed is used, then the immobilized antibody particles can be 
particles to which bio-inactive protein has been attached. 
mixed with 
After the 
competition has occurred, the unreacted Ag is washed away and the elution 
buffer is introduced to elute the labelled analyte (Ag). 
Elution buffer differs from the washing or binding buffer in order to elute the 
bound analyte (Ag). Primarily by lowering pH to 2-4, most bound antigens can 
be eluted. Other ways that the elution buffer differs from binding buffer include 
altering salt concentration or using competitive elution. Additionally, detergent 
(e.g. Tween 20, Tween 80), chaotropic salts (e.g. urea, Guanidine-Hel), 
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organic solvent, or the combination of the above can be added in the elution 
buffer, although these are less desirable, as they might deactivate the 
immobilized antibodies. 
The sandwich assay (Figure 1.5.), where applicable, has some significant 
advantages (also see Section 1.5.1.1). In this assay, all steps involve a large 
excess of one of the reagents, and this tends to drive reactions to completion 
quickly [48, 70-72]. This will have the effect of making the binding reaction 
very rapid even if the concentration is low and it does not remain in the 
reaction zone for more than a few seconds. In order that the reaction zone not 
be prohibitively large, it is therefore important to use immobilization 
geometries that have a very high surface/volume ratio. Each reaction step is 
followed by a wash step. It might seem advantageous to mix the labelled 
antibodies with the antigen prior to reaction with the capture (immobilized) 
antibody in order to save time (pre-incubation). It is very important to carefully 
control the timing of the wash steps, and this is especially easy to do when 
FIA is employed. The detailed comparisons of the excess and limited reagent 
assays were listed in Section 1.5.1.3. 
1.7.3.2 Solid phases in FilA 
The column/immunoreactor/reaction coil (Figure 1.10.) of the FilA system can 
utilise one of a number of rigid supports to couple the antibody or other ligand 
binder. These supports are known as immunosorbents. Some examples of 
immunosorbents are controlled pore glass (CPG) [74], thiophilic gel (T-gel) 
[69], magnetic particle [75], with different antibody binding functionalities, such 
as Protein A [66], [67] and Protein G [68] for non-covalent binding, and 
covalent linking reactions such as the Ultra-Link Biosupport Medium (Pierce) 
which utilizes an azlactone reaction [76]. 
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1.7.3.2.1 Controlled pore glass (CPG). 
Controlled pore glass has gained much acceptance as a support for 
immobilization and has been widely used over the last couple of decades [74, 
77-82]. A coupling mechanism, utilising the cross-linking reagent 
glutaraldehyde is shown in Figure 1. 11. 
OEt 
I 
CPG-O-Si-(CH l-NH + I 23 2 
OEt 
Silanised CPG 
~ ~ ?Et ~ ~ 
HC-(CH2l:lCH-CPG-O-Si -(CH2l,N=C-(CH2l,C-H 
I 
OEI 
A 
Glutaraldehyde Activated CPG 
~Et ~ ~ 
A + AB-NH2 - CPG-O-Si - (1H213 N=C-(CH2l:lC = N-AB 
OEt A 
Figure 1.11. Coupling reaction for CPG 
1.7.3.2.2 Mag netic particles. 
Magnetic particles have been used to purify proteins and separate cells [83]. 
The most commonly used magnetic particles have been that made from 
paramagnetic ferrous oxide. The ferrous oxide is incorporated into a cellulose 
matrix, to which the antibody is coupled to provide a stable reagent with low 
non-specific binding. The particles used exhibit magnetic properties within a 
magnetic field, but retain no residual magnetism when removed from the 
magnetic field. This characteristic enables them to be used as 
immunosorbents that can easily separate free antigens from bound, thus 
minimizing the washing time in immunoassays. Cell separation techniques 
mediated by antibody-antigen reactions are now widely used in both research 
and clinical laboratories. Magnetic beads have since been used as the 
immunosorbents for either enzymes immunoassay [84, 85] or fluorescent 
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immunoassay [75, 86) for high throughput. Magnetic particles can also be 
prepared using either Protein A or protein G coupled to the magnetic beads 
for binding antibodies at their Fc region [87). 
The use of magnetic particles as a surface for immunomagnetic binding has 
been investigated in a continuous flow model [88, 89), A radioimmuoassay 
technique developed by Forrest [89) utilized a magnetic cellulose solid phase 
for binding. Auto analyzer modules made up the system that allowed 10 
minutes incubation time for reaction. A sequential immunoassay (SIIA) 
method has been described [52) which utilizes immunomagnetic beads to 
investigate short-time antibody binding kinetics. In this competitive 
immunoassay presented in [52), the immunomagnetic bead reactor is created 
within the flowing stream by retaining immunomagnetic beads with an 
electromagnet to form an open tu~e reactor, thus the spent beads may be 
discharged after each analysis, which eliminates the problems of instability of 
reaction surfaces and the need for regeneration of the solid phase. 
Like other particles, the magnetic particles also have different derivatives on 
the surface for coupling purpose. The coupling reaction of magnetic beads 
with amine derivative (Pierce) is shown in Figure 1.12. 
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o 
Figure 1.12. Coupling reaction for magnetic amine derivatized beads 
1.7.3.2.3 UltraLink™ Biosupport Medium 
UltraLink™ Biosupport Medium (Pierce) is a polymeric affinity matrix which is 
azlactone activated. It can be coupled to a variety of ligands to yield affinity 
matrices [76]. The reactive groups on the azlactone support are incorporated 
into the support's structure. The azlactone functionally couples nucleophiles 
on ligands via a ring opening reaction to attach the ligand to the support 
through stable covalent linkages. For example, amino-functional ligands will 
form stable amide bonds (Figure 1.13.). Due to the unique azlactone 
chemistry, there is no leaving group as a result of the coupling reaction; 
therefore this coupling chemistry is safe and easy to use [90]. 
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Amide bond formation 
with ring opening 
Figure 1.13. Reaction of amine coupling through azlactone functionality. 
1.7.3.2.4 Protein A. 
Protein A (SpA) is a type of cell wall protein of Staphylococcus aureus (S. 
aureus). It was shown in 1960s that protein A can bind to the Fe of 
immunoglobulin rather than the Fab region (antigen binding site) [91]. This 
characteristic makes protein A a very useful ligand binder reagent. Protein 
G[68] has a similar activity. This category has been extensively reviewed by 
Palmer et al. [67] and Hage [92]. 
Protein A can act as an immunoadsorbent in solution either in its pure form or 
covalently linked to a variety of carrier molecules [93]. It is commercially 
available as an immobilized immunoadsorbent [66, 67, 77]. In this form, 
protein A is covalently linked to carrier matrix, such as sepharose [94], 
controlled pore glass [77], agarose [95), and other polymers such as 
UltraLink™ Biosupport Medium (Pierce), and can be used in a flowing system 
as in a column or reactor. UltraLink™ immobilized protein A (Pierce) was used 
in this project, with cross linking of the antibody and protein A with dimethyl 
pimelemidate (DMP) [94-98] (Figure. 1.14). 
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Figure 1.14. Immobilization of antibodies via protein A 
1.8 Immunochromatography 
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In 1988 a new over the counter pregnancy test (Clearblue easy® developed 
by Unipath) revolutionised diagnostic immunological tests. The test used dyed 
microspheres in a sandwich format to give a one step test eliminating the 
need for colour-generating enzymes [99]. Since Abbott Laboratories 
developed a rapid, self-performing immunochromatography assay [100, 101] 
in 1990, many diagnostic test kits have been developed that utilize the same 
principles. Now many other companies offer similar test for hCG, popular 
infectious disease, and drugs of abuse in urine. A number of company's 
websites, such as Bangslabs, describe this method development intensively. 
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Immunochromatography assay, also called lateral flow test, or simply strip 
tests, is a type of dyed microspheres sandwich test. Various biochemical 
components are separated across an absorbent membrane into discrete 
region. It is an antibody-based test that typically uses capillary flow through an 
absorbent membrane to mix and subsequently separate the various 
components. Immunochromatography is a very useful transportable 
technique. It does not usually require any sophisticated instrumentation but 
may still yield a semi-quantitative result. By using simple instrumentation, 
such as the portable fluorimeter developed by this project, quantitative results 
can be yielded. They are a logical extension of the technology used in latex 
agglutination tests, the first of which is developed in 1956 by Singer and Plotz 
[102]. The benefit of immunochromatography tests include: 
1. User-friendly format, 
2. Very short time to get test result, 
3. Long-term stability over a wide range of climates, 
4. Relatively inexpensive to make. 
These features make strip test ideal for applications such as home testing, 
rapid point of care testing, and testing in the field for various environmental 
and agriculture analytes. In addition, they provide reliable testing that might 
not otherwise be available to developing countries [103]. 
The principle behind the test is straightforward. Basically, any ligand that can 
be bound to a visual detectable solid support, such as dyed microspheres, 
can be tested qualitatively, and in many cases, even semi-quantitatively. 
Some of the more common lateral flow tests currently on the markets are tests 
for pregnancy, strep throat, and chlamydia, which are example of conditions 
for which a quantitative assay is not necessary[104]. Immunochromatography 
can use an enzyme label that is another type of competitive assay. It can also 
use a non-competitive assay (sandwich techniques). 
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The first major target analytes for this test format was human Chorionic 
Gonadotropin (hCG) for the detection of pregnancy. Pregnancy kits have been 
developed that use urine or plasma as test solutions, that use latex, or gold 
conjugates as detector reagents, that require as little as 90 seconds or as 
much as 15 minutes to perform; and that have readout zones which may 
consist of a single bar for a positive reaction (Le., sample containing more 
than 25 mlU mr' of hCG (2 ng mr')), or two bars for a positive reaction (one 
bar in this case would indicate a negative reaction) [105]. Many of the tests 
are equipped with a zone at the end of the test strip that will change colour 
when the sample front reaches it, thereby telling the user that the test is 
complete and it is time to interpret the result. A schematic diagram of the 
lateral flow strip is shown in Figure 1.15. 
S8mpIe Conjugate Cepture Control 
pad pad [Ab) line line 
End of Absorbent 
assay line pad 
Figure 1.15. Schematic of an immunochromatographic test strip 
In addition to the impressive array of commercially available pregnancy tests, 
there are also test strip assays on the market for streptococcus (Strep-A), 
luteinzing hormone (LH) and estradiol (E2) for ovulation predication, malaria 
and a variety of other tropical infectious diseases, hepatitis B (antigen and 
antibody), hepatitis C, HIV (antibody), heliobacter pylori (H. pylori, ulcer 
detection), troponin (cardiac monitoring) and for a range of different drugs of 
abuse. Many more may become available on the market in the near future 
[106]. The majority of the analytes listed above are measured on the basis of 
presence/absence (yes/no), and most of them are detected using 
immunometric assays (sandwich technique). For immunometric type assays, 
a ligand specific for the analytes (normally, but not necessarily an antibody 
[Ab]) is immobilized onto the membrane. The detector reagent, typically an 
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antibody coupled to latex or colloidal metal, is deposited (but remained 
unbound) into the conjugate pad. When sample (urine, plasma, whole blood, 
etc.) is added to the sample pad, it rapidly wets through to the conjugate pad, 
and the detector reagent is solubilized. The detector reagents begin to move 
with the sample flow front up the membrane strip. Analyte that is present in 
the sample will be bound by the antibody that is coupled to the detector 
reagent. As the sample passes over the zone to which the capture reagent 
has been immobilized, the analyte detector reagent complex is trapped. 
Colour develops in proportion to the amount of analyte present in the sample. 
Commercial assay kits utilising competitive immunoassay protocols are also 
available. In this type of assay, the detector reagent is typically the analyte (or 
an analogue of the analyte) bound to latex or colloidal metal. As the sample 
(containing analyte) and the detector reagent pass over the zone to which the 
capture reagent (typically an antibody) has been immobilized (detector zone, 
readout zone), some of the analyte and some of the detector reagent are 
bound and trapped. The more analyte present in the sample, the more 
effectively it will be able to compete with, and/or displace, the binding of 
detector reagent. Thus in most competitive immunoassay kits an increase in 
the amount of analyte in the sample results in a decrease of signal in the 
read out zone. 
All of these tests also have the promises of becoming quantitative assays. If 
the intensity of colour formed could be read by a dry strip reader, for example, 
then a quantitative result could be obtained. Different colours of dyed 
microspheres could be used. 
To develop immunochromatographic test strips, the following reagents and 
materials are needed: antibodies, microspheres, membranes, absorbent pads, 
membrane backing, desiccant and plastic housing. 
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1.8.1 Antibodies 
There are two types of antibodies in stationary phase: capture line antibodies 
and control line antibodies, and one type of antibody in mobile phase, 
conjugate antibodies (antibodies on dyed microspheres, to which the sample 
analyte will bind initially). 
If testing for small molecules using the competitive binding format, purified 
antigen, or an antigen/carrier molecules (BSA) conjugate will also be needed, 
for attachment of test lines. 
The antibodies used in the development of an immunochromatographic 
assay, therefore, must have the following characteristics: 
• Sufficient sensitivity (a high enough association constant Ka), 
• High specificity to accomplish the performance requirements of the finished 
product, 
• Good binding to the membrane, 
o Good solubility when the elution buffer passes. 
1.8.2 Microspheres 
Detector reagents are antibody or antigen coupled to colloidal metal (usually 
gold), dyed microspheres (often called latex, usually < 1 Ilm), or fluorescence 
microspheres. 
Normal lateral flow test utilize dyed (coloured, non-fluorescent) microspheres 
(latex). This is a kind of visual detection method without any aid of an 
instrument. However, as fluorescence techniques provide better sensitivity 
and selectivity, and the development of portable and inexpensive fluorimeter 
is popular, fluorescence dyed latex is investigated in this project. 
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Conjugate antibody or antigen is attached on the microspheres, then the 
microsphere is deposited on the conjugate pad first. The microspheres will 
migrate down the membrane upon introduction of the sample. The criteria to 
choose appropriate microspheres are (106): 
1. Optimal flow rate is achieved by choosing equal or smaller than 1/10 of the 
pore size of the membrane through which they will migrate. 
2. Optimal colours for visualization in various type of samples. 
• whole blood: black or dark blue 
• serum: 
• urine: 
• saliva: 
• cerebral spinal fluid: 
bright red or bright blue 
green, blue, red or black 
any dark colour 
any dark colour 
3. To minimize hindered flow caused by the inherent hydrophobic interactions 
between membrane and particle (in the case of a hydrophobic membrane), 
pre-treatment of the membrane with a substance that will maintain a small 
distance between the microspheres and the membrane, yet that can be 
easily redehydrated, is often helpful. Examples of substances commonly 
used are sucrose, various water-soluble inert polymers, and surfactants. 
The idea is to choose a substance that is stable in dry form, yet dissolved 
easily upon rewetting to allow the antibody bound microspheres to flow 
easily through the membrane upon addition of the sample. In addition to 
treating the membranes, the microspheres themselves can also be pre-
treated with SUrfactants, synthetic or protein-based blockers. If done 
correctly, this can also help to reduce the problem of reagent mobility upon 
sample mixtures of these various polymers, detergents, and blockers. 
1.8.2.1 Dyed microspheres 
Dyed (coloured, non-fluorescent) microspheres are commonly utilized in 
lateral flow tests for its convenience of direct visualizability. There are several 
sizes and polymers to choose from. The general rule to choosing appropriate 
particles should be followed. 
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1.8.2.2 Fluorescence microspheres 
Microspheres are available with a variety of functionalised surfaces, densities 
and special properties (e.g. magnetic). The association of coloured dyes or 
fluorophores adds a further level of flexibility. In fact the incorporation of 
fluorophores has become a particular important feature for assay 
development, conferring benefits such as multiplexing capabilities and signal 
enhancement, and serving as a replacement for radioactive labels [107, 108]. 
Microspheres are commonly dyed after synthesis, through dye entrapment 
(internal labelling) or surface attachment (external labelling). Fluorophores 
diffusion/entrapment involves the swelling of polymeric microspheres in an 
organic solvent/dye solution. The water-insoluble dye diffuses into the polymer 
matrix, and is entrapped when the solvent is removed from the microspheres 
through evaporation or transfer to an aqueous phase. The Dark Red 
Fluorescent Microspheres (Duke Scientific Ud) used in this project are 
labelled this way [109]. The great majority of microspheres are internally 
labelled, which affords many benefits, including: 
• availability of surface groups for coupling reaction, 
• photostability, protection of fluorophores from photobleaching, 
• larger selection dyes, 
• wide range of sizes available, -0.02 IJm + (no upper limit), 
• greater dye loading/brighter microspheres. 
For coloured (non-fluorescent) dyes, an amount of dye equal to approximately 
10-40% of the bead weight may be entrapped compared with only up to 
approximately 1 % of the bead weight for fluorophores, due to problems 
associated with intermolecular interaction of fluorophore molecules 
(fluorescence quenching). 
Microspheres may also be externally labelled with dyes (generally 
fluorophores). These are generally used in cytometry. Surface attachment of 
fluorophores offers other unique benefits, such as [109]: spectral retention 
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(spectra are much like those of free dye), and useful where particles will be 
used in solvents and will swell and dye will not escape. 
1.8.3 Membranes 
The membrane chosen is dependent upon the approach that you choose, as 
previously mentioned. Some options for this include nitrocellulose (high 
protein binding), cellulose acetate (Iow protein binding) and glass fiber 
membrane (non-protein binding). 
Membrane manufacturers generally offer a wide range of material and pore 
size. Millipore offers a collection of the membranes. For this project, we 
investigated nitrocellulose membranes various pore sizes. 
Considerable benefits in overall product performance may be obtained by 
making relatively minor modifications in the capture reagent solutions that are 
applied to the membrane. Improvements in performance may include 
increased assay sensitivity, reproducibility, product manufacturability, and 
greater product stability [106]. Some of the solution parameters that should be 
optimised are discussed in this section. These parameters were not studied, 
as the strips were not made in the author's lab. 
Selection of buffer 
Capture reagent solutions should always be buffered. This is critical to 
achieve manufacturing and performance consistency from batch to batch of 
test strips. At a minimum, the pH of each solution should always be the same 
even if it is not the optimal pH. There are many buffers that can be used to 
control the pH of capture reagent (antibody) solutions. Phosphate, borate, tris, 
and carbonate are commonly used [106]. 
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Ionic strength 
Ionic strength is also an important factor. Ions in solution may interfere with 
electrostatic interactions between the membrane and the capture reagents. In 
addition, physiological concentrations of buffer salts and sodium chloride 
(-150 mM) promote the solubility of most proteins and reduce the 
hydrophobic attraction of the nitrocellulose membrane. Finally, as the molarity 
of the capture reagent solution increases, the amount of solid residue that will 
be left on the membrane after the evaporation will also increase. For these 
reasons, the ionic strength of the buffer should be reduced as much as 
possible. This means that the molarity of the buffer should be lowered to the 
minimum required to maintain a stable pH. Sodium chloride should be 
eliminated in capture reagent solutions unless absolutely necessary to ensure 
protein solubility or stability [106]. 
Choosing pH 
As the solubility of the capture reagent (antibody) in the application solution 
decreases, the tendency of the antibody to bind to (partition onto) the 
membrane increases. This is one of the reasons why the molarity of the 
solution should be kept to a minimum (see previous paragraph). Another 
factor that influences protein solubility is pH. Solubility is at a minimum when 
the protein has no net charge (the pH at which this occurs is known as the 
isoelectric point, pi, of the protein). Therefore, to minimise protein solubility 
while still maintaining a stable solution, it can be helpful to bring the solution 
pH to within ± 1 unit of the pi of the antibody. Most antibodies have isoelectric 
points in the pH range of 5.5 to 7.5, so that using a buffer at pH 7.0-7.5 is 
probably very close to optimal [106]. 
Use of methanol, ethanol or isopropanol 
The addition of a small amount «10% v/v, usually <5% v/v) of methanol, 
ethanol or isopropanol to the reagent application solution can be extremely 
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beneficial for three distinct reasons: First, the alcohol can dramatically 
improve the consistency of reagent application by lowering solution viscosity, 
by lowering solution surface tension (both of which promote entry of the 
solution into the membrane), and by decreasing static repulsion. Second, the 
addition of a small amount of alcohol will decrease protein solubility without 
causing denaturising or precipitation and will also promote the adsorption of 
the protein onto the nitrocellulose membrane. Third, the presence of even a 
low concentration of alcohol will enhance drying and protein fixation. The 
effect of adding alcohol should be determined experimentally. 
Use of detergents 
Occasionally, the addition and subsequent drying of some capture reagent 
solutions may cause the reagent line to wet more slowly than the untreated 
membrane. When this occurs, the flow front may become deformed, and in 
extreme cases it can wrap around the capture reagent line and cause air to be 
trapped so that flow over the line is prevented. To prevent this, it is sometimes 
effective to add a small amount of detergent (e.g., 0.05% SDS or 0.005% 
Triton X-1DO) to promote rewetting of the line. 
Optimising concentration and volume of reagents 
The important parameter to control, in terms of the capture reagent, is the 
amount of protein applied-not the concentration. The shape and size of the 
capture reagent line is controlled for the most part by the volume of the liquid 
that is applied. When adjustments are made to volume in an attempt to obtain 
a narrower or better-defined line, it is important to change the concentration of 
the capture reagent so that the amount applied remains constant. Failure to 
do this may obscure any benefits or cover up any performance losses that 
may result from changes made to the volume dispense rate. 
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1.8.4 Sample pad 
The sample pad can be used to perform multiple tasks. It is used to promote 
the even distribution of the sample volume into the conjugate pad in an even 
and controlled manner. It should help to spread out the sample volume so that 
liquid enters the conjugate pad in an even and controlled manner. It should 
control the rate at which liquid enters the conjugate pad so that flooding of the 
device is prevented. In some instances, the sample pad may also perform a 
much wider range of functions. By pre-treating the sample pad with 
components such as proteins, detergents, viscosity enhancers, and buffer 
salts, the sample pad can also be used to increase sample viscosity 
(modulate flow properties) and enhance the ability of the sample to solubilize 
the detector reagent. 
1.8.5 Conjugate pad 
This is the part of the lateral flow device to which the conjugate is added. 
Ideally, this is a pad made of a material that can absorb a large amount of 
sample, and will then release this sample into the membrane at a steady, 
controlled rate. A good source of information regarding these is Whatman 
[110). 
1.8.6 Membrane backing 
Added to give strength to the membrane, which is often very fragile. This can 
be attached by adhesives or by a process called direct casting. This is 
advantageous, as it eliminates the possibility of adhesives interfering with the 
test. 
56 
Chapter 1 - Introduction 
1.8.7 Desiccants 
These can be either added into the pouch separately or incorporated into the 
absorbent pad and are used to keep the ingredients dry during storage before 
use. 
1.8.8 Plastic housing 
This is the case for the test kit and the foil pouch in which the final product is 
presented. A good source of information regarding the various possibilities for 
each of these is Bio.Dot [111]. 
1.9 Tuberculosis 
1.9.1 Introduction 
Tuberculosis (TB) is a contagious bacterial disease caused by mycobacterium 
tuberculosis. Like the common cold, TB is spread through the air. The main 
source of infection is a person with TB of the lungs (pulmonary TB) who 
coughs, sneezes or spits, and spreads infectious droplets containing the 
bacteria in the air. Once infected with M. tuberculosis, a person stays infected 
for many years, and often for life. The vast majority (90%) of people infected 
with m. tuberculosis do not develop the disease of tuberculosis. Active 
disease occurs in an average of 10% of those who are infected. Various 
physical or emotional stresses trigger progression from infection to disease. 
Any weakening of the immune system-for example, by malnutrition or HIV 
infection - increases the chances for this disease to develop. Left untreated, a 
person with active TB will infect on average 10 to 15 persons a year. The 
most effective approach to TB control is the identification and cure of these 
infectious cases. Proper treatment of infectious cases make them very quickly 
non-infectious so that they can no longer spread TB to others. Because 
effective treatment breaks the cycle of transmission, cure is the best 
prevention. 
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This is even more important because of the emergence of drug-resistant TB. 
Drug-resistant TB is a human-made phenomenon caused by inconsistent or 
partial treatment, when TB bacilli become resistant to the most common anti-
TB drugs. This happens when doctors or health workers prescribe the wrong 
combination of drugs, the drug supply is unreliable, or patients do not take all 
their medicines regularly for the required period of time. Once the bacilli 
become resistant to one or more anti-TB drugs, the infected person can go on 
to infect others with the same drug-resistant strain. Multidrug-resistant TB is 
more difficult and more expensive to treat, and more likely to be fatal. 
According to World Health Organization (WHO) [112), each year, 1 % of the 
global population is infected, 5-10% of those infected become sick or 
infectious. Populations infected in developing countries are especially high 
according to WHO: 
Africa: 35% 
Americas: 18% 
Eastern Mediterranean: 29% 
Europe: 15% 
South-east Asia: 44% 
Western Pacific: 35% 
TB kills more youth and adults than any other single infectious agent in the 
world today. HIV is the most powerful factor known to increase the risk of 
progression from TB infection to disease. In Africa, about 30% of all TB cases 
are now due to HIV. In some of the worst affected countries in sub-Saharan 
Africa, more than 60% of TB patients are HIV-positive. 
1.9.2 Existing diagnostic tests and ongoing researches 
1.9.2.1 Microscopy 
The detection of mycobacteria by microscopic examination after staining of 
the mycobacteria according to Ziehl-Neelsen (ZN) is a simple technique and 
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the cornerstone for the diagnosis of TB in developing countries. The technique 
can be used for sputum, lymph nodes, pleural fluid, urine, cerebrospinal fluid 
and biopsies. The procedure is simple but the detection limit is 104 bacteria 
mr'. However, only a limited number (20) of samples can be handled by a 
microscopist per day [112]. 
The usual means of diagnosing tuberculosis in resource-poor countries where 
culture facilities are not available is by the detection of acid-fast bacteria 
(AFB) in sputum by direct microscopy. Sputum smear-positive patients are the 
most potent sources of transmission in the community. Therefore, the 
presence of AFB in sputum is an important marker of infectiousness. When 
done properly, approximately 60 to 70% of all adults with pulmonary 
tuberculosis can be identified with the current direct microscopy test using 
Ziehl-Neelsen staining (ZN). In practice, however, this proportion is around 40 
to 60% at best with the stringent requirements of the test [113]. This reduced 
sensitivity is related to the problems associated with the stringent 
requirements of the test [114]. For example, if the need for multiple samples 
and multiple patient visits is ignored, then fewer smear-positive cases will be 
identified and treated. The International Union against Tuberculosis and Lung 
Disease recommends on average 20 slides per technician per working day. 
Due to overloading of the diagnostic facilities and lack of staff, most laboratory 
workers, especially in developing countries, process an excessive number of 
slides or have to combine smear examination with other diagnostic 
procedures, resulting in a lower quality of diagnostic service. Moreover, 
patients co-infected with HIV are more likely to have negative sputum AFB 
smears [115]. 
The rising incidence of tuberculosis worldwide means an increasing burden on 
diagnostic facilities, so tests simpler than Ziehl-Neelsen staining are needed. 
The challenge is to develop a simple and inexpensive test that should be 
sensitive, reproducible, and have at least as good detection limit as 104 
bacteria per ml. 
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1.9.2.2 Culture 
Mycobacteria can be cultivated from all kind of samples on variety of solid and 
liquid media. Culture is the good standard for the diagnosis of the 
tuberculosis. The techniques are very sensitive, a few mycobacteria can be 
detected. Mycobacteria are slow growing organisms, therefore culture takes 
4-8 weeks. Modern culture techniques have reduced the time needed for a 
positive culture to 3-4 weeks, but for these techniques, expensive incubator 
and detectors are needed. Because of the shortage of money, most 
developing countries do not use culture for the diagnosis of TB [116]. 
1.9.2.3 Polymerase chain reaction (PCR) 
This highly sensitive technique, comparable with culture but much faster (one 
day), is less practical for developing countries since one needs well trained 
staff and the technique is too expensive for a large scale use. 
1.9.2.4 Detection of antibodies in serum from patients 
Most assays developed so far are based on the detection of specific 
circulating antibodies. The serodiagnosis of tuberculosis has been the subject 
of investigation for a long time, but we still lack a test with widespread clinical 
utility. The available tests have both sensitivity and specificity of around 80% 
[117]. In HIV seropositive patients coinfected with tuberculosis, the sensitivity 
of antibody tests is much lower, between 10 and 40% [118]. More efforts 
should be directed toward developing assays based on the detection of 
antigens in body fluids. Such tests could be useful for the diagnosis and 
follow-up of patients during treatment. 
1.9.2.5 Antigen detection in sputum and other body fluids 
Mycobacterial antigen has been detected by enzyme linked immunosorbent 
assay in sputum [119] and cerebrospinal fluid [120], and by latex agglutination 
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assay in cerebrospinal fluid [121]. Lipoarabinomannan (LAM) is a major 
component of the mycobacterial cell wall, has been detected in the serum 
[122] and sputum [123] of patients with tuberculosis, although none of these 
tests to detect mycobacterial antigens has achieved widespread use for the 
diagnosis of active tuberculosis. Pereira Arias-Bounda et al [124] have 
developed an ELlSA test which could detect 1 ng of purified LAM per ml and 
104 Mycobacterium tuberculosis (Mtb) whole cells per ml. This test is based 
on a capture ELlSA using as a capture antibody a monocional antibody 
against LAM with a rabbit antiserum against Mycobacterium tuberculosis 
bacteria as a source of detector antibodies. 
1.9.2.6 Antigen detection by immunochromatography 
Lateral flow based tests for TB are being developed by lots of diagnostic 
companies (InBios International, American Bionostica Inc., etc.). InBios 
International [125] is developing a lateral flow based test that has been 
designed for the qualitative determination of antibodies against Mtb infection. 
American Bionostica [126] is developing a test that "utilizes a lateral flow 
design, and has a unique antigen that allows the detection of human TB 
antibody present in human being infected with Mycobacterium tuberculosis at 
a sensitivity of greater than or equal to 85 percent, and a specificity of greater 
than or equal to 92 percent. The detection limit for this rapid test exceeds 
anything in the point of care market today". These lateral flow tests, however, 
all test the TB antibody rather than antigen. Antigens appear in the serum in 
the earlier stage of infection, while antibodies develop after the infection is 
established. Obviously, detection of antigen would be more advantageous 
than the detection of antibody. 
Most of the lateral flow test kits utilise gold latex conjugates that would show 
colour if the sample is positive, this colour (usually pink) can usually be seen 
by naked eyes. Obviously this would require higher concentration of the 
antibody present in the sample to be detected. Using the recently developed 
long wavelength fluorophore integrated in the latex, and a simple fluorimeter, 
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low concentration of antigen (LAM) in the serum on the lateral flow format 
could be detected. This project investigated the possibility in this area. 
1.9.2.7 Lipoarabinomannan 
Mycobacterium tuberculosis, the bacterium that causes this disease, is 
protected from the host by a unique cell wall. One of the main components of 
this cell wall is lipoarabinomannan (LAM), a glycoconjugate that is involved in 
many interactions with the host's immune system and therefore likely to 
contribute to the pathogen's survival (127). 
The structure of LAM has been investigated in the early 90s by Delphi 
Chatterjee and coworkers [128-133). The back bone of LAM consist of a linear 
a 1-6 mannosyl polymer that is linked to a phosphatidylinositol anchor. Most 
mannosyl residues are substituted on their C-2 with another single mannose. 
This mannosyl backbone carries an unknown number of branched arabinosyl 
side chains, which consist of the rare a-O-arabinofuranose. The arabinosyl 
branches are based on a linear a 1-5 linked backbone. Branching residues 
carry an additional a 1-3 linked arabinofuranose. At their non-reducing ends, 
the a-arabinofuranans are capped with a p 1-2 linked arabinofuranose. Slow 
growing mycobacteria like Mycobacterium tuberculosis attach one or more a-
mannoses to these p-arabinose termini. In total, one molecule of LAM 
contains about 30 mannose units and 50 arabinofuranoses (structure shown 
in Figure 1.16) (127). The LAM molecules are intrinsically heterogeneous. This 
molecular heterogeneity was first illustrated by their behavior in SOS-
polyacrylamide gel electrophoresis (SOS-PAGE), showing a broad band 
around 30 kOa (134), and more precisely defined by matrix-assisted laser 
desorption/ionisation mass spectrometry analysis. The average molecular 
weight of LAM was determined at 17 kOa [135]. Purified LAM and monoclonal 
anti LAM or rabbit anti LAM were kindly supplied by Newmarket Laboratories 
Lld (from another source) throughout the assay development. 
62 
Chapter 1 - Introduction 
b a-Mannose 
• Inositol 
'0 a-Arabinose 
'® ~-Arabinose 
p Phosphate 
Figure 1.16. Current (incomplete) model of the structure of LAM [127). 
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This chapter describes the instrumentation, apparatus, basic methods and 
reagents used throughout the work. 
2.1 Instrumentation 
2.1.1 Perkin-Elmer LS-50 B fluorescence spectrometer 
The appearance of the LS-50B Spectrophotometer is shown in appendix A. 
The optical layout of the LS-50B (from the user's manual) can be seen in 
appendix B. The LS-50B is composed of a pulsed xenon excitation source, a 
scanning excitation monochromator, a scanning emission monochromator, 
and a red-sensitive R928 photomultiplier tube. The LS-50B is fitted with FL 
WinLab version 2.01 software. The parameters are illustrated in Table 2.1. 
along with the ones of Hitachi F4500. 
2.1.2 Hitachi 4500 fluorescence spectrometer 
The appearance of the F-4500 spectrophotometer is shown in appendix C. 
The block diagram of the signal processing and control systems of the F-4500 
can be seen in appendix D. The spectrophotometer mainframe has a xenon 
lamp light source, the beam of which is incident on the excitation 
monochromator. The beam after wavelength selection with the excitation 
monochromator (Aex) is irradiated onto the sample cell. Light emitted from the 
sample in the form of fluorescence (Aem) then passes through the emission 
monochromator (which is at right angles to the incident light) to remove any 
light that is not at the emission wavelength. The intensity of fluorescence is 
detected via a red-sensitive photomultiplier tube. Instrument parameters are 
shown in Table 2.1. 
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Table 2.1. Instrument parameters for the Perkin Elmer LS - 50 Band Hitachi F4500. 
PARAMETERS F-4500 LS-50B 
Light source 150 W Xenon lamp Xenon flash lamp, 
pulsed at line frequency 
(50 or 60 Hz) 
Monochromators Excitation: 200 - 600 nm Excitation: 200 - 800 nm 
Emission: 200 - 900 nm Emission: 200 - 900 nm 
Excitation band width 1.0, 2.5, 5.0, 10.0 nm 2.5 - 15 nm in 0.1 nm 
increments 
Emission band width 1.0, 2.5, 5.0, 10.0, 20.0 nm 2.5 - 20 nm in 0.1 nm 
increments 
Scanning speed 15,60,240,1200,2400, 10 -1500 nm I min in 1 
12000,30000 nm I min nm increments 
Wavelength ± 2.0 nm ± 1.0 nm 
accuracy 
Response time 0.004, 0.01, 0.05, 0.1, 0.5, 0.02 - 9.98 seconds in 
2.0, 8.0 seconds 0.01 s increments 
PMTVoltage 400,700,950 V Auto 
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2.1.3 In house made portable long-wavelength laser fluorimeter and its 
characterisation 
Development of a portable long-wavelength laser fluorimeter was the first aim 
for this project. It has been designed by Prof. J. N. Miller and the author, built 
up by Mr. Bert Bower, and characterised and adapted to the immunoassay 
methods developed by the author. 
The main aim was to develop a portable, simple and sensitive instrument 
adaptable to FIA and immunochromatography test strips. A schematic 
diagram of the fluorimeter is shown in Figure 2.1, The main components are: 
a. Lasers (635 nm, 650 nm); b. Photomultiplier Tube (PMT); c. Cell Holder; d. 
Filter(s); e. Lens. All the parts, optically lined up, electrically and electronically 
connected, were packed inside a 30 x 30 cm metal, light tight box. The 
fluorescence signal is shown as a digit on the LED display unit of the 
fluorimeter, and also shown on a PC as a profile via an analogue to digital 
converter (ADC). A photograph of this fluorimeter is shown in Appendix E. 
I Display I 
B-i:IIA~~ r ::verterD AI 
'f PC 
c::::> - Lens 
i 
i 1- Filters 
B-1 I P ,~ I ~ 
Laser635nm cea Holder Laser650nm 
(Movable up 
and down) 
Figure 2.1. The schematic diagram ofthe portable laser fluorimeter 
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The components of the portable laser fluorimeter and their sources are listed 
below in Table 2.2. Details of the components are described in the following 
sections. 
Table 2.2. The components of the portable laser fluorimeter and the sources 
COMPONENT SUPPLIER 
Photo Multiplier Tube (PMT) Hamamatsu 
Laser635,Laser650 Coherent 
Lenses Coherent 
Cut-off filter at 665 nm Edmund Scientific Ltd 
Long pass edge filter at COWL 660 nm Coherent 
Case and all the electric components RS 
ADC-16 Data Logger Pico Technology Ltd 
2.1.3.1 Photo Multiplier Tube (PMT) 
A photomultiplier tube, useful for light detection of very weak signals, is a 
photo emissive device in which the absorption of a photon results in the 
emission of an electron. These detectors work by amplifying the electrons 
generated by a photocathode exposed to a photon flux (Figure 2.2). 
Photomultipliers acquire light through a glass or quartz window that covers a 
photosensitive surface, called a photocathode, which then releases electrons 
that are multiplied by electrodes known as metal channel dynodes. At the end 
of the dynode chain is an anode or collection electrode. Over a very large 
range, the current flowing from the anode to ground is directly proportional to 
the photoelectron flux generated by the photocathode. Diagram and 3D 
drawings of a PMT are shown in Appendix F. 
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A low voltage (11.5V to 15.5V) and low power (5 mW) Hamamatsu PM tube 
was used in this project. It was packed in a metal package and included its 
own power supply. 
2.1.3.2 Lasers 
Long wavelength lasers are commercially available. Coherent variable focus 
635 nm and 650 nm diode laser modules were chosen to be compatible with 
the commercially available long wavelength fluorescent labels (Cy5, Alexa 
Fluor 647, etc, see Section 1.6.3.4 and 1.6.3.5). Laser 635 nm was mainly 
used in this work and laser 650 nm was reserved for the potential use of 
another longer wavelength fluorophore. They were mounted on either side of 
the cell/strip holder. The output power of the two lasers was both about 5 mW. 
The beam shapes were elliptical, ca. 40 x 120 flm. Power was supplied by 
Coherent universal power supply. A photograph of the laser module is shown 
in Appendix G. 
2.1.3.3 Lens 
An equi-convex lens (focal length 15.0 mm) from Coherent was fitted between 
the filter slot and the PMT detector. This lens had positive focal lengths and 
was the optimum shape for producing real images at 1:1 magnification. The 
lens position was adjustable from outside the metal box. 
When the emission light is made parallel in a single biconvex lens, the focal 
point F2 can be located on the surface of a photo detector as shown in Figure 
2.2. As the emission light side from the cell/strip is brought close to the lens, 
or moved away from it, the distance of the photo detector side changes 
accordingly. The calculated light path between cell/strip holder and the PMT 
tube should at least be 83.5 mm using the normal Gaussian formula equation. 
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2.1.3.5 Amplifier 
The portable fluorimeter was designed to have a signal amplifier with the 
intention of further enhancing the sensitivity of assay. The estimated amplifier 
folds are shown in Table 2.3. 
Table 2.3. Estimated amplifier fold of the portable fluorimeter. 
Amplifier Fold 
A 1 
B 5 
C 15 
D 30 
X 80 
2.1.3.6 ADC-16 Data Logger 
ADC-16 Data Logger from Pico Technology Lld was used to convert the 
analogue signal produced by the PMT to a digital signal that will be collected 
via a PC through data collecting software. The ADC-16 offers high resolution 
(16 bits) and is capable of detecting signal changes of 40 !-IV. The signal could 
be shown as a plot of the fluorescence vs time or as an Excel file. while a strip 
was scanned by passing through the laser beam. A typical strip scanning 
profile is shown in Figure 2.3. 
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Figure 2.3. A profile of the fluorescence conjugate on the strip recorded by the 
portable laser fluorimeter 
2.1.3.7 Characterisation - precision and sensitivity 
The precision and sensitivity of the portable laser fluorimeter using Cy™5 dye 
as a sample in a static system is illustrated as a calibration graph in Figure 
2.4. The limit of detection of the portable fluorimeter was 2.17 x 10 -11 M 
compared with 3.51 X 10-9 M of the Perkin Elmer LS-50B Fluorimeter, the 
three times relative standard deviations shown as error bars in the graph 
indicate the signal given by the fluorimeter were repeatable. And the 
regression was 0.994 and 0.985, respectively. 
The portable fluorimeter was used especially for the development of the 
immunochromatography assay. The precision for measuring the same 
labelled anti LAM immobilised strip is about 4% (n=13) of relative standard 
deviation, which include the effect of photodecomposition (see Section 
6.2.5.1 and Figure 6.4). 
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y = 2E+12x + 14.921 
R2 = 0.994 
1E-10 2E-10 3E-10 4E-10 5E-10 6E-10 7E-10 
[Cy5] I M 
y = 1E+09x + 7.6514 
R2 = 0.9851 
2.E-08 4.E-08 6.E-08 8.E-08 1.E-07 1.E-07 1.E-07 2.E-07 
[Cy5] I M 
Figure 2.4. Calibration curves of the portable laser fluorimeter (top) and Perkin Elmer 
(LS-508) showing the precision and the sensitivity using Cy5 
2.1.4 UVNIS spectrometer 
Absorbance measurements were carried out on a Unicam 8700 Series 
UVNisible Spectrometer using distilled water or buffer solution to obtain a 
baseline. 
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2.2 Apparatus 
2.2.1 pH measurement 
pH measurements were carried out using a Whatman PHA 230 bench pH 
meter, with a pH range of 0.00 to 14.00 and an accuracy of ± 0.01 pH. The 
instrument was calibrated with high-resolution buffer solutions at pH 4.000, 
7.000, and 10.000, ± 0.005, before use. 
2.2.2 Water purification 
Solutions were prepared using triply deionised water purified by a Maxima 
ultra pure water system (USF Elga Ltd.). 
2.2.3 Mass determination 
Weighing measurements were carried out on two balances depending on the 
weighing range needed: a Precisa 300 series electronic balance, weighing 
range from 41 g to 12400 g, and a Precisa 40SM-200A four decimal place 
electronic balance. 
2.2.4 Pipetting 
Pipetting was carried out using Gilson (supplied by Anachem), Eppendorf, and 
Elkay variable volume automatic pipettes. 
2.2.5 Flow Injection equipment 
A schematic diagram of the flow injection analysis (FIA) system is shown in 
Figure 1.10, Chapter 1. Following are the detailed description of the FIA 
system. 
74 
Chapter 2 - Instrumentation, materials and general procedures 
2.2.5.1 Peristaltic pump 
A Minipuls 2 peristaltic pump from Gilson was employed to propel the buffer 
through the flow injection system. The pump head consists of four rollers and 
is capable of propelling up to four channels of buffer via the PVC pump tubing 
(Anachem). Different flow rates could be achieved by either altering the 
rotational speed of the pump head or the diameter of the PVC pump tubing. 
2.2.5.2 Flow rate calculations 
The buffer reservoir was charged with deionised water and pumped through 
the system. The system effluent was collected for one minute in a pre-
weighed glass vial. After this time, the sample vial was re-weighed and the 
flow rate calculated using a density of 1.0 g/cm3 for water. 
2.2.5.3 Valves and tubing 
The injection valve used was a low pressure Omnifit manual sample injection 
valve. All switching valves used were from Omnifit. A 25 ~I injection loop was 
used. 0.8 mm ID Teflon transmission tubing (Omnifit) was used throughout. 
2.2.5.4 Column equipments 
The borosilicate columns used for packing the material were supplied by 
Omnifit. 
2.2.5.5 Flow cell 
The flow cell used in the LS-50 B fluorimeter was supplied by Hellma, and has 
a volume of 25 ~1. The flow cell used in the Hitachi F-4500 fluorimeter came 
with the instrument from Hitachi, and has a volume of 100~1. 
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2.3 Reagents 
Table 2.4. Reagents used and their respective suppliers 
REAGENT SUPPLIER 
Buffer reagents 
Citric acid. dihydrate Sigma 
Glycine Sigma 
Sodium carbonate, anhydrous Sigma 
Sodium hydrogen carbonate Fisher Scientific UK 
Sodium dihydrogen orthophosphate Fisher Scientific UK 
Sodium phosphate, dibasic anhydrous Sigma 
Trizma® Hydrochloride (Tris) Sigma 
Borax (sodium tetraborate) Sigma 
ImmunoPure Binding Buffer Pierce 
ImmunoPure IgG elution binding buffer Pierce 
Cyanoborohydride coupling buffer Sigma 
Triethanolamine Fisher Scientific UK 
Ethanolamine Fisher Scientific UK 
Bicine Sigma 
Fluorescent labels 
Alexa Fluor 647 labelling Kit Molecular Probes 
Alexa Fluor 660 labelling kit Molecular Probes 
CyTM 5 Bisfunctional dye Amersham Pharmacia 
Biotech UK 
Fluorescein Isothiocyanate (FITC) isomer I Sigma 
Dark Red Fluorescence Latex (640nm/660nm) Duke Scientific Corporation 
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Immobilization supports 
Aminopropyl controlled pore glass, 170 microns Sigma 
average diameter, 200-400 mesh 
UltraLink™ Biosupport Medium (50-80 microns) Pierce 
MagnaBind IIVI Amine Derivatized Beads Pierce 
UltraLink'M Immobilized Protein A Plus Pierce 
Proteins: antigens and antibodies 
y-globulins from bovine blood plasma Sigma 
(MWt. 170 kDa) 
Albumin, bovine Sigma 
Albumin, human Sigma 
Rabbit anti human albumin Sigma 
Treponem pallidum Newmarket Laboratories Ltd 
Anti treponem pallidum Newmarket Laboratories Ltd 
Lipoarabinomannan(LAM) Newmarket Laboratories Ltd 
Monoclonal anti LAM IgM Newmarket Laboratories Ltd 
Rabbit anti LAM IgM Newmarket Laboratories Ltd 
Other reagents 
Bicinchoninic Acid (BCA) Sigma 
Copper (11) sulfate pentahydrate 98 % Sigma 
N, N-dimethylformamide (DMF) Sigma 
Dimethyl sulphoxide (DMSO) Sigma 
Ethanolamine Fisher Scientific UK 
Glutaraldehyde grade 11 Sigma 
Urea Fisher Scientific UK 
Sodium Azide Sigma 
Dimethyl pimelimidate dihydrochloride (DMP) Sigma 
Ethylene glycol Fisher Scientific UK 
Coomassie protein assay reagent Pierce 
Tween 20 Sigma 
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Tween 80 Sigma 
(SIL WET) L-77 (80% w/w polyalkylene oxide Loveland Industries Ltd, 
modified heptamethyl-trisiloxane and 20% w/w/ Cambridge 
allyloxypolethylene glycol methyl ether) 
Bovine serum albumin (BSA) Sigma 
Casein (Hammarsten grade) (kind gift) Newmarket laboratories Ltd 
Fish skin gelatin (FSG) (kind gift) Newmarket Laboratories Ltd 
Byco (Hydrolysed gelatin) Newmarket Laboratories Ltd 
Type AlB gelatin Newmarket Laboratories Ltd 
2.4 General procedures 
2.4.1 General dye-protein conjugation procedure 
Dye-protein conjugation procedures varied depending on the reaction 
conjugation times, concentrations of dye and protein, conjugation buffer, stop 
solution, separation column/methods, etc. The following general procedure, 
according to Cy™5 manufacturer's guideline [136), using the example of y-
globulins-Cy5 conjugate, was applied in all cases with different optimum 
conditions. 
1. y-globulin was dissolved at 2.5 mg mrl in sodium carbonate-sodium 
bicarbonate buffer (0.1 M, pH 9.3). 
2. The y-globulin solution (1 ml) was added to a 1 mg Cy5 dye vial 
(Amersham). The vial was capped and mixed thoroughly. Care was taken 
to prevent foaming of the protein solution. 
3. The amount of Cy5 in a vial was 1 mg that was 1.025 Ilmole (the 
molecular weight of Cy5 is 975.15). 
4. The amount of y-globulins was 2.5 mg, which was 14.7 nanomoles (the 
molecular weight of y-globulins is 150 kDa.). 
5. The molar ratio of reactant was 69.7 (dye / protein). 
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6. The reaction mixture was incubated at room temperature in the dark for 
various lengths of time (0.5 to 2 hours) with additional mixing 
approximately every 10 minutes. 
7. Phosphate buffered saline 1.5 ml (pH 7.2, 0.1M, containing 0.1% sodium 
azide) (PBS) was added to the labelled antibody solution to make it up to 
2.5 ml. 
8. The above solution was added to a previously equilibrated PD-10 column 
(gel permeation chromatography column from Amersham), and the eluent 
discarded. 
9. When the sample had run into the column, the high molecular weight 
components, e.g. labelled antibody were eluted with 3.5 ml elution buffer 
(PBS). 
10. The final dye/protein ratio calculation is shown in the next section. 
11. The labelled antibody was kept in a brown screw capped bottle in the 
freezer until use. It was stable for at least 6 months. 
2.4.2 Calculation of the final dye/protein (D/P) ratio. 
A portion of the labelled protein solution was diluted so that the maximum 
absorbance was 0.5 to 1.5 AU. Final dye:protein (D:P) ratios were calculated 
using the Beer Lambert Law, which states that absorbance is related to the 
molar extinction coefficient E (in cm·1 M'\ concentration c (in M), and path 
length b (in cm) by A = Ecb. Absorbance values were taken for the conjugate 
at protein and dye wavelengths, which were corrected for dye absorbance at 
the protein wavelength and vice versa. Using the Beer Lambert Law, 
assuming the extinction coefficient E of protein and dye were not changed 
after the conjugation, the concentration of both dye and protein was 
calculated using the actual protein and dye absorbance values and their 
respective molar extinction coefficients. The dye concentration divided by the 
protein concentration gave a final dye:protein ratio. 
79 
Chapter 2 - Instrumentation, materials and general procedures 
2.4.3 Immobilization 
2.4.3.1 y-globulins-Cy5 conjugate immobilization to CPG beads 
The following method was adapted from [74]. 
1. 3 ml of 12% glutaraldehyde (w/v) was added to 0.5 g aminopropyl glass 
(Sigma), and the mixture was allowed to react for one hour on a roller bed 
at room temperature. 
2. The reaction mixture was washed carefully with cold distilled water. 
3. 2.35 ml of cold y-globulin-Cy5conjugate ([Cy5] = 5.88 I-IM = 5.74 I-Ig mrl, 
[y-globulin] = 3.07 I-IM = 460 I-Ig mrl) was added to the activated CPG, 
oxygen free nitrogen was bubbling through while mixing. 
4. The solution was kept at 4°C for 2.5 hours, with oxygen free nitrogen 
bubbling through briefly every 10 minutes for the first 30 minutes to 
remove oxygen. 
5. The y-globulin-Cy5 immobilized CPG was washed four times with cold 
distilled water, the supernatant was aspirated out each time for antibody 
concentration test by UV absorption. 
6. The finished product was stored in the fridge in tris-HCI buffer (0.1 M, pH 
6.0) to saturate the activated free spot on CPG. 
7. The supernatant excitation and emission was measured to determine the 
concentration of Cy5 and y-globulins. 
The Mechanism of the immobilization is shown in Figure 1.11. 
2.4.3.2 Immobilization of UltraLink™ Biosupport Medium 
Antibodies were immobilized onto UltraLink™ Biosupport Medium following 
manufacturer's instruction [90], briefly: 
1. Protein solution was added directly to the dry beads. 
2. The mixture was vortex mixed and gently rocked for one hour on a roller 
bed at room temperature. 
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3. The mixture was centrifuged at 1200 x g for 5 to 10 minutes or until beads 
are pelleted. 
4. Supernatant was removed by aspiration. 
5. Quenching solution was added to the beads. 
6. The mixture was vortex mixed and gently rocked for a further 2.5 .hours on 
a roller bed at room temperature. 
7. The mixture was centrifuged at 1200 x g for 5 to 10 minutes or until beads 
are pelleted. The supernatant was aspirated. 
8. The pelleted beads was resuspended and washed with PBS followed by 
centrifuge. 
9. Beads was washed one more time with PBS following step #8. 
10. Beads were washed with 1.0 M NaGI as in steps #8. 
11. Beads was washed with PBS twice as in steps #8. 
12. Beads were resuspended in final buffer of choice and store at 4°G. 
The immobilization reaction of antibody to UltraLink™ Biosupport Medium was 
shown in Figure 1.13. 
2.4.3.3 Immobilization of MagnaBind™ Amine Derivatized Beads 
The method of immobilizing y-globulins-Gy5 conjugates on MagnaBind™ 
Amine Derivatized Beads was adapted from Pierce's instruction for 
MagnaBind™ Amine Derivatized Beads [137]. 
1. 1 ml MagnaBind™ Amine Derivatized Beads was washed with 3 x 1 ml 
PBS (20 mM, 0.15 M NaGl, pH 7.5) with gentle agitation. It was then 
magnetically separated, and the supernatant was aspirated and discarded. 
2. The y-globulin-Gy5 conjugate solution was added to the mixture, and 0.4 
ml of 5 mM BS3 (cross linker solution must be prepared just prior to use) 
was added, making its final concentration 1 mM, the mixture was gently 
agitated and incubated for 45 minutes on a roller bed at room temperature. 
3. 100 III stop solution (1.0 M Tris buffer, pH 7.5) was added, and mixture 
was incubated for 10 minutes on a roller bed at room ternperature. 
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4. The mixture was separated by magnet, and the supernatant was aspirated 
for determination of y-globulin-Cy5 conjugate coupling efficiency. 
5. The immobilized beads were washed 3 times with 1 ml PBS buffer each 
and were stored in PBS at 4°C. 
The immobilization reaction of the MagnaBind™ Amine Derivatized Beads 
was shown in Figure 1.12. 
2.4.3.4 Immobilization of UltraLink™ Immobilized Protein A Plus 
The method of immobilizing UltraLink™ Immobilized Protein A Plus with anti-
treponum pal/idum (t. pal/idum) was adapted from Pierce's instruction for 
UltraLink ™ Immobilized Protein A Plus [90, 138). 
1. Anti treponema pal/idum IgGs was dialyzed against ImmunoPure Binding 
Buffer overnight. This buffer is claimed by the manufacturer to give the 
highest binding capacity. 
2. Protein A beads were washed three times with PBS buffer (0.1 M, pH 7.2), 
then allowed to settle, the supernatant was then aspirated and discarded. 
3. The beads were washed three times with ImmunoPure Binding buffer (A) 
to equilibrate (see step #1). 
4. The dialyzed anti t. pa/lidum was added to the above beads, incubated 
overnight on a roller bed at room temperature. 
5. The supernatant was aspirated for the coupling efficiency determination by 
BCA test. 
6. The beads were washed 5 times with 2 ml binding buffer. The supernatant 
was kept for coupling efficiency determination by BCA test, 
7. The beads were stored in PBS with 0.05% sodium azide at 4°C until use. 
The reaction of the protein A immobilization is shown in Figure 1.14. 
2.4.4 Determination of protein concentration 
2.4.4.1 Assay using absorbance at 280 nm 
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Protein concentration is commonly determined by assay using the absorbance 
of protein at 280 nm. According to Beer-Lambert law 
A=Ecb 
Where A is the absorption, E is the molar extinction coefficient (where for 
typical IgG it is 203000 M-1 cm-\ b is the light path of the sample cell (1 cm 
for a standard UV-Vis cell), and c is the molar concentration of the protein. So 
the protein concentration is determined as 
Protein concentration (M) = A2sol203000 
For IgM, as the molecular weight is about 1000 kDa, the molar extinction 
coefficient is different, the concentration in mg mr1 is conventionally 
determined as 
Concentration (M) = (A2sol1.2) x 10-6 
2.4.4.2 Assay using emission fluorescence at 335nm 
Proteins have intrinsic fluorescence emission at 335 nm when excited at 280 
nm. The emission fluorescence of very diluted (~g mr1) protein solution is 
directly proportional to its concentration. Using this property, a calibration 
curve could be graphed at low concentration of protein, and unknown 
concentration of protein sample could be interpolated from the calibration 
curve. 
2.4.4.3 Bicinchoninic acid (BCA) assay 
The BCA assay [139] was used to determine indirectly the amount of antibody 
immobilized on to beads. This method was used to determine the protein 
concentration in solution before and after the immobilization. It was adopted 
83 
Chapter 2 - Instrumentation, materials and general procedures 
because the use of Triton X-100 or other surfactant in the bead products may 
have interfered with any assay using absorbance at 280 nm, or when the 
concentration was too low for the assay at 280 nm. Both the standard protocol 
(370 C for 30 minutes, working range 20-200 I-Ig mr') and the enhanced 
protocol (600 C for 30 minutes, working range 5-250 I-Ig mr') were used 
according to the BCA reagent manufacturer's instruction [140]. 
2.4.4.4 Coomassie blue assay 
The Coomassie brilliant blue assay (141) was also used to determine 
microgram quantities of protein concentration for its convenience according to 
the kit manufacturer's instructions (142). The standard test tube protocol 
(working range 100-1500 I-Ig mr') was used. When determining low 
concentration of big protein such as IgM (M. Wt. 1000 kDa), BCA was used. 
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INTRODUCTION 
As mentioned in Section 1.7, flow injection analysis (FIA) is inherently easier 
to automate for immunoassay than other formats such as microtitre plates. 
Many works have been done and many reviews have been published [42, 49, 
53,72]. 
There are two principal labelling formats used in immunoassay, as described 
in Section 1.5.1. One can label the antigen, as in the case of a limited reagent 
(competitive) immunoassay (Section 1.5.1.2), or the antibody, as in the case 
of the two-site immunometric assay (Section 1.5.1.1). There are advantages 
and disadvantages in both formats as discussed in 1.5.1.3. The best format in 
practice may depend on the various reagents needed for development and on 
commercial pressures. 
Many flow injection immunoassays have used heterogeneous competitive 
assay format with an immunoreactor (a small immunoaffinity column) packed 
with material coated with protein A [67, 143], and most of all antibodies [48, 
72]. On the other hand, very few studies have been done on flow injection 
based sandwich assays. For commercial reasons, the two-site immunometric-
sandwich-assay format was chosen for this project. This chapter describes 
the investigation of the flow injection sandwich immunoassay. 
The proposed method involves trapping the target organism on antibody 
immobilised on beads, and then flowing through the fluorophore labelled 
antibody specific to the target organism to make a 'sandwich'. The 
fluorescence signal from the beads is then detected as they sedimenUpass in 
front of the light beam in a flow cell after unreacted labelled antibody has been 
washed away. This project employs the concept of the bead injection (BI) 
method developed by Ruzicka [62], but using a manual injection valve instead 
of the jet ring cell. Controlled pore glass (CPG) (Section 3.2) and UltraLink ™ 
Biosupport Medium (Section 3.3.) were investigated as bead phase. 
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Alternatively, the sandwich complex on the beads can be eluted and passed 
through the light beam, the fluorescence signal is then detected. This format 
employs the concept of sequential injection (SI) developed by Pollema and 
Ruzicka et al [52]. This format was used to investigate the immuno magnetic 
MagnaBind™ Amine Derivatized Beads (Section 3.4) and UltraLink™ 
Immobilized Protein A Plus (Section 3.5). 
3.1 Preliminary experiments 
Fluorescent dye conjugation procedures vary with proteins and dyes. The 
conjugation conditions need to be optimised accordingly. The conditions 
commonly optimised are the pH value of conjugation buffer, starting reactant 
ratio, and conjugation time. The general conjugation procedures and the 
separation of conjugates from free dyes were described in Section 2.4.1. The 
calculation of the final DIP ratio was described in Section 2.4.2. Commercial 
fluorescence dyes Cy5 (Amersham), Alexa Fluor 647 and 660 (Molecular 
Probes) and FITC isomer I (Sigma) were used in this project. so the 
conjugations were done using the manufacturers' procedures and optimum 
conditions. 
Immobilization of antibodies on to beads was another preliminary experiments 
for immunoassay development. Again the conditions which commonly need to 
be optimised are pH value of the immobilization buffer, immobilization time, 
starting reactant ratio of the antibody and the beads. The immobilization 
procedures in this project were described in Section 2.4.3 adopted from 
literature (for the CPG) and the beads manufacturer's instruction (PIERCE for 
UltraLink™ Biosupport Medium, MagnaBind™ Amine Derivatized Beads, and 
UltraLink™ Immobilized Protein A Plus). 
3.2 Investigation of controlled pore glass as carriers 
The possibility of controlled pore glass (CPG) as the beads carrier was 
studied. The y-globulins-Cy5 conjugates were immobilized on the beads 
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following the procedures described by Masoom [74]. The beads were injected 
into the FIA system using a manual injection valve, passed through the light 
beam, and stopped for a few seconds to detect the fluorescence intensity. 
The fluorescence of the immobilised y-globulin-Cy5 conjugate was 
investigated by stopped flow injection analysis with the PE LS-50B fluorimeter 
as the detector. The CPG suspension treated was gently shaken to make the 
suspension homogeneous. 25 III of the suspension were injected into the flow 
system, and the profile was monitored (Figure 3.1 a). The pump was stopped 
when the CPG suspension had moved to the flow cell, the CPG beads in the 
flow cell were scanned and the fluorescence spectrum was recorded (Figure 
3.1b). 
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Figure 3.1. Stopped flow time drive profile (a) and the corresponding static fluore-
scence spectrum of y-globulins-Cy5 conjugate immobilized on CPG (b) ("EX = 649 nm) 
It could be concluded that the methodology of detecting fluorescence of the 
labelled antibody immobilized on CPG was possible, although in this case, the 
intensity was very low, it is not necessary to quantify the experiment at this 
stage. One problem encountered was that the density of glass beads was 
high: they sediment so fast that it was very difficult to take repeatable sample 
from the bead suspension. In addition, the manual injection valve was easily 
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jammed by the beads. Beads with lower density needed to be investigated 
next. 
3.3 Investigation of UltraLink™ Biosupport Medium as carriers 
The possibility of UltraLink™ Biosupport Medium as bead phase was studied, 
as these polymer beads have a lower density than CPG, and therefore 
sediment slower. Another reason for choosing this medium was because of 
the simplicity of the reaction in binding proteins to the beads [76., 90]. This 
amine coupling reaction was shown in Figure 1.13. 
The coupling efficiency of antibody immobilized on to beads was determined 
by either indirectly examining the antibody left in the supernatant, or directly 
detecting the fluorescence on beads. As proteins emit fluorescence at ca 335 
nm when excited at 280 nm, the concentration of the un-reacted y-globulin in 
the supernatant can be determined with the aid of a calibration curve 
constructed using pure y-globulins (Section 2.4.4.1). Alternatively, 
bicinchoninic acid (BCA) assay or coomassie blue assay could also be used 
for protein concentration determination in the supernatant (Section 2.4.4.2 and 
2.4.4.3), especially when there is absorbance interference around 280 nm, or 
when the protein concentration is too low for direct absorbance measurement. 
These coupling efficiency experiments were conducted by two immobilization 
routes: immobilizing y-globulins-Cy5 conjugates on to beads; and immobilizing 
y-globulins on to the beads, followed by labelling of Cy5 onto the y-globulins. 
3.3.1 Immobilizing y-globulin-Cy5 conjugate on to UltraLink™ 
Biosupport Medium 
y-globulin-Cy5 conjugate was immobilised on to the UltraLink™ Biosupport 
Medium following the procedures described in Section 2.4.3.2. The 
conjugates in supernatant were studied by the fluorescence of y-globulin at 
335 nm (ex 280 nm) and Cy5 at 670 nm (ex 649 nm), and the conjugates 
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immobilised on the beads were studied by the fluorescence of Cy5 at 670 nm 
(ex 649 nm). 
There was neither fluorescence at 335 nm when excited at 280 nm in the 
supernatant nor at 670 nm when excited at 649 nm. This indicated near 100% 
immobilisation of y-globulin-Cy5. This was feasible as the functionality 
capacity of the beads was high (>10 Ilmol functional group for 40 mg beads) 
compared with the y-globulins that were added (6.6 nmol for 2.2 ml y-
globulins). 
The immobilized beads were injected in the normal flow system at the highest 
manageable concentration, and the eluent fluorescence was monitored using 
excitation wavelength at 649 nm and emission wavelength at 670 nm. When 
the peak appeared (Figure 3.2 a), the flow was stopped immediately, and the 
fluorescence spectrum was obtained using excitation wavelength 649 nm 
(Figure 3.2 b). 
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Figure 3.2. The stopped flow profile (a) and the corresponding fluorescence spectrum 
(b) of UltraLink ™ Biosupport Medium immobilized with y-globulins-Cy5 conjugates 
Figure 3.2 confirmed the fluorescence of Cy5 on the beads. However, 
fluorescence intensity of Cy5 on beads was very low. The reason could be 
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that the excitation light shone only on one side of the beads, and the y-
globulin-Cy5 conjugates immobilised on other sides could not be excited; also 
only fluorescence at right angle could be detected. 
B. Immobilizing y-globulin on to UltraLink™ Biosupport Medium, 
followed by conjugating Cy5 on to y-globulins 
The y-globulins were first immobilized on to the UltraLink™ Biosupport 
Medium using the same procedure as described in Section 2.4.3.2, with 
alterations in the amount of y-globulins and UltraLink™ Biosupport Medium 
used. Two different concentrations of y-globulins were studied. 
Again the supernatant showed no fluorescence at 335 nm when excited at 
280 nm. This suggested that the coupling efficiency was nearly 100%. Studies 
of the supernatant using SCA assay also showed no presence of protein in 
the supernatant, confirmed the near 100% coupling efficiency. 
Cy5 was then added to the UltraLink™ Biosupport MediulTl with y-globulins 
immobilized on it. The conjugation was made following the procedure 
instructed by the supplier of Cy5 [136]. The fluorescence of the UltraLink ™ 
Biosupport Medium complexes was determined both as y-globulins (ex 280 
nm), and Cy5 (ex 649 nm) (Figure 3.3). The protein peaks were detected first, 
the Cy5 peak was detected when the suspension had sediment a little, this 
was why the signal of Cy5 was a little smaller than y-globulins. 
The Cy5 labelled y-globulin immobilized beads were injected into the FIA 
system. Figure 3.4 (a) shows the time drive plot of Cy5 (ex 649 nm, em 670 
nm) and (b) shows the stopped flow fluorescence spectrum of Cy5 (Ex 649 
nm). 
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Figure 3.3. Fluorescence of y-globulins and the Cy5 immoblised on the UltraLink™ 
Biosupport Medium 
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Figure 3.4. Flow injection time drive plot (a) and the stopped flow fluorescence profile 
(b) of the y-globulins-Cy5 conjugate immobilized on UltraLink™ Biosupport Medium 
The above experiments showed that y-globulins/y-globulins-Cy5 conjugates 
were successfully immobilized onto UltraLink™ Biosupport Medium. Although 
it was difficult to quantify, the fluorescence of the bead complex made by 
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route A seemed to be less intense than by route B. This was probably 
because the fluorescence of Cy5 in route A was quenched by the steric 
hindrance of y-globulins-Cy5 conjugate. 
With the 50-80 flm sized beads, although the density was smaller than CPG, 
sedimentation still occurred too fast for stopped flow analysis. In addition, the 
beads easily jammed in the flow system, especially in the flow through cell, 
and it was very difficult to quantify the injected beads, as during the 
centrifugation and aspiration procedure, some beads were lost. Another 
concern of this format was that, even if these beads worked all right as carrier, 
washing off the excess labelled antibodies from the sandwich complex on the 
beads before injection was difficult because some beads would be lost in the 
process. 
To solve this problem, the idea of using magnetic beads as the carrier 
seemed more practical. Para-magnetic beads could be trapped in a magnetic 
field before flowing into the detector cell, and the excess labelled antibodies 
could be washed away from the complex. The magnetic field could then be 
turned off and the magnetic beads flow into the detector for fluorescence 
detection. 
3.4 Investigation of MagnaBind™ Amine Derivatised Beads as 
carriers 
A sequential immunoassay (SI lA) method has been described in [52] which 
utilizes immunomagnetic beads to investigate short-period antibody binding 
kinetics. In the competitive immunoassay, the immunomagnetic beads are 
retained with an electromagnet to form an open tube reactor. Thus the spent 
beads may be discharged after each analysis, eliminating the problems of 
instability of reaction surfaces and the time traditionally required for 
regeneration of the solid-phase. Several reports have appeared where 
biologically modified magnetic particles are used in conjunction with flow 
system [144, 145]. 
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The possibility of using magnetic beads as carrier for bead injection analysis 
had been studied. MagnaBind™ Amine Derivatised Beads (Pierce) (0.5-1.5 
microns in diameter) were used for the investigation. Similar to the 
immobilization of the UltraLink™ Biosupport Medium, the coupling efficiency 
experiments were conducted through two immobilization routes: immobilizing 
y-globulins-Cy5 conjugates on to beads; and immobilizing y-globulins on to the 
beads, followed by labelling of Cy5 onto the y-globulins. The immobilization of 
antibodies on to the magnetic beads was done following the manufacturer's 
instruction (Section 2.4.3.3). The immobilization mechanism was shown in 
Figure 1.12. 
For both routes, the coupling efficiency has been investigated by detecting the 
antibody left in the supernatant, and by detecting the fluorescence of the 
antibody immobilized on the magnetic beads. The coupling efficiency by 
subtracting the antibody in the supernatant suggested a near 100% coupling 
efficiency. This is highly feasible, as the magnetic beads used had much more 
amine loading capacity compared to the antibody added for the 
immobilisation. 
However, neither antibody (Aex = 280 nm, Aem = 335 nm) nor Cy5 (Aex = 649 
nm, Aom = 670 nm) could be detected on the beads. So where did the 
conjugates go? If the conjugates were immobilized on to the beads, why 
could not they be detected on the beads? One possible reason could be that 
the excitation light was absorbed or quenched by the dark magnetic beads, so 
neither y-globulins nor Cy5 on the beads could be excited. Another possible 
reason was that, even if y-globulins or Cy5 were excited, the fluorescence was 
absorbed by the dark surface of the beads, therefore could not be detected by 
the detector. For these reasons, MagnaBind™ Amine Derivatized Beads 
could not be used as bead injection carriers. However, it could be further 
investigated for the possibility as an open tubular micro column for flow 
injection fluoro-immuno-sandwich-assay with good potential. Unfortunately, 
this investigation was not pursued further, as beads injection was proposed in 
this project. This will be discussed in Section 7.2. 
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3.5 Investigation of UltraLink™ Immobilized Protein A Plus as 
carriers 
The techniques of binding the antibodies to a protein A support and then 
cross linking them has been used to orient IgGs on surfaces. By using 
immobilised protein A, antibodies can be sequestered via their Fc regions [77, 
146-148). Several researchers have improved the stability of these surfaces 
by cross-linking the IgG-protein A complex with dimethyl pimelemidate (DMP) 
[94, 95) and therefore improved the capacity of the antibodies. In this work, 
anti t. pallidum IgG was reacted on to UltraLink™ Immobilized Protein A plus 
beads (50-80 microns average diameter). DMP reagent was used to cross link 
the amine groups on protein A and IgG to improve the stability of the 
immobilized antibody (Figure 1.14). 
Labelled antibody was immobilised on to the beads in order to investigate the 
possibility of the protein A as the carriers following the procedure in Section 
4.1.2.1. Results showed that the fluorescence signal of the beads suspension 
was proportional to the amount of the labelled antibody, indicating the 
feasibility of the bead as carriers. 
Further sandwich experiments were conducted: anti t. pal/idum IgG was 
immobilized on to the protein A beads and excess active sites was blocked 
with y-globulin and cross linked with DMP; a series of amount of antigen 
(including blank) was added; then excess amount of labelled antibody was 
added. However, the final 'sandwich' beads revealed similar fluorescence 
regardless of the amount of antigen or blank added. Repeated sandwich 
experiments revealed similar results. These were probably because of the 
non-specific binding (NSB) of the labelled antibody onto the protein A beads. 
3.6 Conclusions and discussions 
Bead injection using manual injection valve was proved not competent for the 
proposed immunoassay, as the difficulties encountered mainly below: 
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• Size of beads was generally too big, causing jamming in the manual 
injection valve and the flow through cell. 
• Fast sedimentation of the carrier beads made the precision and 
reproducibility of the experiments poor. This was caused by the size of 
beads in the case of UltraLink™ Biosupport Medium and UltraLink™ 
Protein A plus, or the high density of the beads in the case of CPG and 
MagnaBind™ Amine derivatised beads. 
• In the case of MagnaBind™ Biosupport Medium, the fluorescence of the 
label was either quenched or absorbed by the beads, so the fluorescence 
could not be detected. 
• The NSB was realised to be a big problem causing the "sandwich" not to 
work properly, although at this stage it was not investigated further. 
It was concluded that bead injection methods were not competent for immuno-
sandwich-assay using a simple FIA system with manual injection valve, 
although the magnetic beads format could be further investigated as an open 
tubular micro column format (this will be discussed in Section 7.2) if time and 
facility permit. 
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As mentioned in Chapter 3, flow injection analysis (FIA) allows automation of 
an analysis with high throughput. This chapter describes the development of 
FIA immunoassays using micro columns, packed with immobilised antibodies 
(see Figure 1.10). Three systems have been investigated: 
• Anti treponema pal/idum IgGs immobilized on UltraLink™ Immobilised 
Protein A beads. 
• Anti treponema pal/idum IgGs immobilized on UltraLink™ Biosupport 
Medium. 
• Anti human albumin immobilized on UltraLink™ Biosupport Medium. 
4.1 Anti treponema pal/idum IgGs immobilized on protein A 
UltraLink™ Immobilised Protein A Plus was chosen as the immunosorbent for 
the reasons discussed in Section 3.5. This section describes two methods for 
immobilizing antibodies on to protein A that were used in the micro columns: 
protein A beads were packed into a micro column first, then the anti t. 
pallidum IgGs were added; anti t. pal/idum IgGs were immobilized and cross 
linked with protein A beads, then packed into a micro column. The 
immobilisation reaction of antibodies to protein A beads with DMP cross 
linking was shown in Figure 1.14. 
4.1.1 Anti t. pallidum IgGs immobilized on to protein A beads before 
packing in a micro column 
The materials used in this experiments were: 
UltraLink™ Immobilized Protein A Plus (Pierce) 
Binding buffer 1: 0.1 M PBS, pH 7.2, 0.1% Tween 20,0.1 % BSA 
Binding buffer 2: 
Elution buffer: 
50 mM PBS, pH 7.2, 0.1% Tween 20, 0.1 % BSA 
50 mM sodium citrate-sodium hydroxide, pH 2.0 
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Cross-linking reagents: 
Capture antibody: 
Antigen: 
Labelled antibody: 
y-globulins: 
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50 mM dimethyl pimelimidate (DMP 2HCI), pH 7.2, 
in 0.2M triethanolamine, freshly made up 
anti t. pal/idum IgGs (Newmarket Laboratories Ltd.) 
t. pal/idum (Newmarket Laboratories Ltd.) 
anti t. pal/idum IgGs- Alexa Fluor 647 
4.0 mg mr1 in 0.1 M PBS 
The following procedure was derived from the method of De. Ruiter [97], and 
Schneider [94]. The protein A immunoaffinity micro columns were prepared 
using following method: 
1. Protein A beads were packed into a 20 mm length 3.0 mm diameter micro 
bore column. A column was packed by mounting the column vertically, and 
connecting the bottom of the column to a peristaltic pump that allowed 
suction of loaded protein A beads through the top end of the column 
downwards. 
2. The beads in the column were washed with 20 ml of binding buffer 1, using 
a peristaltic pump at a flow rate of 0.3 ml/min. 
3. 4.0 mg of anti t. pal/idum IgGs was dissolved in 1 ml of 0.1 M PBS and 
pumped slowly through the column for 1 hour. 
4. The column was washed with excess (10 ml) of binding buffer 1. The 
eluent was collected in 1 ml fractions, and tested for coupling efficiency 
using the Coomassie Blue assay. 
5. 4.0 mg of non-specific y-globulins in 1 ml of 0.1 M PBS were pumped 
slowly through the column for 1 hour. This step was intended to block any 
active protein A sites left unused by the specific anti t. pal/idum IgGs. 
6. Step 4 was repeated to determine any un bound y-globulins, 
7. The column was washed with 10 ml of 0.2 M triethanolamine (pH 7.2). This 
step was to block any active sites that were left on the UltraLink™ beads. 
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8. The IgG was covalently bound to the protein A by rinsing the column with 
20 ml (0.3 ml/min) of 50 mM dimethyl pimelimidate (DMP 2HCI) (freshly 
made up in 0.2 M triethanolamine with the pH readjusted to 7.2) [94]. 
9. The column was rinsed with 10 ml of 50 mM ethanolamine (pH 7.2) to 
further block any active site left on the protein A beads, and finally washed 
with 10 ml of binding buffer 1. 
10. The column was rinsed three times with 20 ml of 0.1 M sodium citrate 
buffer (pH 2.0) and then tested for the presence of any antibody in the 
solution using Coomassie Blue methods. 
The antibody binding efficiency experiment was carried out by subtracting the 
antibody determined by the UV spectrometry in the 2.9 ml eluent and the first 
ten fractions of 1 ml eluent by Coomassie Blue assay. It was concluded that 
3.24 mg out of 4.05 mg anti t. pallidum IgGs were immobilized onto the 
column. Although the capacity of the protein A material packed in this column 
was 8.1 mg, the rest of the active sites were theoretically occupied by the non-
specific y-globulin. Any active site on the protein A beads should have been 
blocked by triethanolamine and ethanolamine. 
Binding buffer 
Elution buffer 
Pump 
Figure 4.1. Two channel FIA system 
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After the immobilization and cross linking steps, the micro column was 
incorporated into the FIA system. The Perkin Elmer LS-50B fluorimeter was 
used as the detector. Then the flow injection immuno-sandwich assay was 
carried out using the following procedure. This FIA system has two channels 
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controlled by a switching valve for binding buffer and elution buffer. This is 
illustrated in Figure 4.1. 
Flow injection immuno-sandwich-assay (FilA) was carried out. The injection 
loop was 25 Ill. The system was run at room temperature with flow rate of 0.2 
ml/min using binding buffer 2, and 50 mM sodium citrate buffer (pH 2.0) as 
eluents. T. pal/idum antigen was injected, and then elution was carried out 
with 4 ml of binding buffer 2. Alexa Fluor 647 labelled anti t. pal/idum IgGs 
(labelled antibodies or indicating antibodies) was injected, followed by 4 ml of 
binding buffer 2. 4 ml of elution buffer was run through, followed by 4 ml of 
binding buffer 2 for equilibration. 
The amount of the antigen/antibody used was based on the following 
calculations. The amount of capture antibody and labelled antibody were three 
times in excess over the antigen concentration as there were only limited 
amount of antibodies available. 
The concentration of t. pal/idum antigen injected was 5 Ilg mr1 = 0.294 IlM 
(molecular weight of t. pal/idum is 17000. g/mol), so the labelled antibody 
concentration injected need to be at least 0.294 IlM x 3 = 0.706IlM. 
A profile of such an FIA assay is shown in Figure 4.2. Peak 1 was the excess 
labelled antibody appeared after the injection of the labelled antibody with 
binding buffer 2, it should decrease in size as the analyte antigen 
concentration increases; peak 2 was the sandwich complex peak appeared 
during the elution period, it was expected to be proportional to the amount of 
analyte injected; and peak 3 was an interference peak, it appeared when the 
elution buffer was switched back to binding buffer. This peak was also 
observed by other researchers in the same group, it may be due to the 
labelled antibody which was entrapped in part of the column which was then 
released when the pressure was changed due to the elution buffer changing 
back to binding buffer to re-equilibrate the column. This peak could not be 
eliminated despite various efforts, including ensuring that the two buffer 
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channels were at the same pressure, using the same channel for both buffers, 
or stopping the pump when switching them, etc. 
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Figure 4.2. A standard flow injection immuno-sandwich assay graph. 
4.1.1.2 Results and discussion 
A series of immuno-sandwich assays were investigated. However, this 
method did not work as expected. When the amount of analyte injected 
increased, the fluorescence signal increased randomly. The suspected cause 
would firstly be the immobilised antibody not functioning properly, or perhaps 
it did not bind properly on to the protein A beads, and being eluted quickly 
during the first few runs. An attempt to solve this problem would be to 
immobilize and cross link the antibody onto the protein A beads in a tube, then 
pack it into a column. This is described in the next section. 
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In addition, high backpressure of the micro column was experienced. The 25 
Ilm polyethylene frit, which was the suspected cause, was changed to a 2 Ilm 
stainless steel frit. 
4.1.2 Anti t. pal/idum IgGs immobilized and cross linked onto protein A 
beads and then packed into a micro column. 
The following procedure was adopted with modification from the method of 
Haginaka [149], therefore binding buffer was changed to 0.1 M borate buffer 
pH 8.2. 
4.1.2.1 Procedures 
The materials used in the experiments were 
Beads: 
Immobilization buffer: 
Ethanolamine: 
Triethanolamine: 
Cross linking reagents: 
Binding buffer: 
Elution buffer: 
Capture antibody: 
Antigen: 
Labelled antibody: 
UltraLink ™ Immobilized Protein A Plus 
borate buffer, 0.1 M, pH 8.2 
50 mM, pH 8.2 
0.2 M, pH 8.2 
DMP (dimethyl pimelidate dihydrochloride), made 
up freshly in 0.2 M triethanolamine with pH 
readjusted to pH 8.2 
0.1 M borate buffer, pH 8.2, 0.1 % BSA, 0.1 % 
Tween 20 
0.1 M citrate, pH 2.0 
anti t. pal/idum IgGs 
t. pal/idum 
anti t. pal/idum IgG-Alexa Fluor 647 
Protein A immuno-affinity columns were prepared using the following 
procedures. Two preparations were studied, with and without the further 
saturation of the active sites with y-globulin as described in step 3: 
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1. A 0.8 ml protein A beads suspension was mixed with 3.67 ml of 3.27mg 
mr1 anti t. pal/idum IgGs in immobilization buffer, pH 8.2 for 30 minutes at 
room temperature with gentle rocking. 
2. The protein A beads were washed 3 times with excess borate buffer for 15 
minutes, and then washed with 0.2 M triethanolamine (pH 8.2) for 15 
minutes. 
3. The protein A beads were divided into two aliquots, one was treated 
immediately as described in step 6. 
4. The second aliquot of beads was mixed with 1.83 ml of 3.27 mg mr1 y-
globulin at pH 8.2 for 30 minutes at room temperature with gentle rocking. 
This step was intended to block any active protein A sites left unoccupied 
by the specific anti t. pal/idum IgGs. 
5. Step 2 was repeated. 
6. The centrifuged pellet was resuspended in 20 volumes of 50 mM dimethyl 
pimelimidate dihydrochloride freshly made up in 0.2 M triethanolamine with 
the pH readjusted to pH 8.2. The mixture was agitated gently for 45 
minutes at room temperature. 
7. The reaction was stopped by centrifuging the beads (500 x g for 1 min) 
and resuspending in an equal volume of 50 mM ethanolamine, pH 8.2 (the 
same molarity as the DMP solution) with gentle rocking for 5 minutes. 
8. The beads were washed three times with immobilization buffer. 
9. The beads were packed into two 20 mm x 3 mm micro column separately. 
Excess beads were stored in the immobilization buffer with 0.02% sodium 
azide at 4°C for later use. 
The two aliquots of protein A-antibody beads columns were compared by 
following the flow injection immuno-sandwich-assay procedures described in 
Section 4.1.1. The amount of the antigen/antibody used was also based on 
the calculations described in Section 4.1.1, with capture antibody and labelled 
antibody at least three times in excess. Different elution buffers have been 
tried, in case the binding between the antigen and antibody on the column 
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were too strong for the citrate buffer (pH 2.0) to break, e.g. citrate buffer pH 
2.0, 2.5, 3.0, 3.5, 4.0, glycine pH 2.5, urea 4 M, 6 M, 8 M. 
4.1.2.2 Results and discussions 
Both of these columns showed poor results. The binding specificity test with t. 
palJidum-Alexa Fluor 647 conjugate showed that less than 20% antigen was 
bound and eluted from the column (data not shown), which was too low. 
The possible reasons for these poor results might be that anti t. palJidum IgG 
lost its activity when cross-linked by DMP after immobilization on to the 
protein A beads, or the affinity between the antibody and antigen was not 
strong enough. 
To investigate the first possibility, that DMP cross-linking caused loss of the 
antibody activity, the next experiment was to simply immobilize anti 
treponema palJidum IgGs to UltraLink™ Biosupport Medium directly. In this 
way, although the orientation of the antibodies provided by protein A could not 
be obtained, the possibility of reduction of the antibody activity caused by 
DMP cross-linking is eliminated. 
4.2 Anti t. pal/idum IgGs immobilized UltraLink™ Biosupport 
Medium packed in a micro column 
The immobilization mechanism and the procedure were described in Section 
1.7.3.2.3 and Section 2.4.3.2, respectively. The reaction scheme was shown 
in Figure 1.13. 
4.2.1 Procedures 
The materials used are: 
UltraLink ™ Biosupport Medium 
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Binding buffer: 
Elution buffer: 
Capture antibody: 
Antigen: 
Labelled antibody: 
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0.1 M PBS, pH 7.2 
0.1 M PBS, pH 7.2, 0.1% Tween 20, 0.1% BSA 
0.1 M citrate, pH 2.0 
anti t. pal/idum IgGs 
t. pal/idum 
anti t. pal/idum IgG- Alexa Fluor 647 
The IgG immobilization onto the UltraLink™ Biosupport Medium was carried 
out following the manufacturer's instruction (see Section 2.4.3.2). After 
immobilization, the anti t. pal/idum IgGs immobilized Ultralink™ Biosupport 
Medium were packed into a 6.6 mm (id) x 2.5 mm (length) adjustable micro 
column. The column was investigated by following the flow injection immuno-
sandwich-assay procedure in Section 4.1.1.1. The amounts of antigen and 
antibody used were based on the calculations in Section 4.1.1.1 as well, with 
capture antibody and labelled antibody at least three times in excess of the 
antigen. 
4.2.2 Results and discussions 
These columns did not work either. The preliminary study showed they would 
not bind antibody (anti t. pal/idum IgGs), which was good, nor antigen (t. 
pal/idum) , which was unexpected (data not shown). If the anti t. pal/idum IgGs 
were successfully bound on the column, as found after the immobilization and 
packing, it should have bound its own specific t. pal/idum, if the affinity 
between the antibody and antigen was strong enough. 
The possible reasons for these results might be that the anti t. pallidum IgGs 
lost its activity when immobilized on to the UltraLink™ Biosupport medium, as 
well as on the UltraLink™ Immobilized Protein A Plus as stated in Section 
4.1.2.2, or the affinity between the antibody and antigen was not strong 
enough. 
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The first possibility was very unlikely. In order to study the second possibility, 
commercially available rabbit anti human albumin and human albumin were 
tried as the antibody and antigen. 
4.3 Anti human albumin immobilized UltraLink™ Biosupport 
Medium packed in micro column 
4.3.1 Procedures 
The materials used are listed below: 
Beads: 
Immobilization buffer: 
Binding buffer 
Elution buffer1: 
Elution buffer2: 
Capture antibody: 
Antigen: 
Labelled antibody: 
UltraLink ™ Biosupport Medium. 
PBS, 0.1M, pH 7.2 
PBS, 0.1M, pH 7.2, (no BSA added as the antigen 
is human albumin) 
citrate 0.1 M, pH 2.0 
0.1 M glycine hydrochloride in 50% (v/v) ethylene 
glycol pH 1.75 
rabbit anti human albumin IgGs 
human albumin 
anti human albumin IgGs-Alexa Fluor 647 
The manufacturer's instruction for IgG immobilization on the UltraLink™ 
Biosupport Medium was followed as described in Section 2.4.3.2. The anti 
human albumin immobilized UltraLink™ Biosupport Medium was packed into 
6.6 mm (id) x 2.5 mm (length) adjustable micro column, the immuno-
sandwich-assay was carried out following the procedures described in Section 
4.1.1.1. 
Preliminary experiments showed that, both antibody and antigen bound to the 
column, but the citrate pH 2.0 elution buffer could not elute them off. As 
antibody and antigen were not as precious in this case as the anti treponema 
pal/idum IgGs and its antigen, an acidic solution (0.1 M glycine hydrochloride 
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in 50% (v/v) ethylene glycol pH 1.75) [150] was applied. This solution was 
said to be strong enough to break the antibody-antigen complex but with 
some risk of deactivating the function of the antibody. Citrate and glycine 
buffer at pH 2.0 may be not strong enough to break antibody-antigen complex, 
although it is gentle enough to preserve the antibody. 
4.3.2 Results and discussions 
The flow injection immuno-sandwich assay worked with this acidic elution 
buffer. The FIA immuno-sandwich assay was done in two ways: 
On-line incubation, the injection sequence in this format was: 
1. Antigen was injected in binding buffer to form complexes with the 
immobilized antibody in the column. 
2. Excess amount of labelled antibody was then injected in binding buffer to 
form 'sandwich' complexes, and the excess labelled antibody was washed 
off. 
3. The binding buffer was switched to elution buffer and the sandwich 
complex was broken up and the antigen and the labelled antibody were 
eluted off, the labelled antibody that should be proportional to the antigen 
was detected. 
4. The elution buffer was switched back to binding buffer for equilibration of 
the column ready for the next run. 
Pre-incubation, the injection sequence in this format was 
1. Labelled antibody was mixed with analyte antigen, incubated for 5 minutes 
to allow to form complexes; 
2. The antigen-labelled antibody complex mixture made above was then 
injected into the FIA system in binding buffer to form 'sandwich' complexes 
with the immobilized antibody in the column, and any excess labelled 
antibody was washed off; 
3. The binding buffer was switched to elution buffer and the sandwich 
complex was broken up and the antigen and the labelled antibody were 
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eluted off, the labelled antibody which should be proportional to the antigen 
was detected; 
4. The elution buffer was switched back to binding buffer for equilibration of 
the column ready for the next run. 
When the column was integrated with the Perkin Elmer LS-50B detector, the 
rough calibration graph for the on-line incubation and pre-incubation are 
shown in Figure 4.3: 
200 
~ 180 ~ 
~ 160 
III 140 c 
.s 120 c 
Cl) 100 u 
c 80 Cl) 
U 
III 60 Cl) 
I!! 40 0 
::::I 20 LL. 
0 
0.01 
150 
100 
50· 
0 
0 
0.1 1 
[Albumin] (mg/ml) 
• On-line Incubation 
• Pre-Incubation 
y = 24.001 Ln(x) + 133.9 
R2 = 0.9973 
y = 23.93Ln(x) + 105.96 
R2 = 0.9963 
10 
Figure 4.3. Comparison of the rough calibration curve of on-line and pre-incubation 
The rough calibration curve obtained through PE LS-50B was logarithmically 
linear at the range of 0.05 - 2 mg mr1 for both on-line incubation and pre-
incubation methods. 
When the column was integrated with Hitachi F4500 detector that is about ten 
times more sensitive than the Perkin Elmer LS-50B, the rough calibration data 
are shown in Table 4.1. As can be seen, in the pre-incubation method, there is 
a big gap between the fluorescence intensity of 5 Ilg mr1 and the blank 
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(highlighted), that might indicate lower limit of detection, so a finer calibration 
curve was made. 
Table 4.1. Data for the fine calibration curve 
[Albumin] On-line Pre-incubation 
Img mr1 Incubation 
0 ,155.0 52)15 
0.005 ;1512 i102:3 
0.05 185.7 111.7 
0.5 256.8 125.5 
1 402.5 165.1 
2 518.2 270.2 
A calibration curve was made for the pre-incubation method in a lower 
concentration range using Hitachi F4500 fluorimeter. The graph is shown in 
Figure 4.4. 
This fine calibration curve obtained was logarithmically linear at a broad range 
of 1.0 Ilg mrl-500 Ilg mrl. The limit of detection by the definition of 3 times 
standard deviations ofy-residues [151) was determined at 1.79 1lg mrl. 
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Figure 4.4. A fine calibration curve of human albumin by pre-incubation method on the 
anti human albumin column by Hitachi F 4500 fluorimeter 
4.4 Conclusions and discussions 
The above results showed that using the acidic elution buffer, the assay 
worked for human albumin and anti human albumin. The limit of detection of 
human albumin using the pre-incubation immuno-sandwich FIA assay was 
roughly at - 1.79 /1g mr' using the definition of 3 times of standard deviations 
of y-residues, and a broad logarithm linear range of 1 /1g mr'-500 g mr' (58.8 
nM-29.4 /1M). These results showed that the pre-incubation way of immuno-
sandwich FIA assay was a very promising way for high throughput diagnosing 
purpose. This method needs further optimisations and validation for its 
precision, repeatability, reproducibility and limit of detection. It could also work 
for the t. pal/idum or even TB diagnosis system with fine-tuning and 
optimisation. However, for commercial reason, the project was subsequently 
redirected into the area of immunochromatography. 
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CHAPTER 5 
Experimental: Investigation 
of Immunochromatography 
Assay for Human Albumin 
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INTRODUCTION 
As introduced in Section 1.8 and 1.9, research and development in 
immunochromatography (also called lateral flow) is very active. The 
commonly used microspheres are dyed (coloured, but non-fluorescent) for 
direct visualisation. There are some diagnostic companies developing lateral 
flow assay for preliminary diagnosis of tuberculosis (TB) as mentioned in 
Section 1.9.2.6, most of them are using dyed microspheres, and detect TB 
antibodies instead of antigen. Antigens appear in the serum in the earlier 
stage of infection, while antibodies develop after the infection is established. 
Obviously, detection of antigen with high sensitivity would be more 
advantageous than the detection of antibody for earlier diagnosis. 
Chapter 5 describes the investigation of the imunochromatography method for 
commercially available human albumin as the preliminary experiment for the 
TB diagnosis. Alexa Fluor 647 was used as the fluorescence label for the 
detector antibody: anti human albumin IgG-Alexa Fluor 647 conjugate. Alexa 
Fluor 647 had been used for the development of the FIA immunoassay 
described in Chapter 3 and 4, thus was chosen for this preliminary 
experiment. 
A couple of preliminary tests had been carried out as follows and shown in the 
following sections: 
1. Characteristic of the portable fluorimeter for testing the lateral flow strips. 
2. Development of the immunochromatography method for human albumin 
using rabbit anti human albumin as the capture antibody and for the 
detector antibody (conjugate), with Alexa Fluor 647 as the fluorescent 
label. 
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5.1 Immunochromatography procedures 
Basically, fluorescence labelled detector antibody (conjugate) was applied on 
the sample pad adjacent to the cellulose nitrate membrane, the strip was then 
dipped in analyte antigen in solution. The analyte antigen and the 
fluorescence conjugate was then forming fluorescence complex, and the 
fluorescence complex migrated up through the membrane by capillary flow 
forces, forming fluorescent 'sandwich' with the capture antibody deposited as 
a thin line on the membrane previously. The excess conjugate would then 
pass through and was absorbed into the absorbance pad adjacent on the 
other end of the membrane (see Figure 5.1). The strip was then inserted in 
the measuring compartment of the portable fluorimeter. The measuring 
compartment was then moved down passing through the laser light beam, a 
fluorescent profile was collected by PC through a data logger interface, 
showing the fluorescent sandwich line as a peak like a chromatogram. 
The test strips were made with a deposited capture antibody line and cut into 
size at Newmarket Laboratories Ltd. All the information about the test strips 
was provided by the company. The strips were sent without plastic housing as 
at the development stage. The format of the strips is shown in Figure 5.1. The 
antibody-Alexa Fluor 647 conjugate was made following the manufacturer's 
instructions [152]. 
1E-16mm~1 E 21 mm ~ 1 E 22 mm ~ 1 t 
/1 
III c::::::> I I I I I 4mm 
l' l' l' l' , i Dip in Conjugate S.mple S.mple Control Membrane S.mple 
.j, Flow lone Line ~ .j, V • ~ .j, .j, n . I 
i i 
S.mple P.d Absorbent P.d 
Figure 5.1. Strip format 
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5.2 Characteristics of the portable fluorimeter for testing of lateral flow 
strips 
Among the Hitachi, PE LS-50B, and the portable fluorimeter, initial trials 
showed that the portable fluorimeter gave the best repeatable and most 
sensitive signals. In addition, the portable fluorimeter was able to scan the 
strip, while the Hitachi F-4500 and the Perkin Elmer LS-50B were not able to 
do so. A fluorescence profile made by scanning a strip was more 
distinguishable than a static fluorescence reading. So the following 
experiments were all done using the portable fluorimeter (details of the 
fluorimeter was described in Section 2.1.3). 
As mentioned in Section 2.1.3, the cell holder of the portable fluorimeter was 
designed so that it can move up and down in the laser beam for the scanning 
of the test strips. This section describes investigations of the testing ability, 
sensitivity and the spatial resolution of the portable fluorimeter. 
5.2.1 Testing ability of the portable fluorimeter 
Blank strips (with no capture antibodies deposited) were used for this 
purpose. Alexa Fluor 647 labelled antibodies (conjugate) was applied as a line 
directly onto the strip using an electrophoresis applicator. The conjugate was 
applied none, once, twice, three times at different places well apart on four 
separate strips, respectively. The strips were then scanned in the portable 
fluorimeter. The profiles and the corresponding test strips scanned are shown 
in Figure 5.2 together with the diagram of the corresponding strips. The black 
lines on the strip diagrams represent the conjugate lines applied. Note that the 
peak heights were different, as the electrophoresis applicator was not meant 
for quantitative use. 
The scanning rate of the portable fluorimeter was 0.45 mm second-1 (19mm 
per 42 second) fixed as at the development stage. It demonstrated that the 
portable fluorimeter was capable of scanning the strips and showed a 
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reasonable profile with peaks representing the conjugate complex on the 
strips. 
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Figure 5.2. Using the portable fluorimeter to identifiy fluorescence lines on strip 
5.2.2 Spatial resolution of the fluorimeter on strip 
In order to have a rough guide for the sample and control deposition, the 
spatial resolution was estimated. Basically, Alexa Fluor 647-anti human 
albumin conjugate was applied directly onto a blank strip three times at a 
distance of 3 mm and 1 mm apart respectively (trial and error) using a sample 
applicator. The conjugate line on the membrane was about 1.5 mm wide and 
the fluorimeter laser spot diameter was around 1.5 mm. The membrane was 
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scanned in the fluorimeter. The profile and diagram of the strip are shown in 
Figure 5.3. 
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Figure 5.3. Spatial resolution of the portable fluorimeter on strip 
Conclusion: 
According to Figure 5.3 and taking into account of the laser spot size (1.5 to 2 
mm in diameter), the spatial resolution was estimated at least 2 mm. This 
means that when two fluorescence lines on the strip were applied at least 2 
mm apart on the strip membrane, they could be resolved as two peaks. 
5.2.3 Choosing filters for the Alexa Fluor 647 
As the Stokes' shift of the fluorescence of Alexa Fluor 647 was small (18 nm, 
excitation wavelength was 650 nm, emission wavelength was 668 nm), 
appropriate optical filter(s) need to be considered to fit in between the strip 
holder and the PMT detector. 
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In order to do these, a long edge pass filter at 660 nm, a Schott RG 665 nm 
cut-off filter (Section 2.1 .3.4), and a combination of these two have been 
examined to measure the appropriate concentration of Alexa Fluor 647 at 650 
nm excitation wavelength using the LS-50B fluorimeter. The fluorescence 
plots are shown in Figure 5.4 (The laser 635 nm light source's profile is 
imagined). 
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Figure 5.4 Comparison of fluorescence spectrum of Alexa Fluor 647 with d ifferent 
filters in LS-50B. 
Conclusions: 
From Figure 5.4, it can be seen that 
1. When there was not filter fitted , the emission wavelength (668 nm) was so 
close to the excitation wavelength (650 nm), that the signal picked up by 
the portable fluorimeter PMT tube would have very high background due to 
the excitation scattered light (Rayleigh scattering ). 
2. With only a Schott RG 665 nm cut-off filter, the fluorescence emission 
wavelength (672 nm) was far enough to stay away from the Rayleigh 
scattering light. 
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3. With only a long edge band filter at COWL 660 nm, the fluorescence 
emission wavelength (674 nm) was also far enough to stay away from the 
Rayleigh scattering light. 
4. The combination of the Schott RG 665 nm cut-off filter and the long edge 
pass filter 660 nm filter was chosen for the portable fluorimeter on the safe 
side, further away from the laser 635 excitation light wavelength, as the 
emission wavelength was optimised at 676nm, and yet the intensity is 
about 3 quarters of using only a Schott RG cut-off or edge-pass filter 
alone. In addition, it was found that the combination of the filters made the 
signal much more stable than any of the filter alone. This combination of 
the filters was also chosen for the TB diagnosis immunochromatography 
method development later on (Section 6.2.3). 
5.3 Immunochromatography assay development using Human 
albumin, rabbit anti human albumin 
As the FIA immunoassay for human albumin, using rabbit anti human albumin 
labelled with Alexa Fluor 647, works well with the FIA system (see Chapter 4), 
this antigen was studied first with the lateral flow system. 
5.3.1 Materials 
A. Reagents 
The antibody used was rabbit anti human albumin IgGs. The antigen used 
was human albumin (96-99%). The fluorescence label was Alexa Fluor 647. 
The Alexa Fluor 647 and the anti human albumin were conjugated according 
to the manufacturer's instructions. The conjugate DIP ratio was 1.54. The total 
protein (including anti human albumin IgGs) concentration in the original 
conjugate was 40.5 f.lM (6.9 mg ml"), and the Alexa Fluor 647 was 62.5 f.lM. 
1:8 dilution of the conjugate were used in the following experiments unless 
otherwise stated. 
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B. Strips 
The strips used in the following experiment incorporated a 20 x 4mm sized 
(length x width) nitro cellulose membrane on a Mylar® backing, mounted on 
adhesive card. The conjugate pad was glass fibre, and the absorbent as well 
as the above material were all from Millipore. The membranes used were 
HF240, HF135, HF120, HF90, etc, which means, for example, the flow rate of 
HF240 (Hi-Flow Plus 240) membrane has a nominal flow rate of 240 seconds 
along 4 centimetres of membrane. HF135 membrane has a nominal flow rate 
of 135 seconds along 4 centimetres of membrane, and so on. The estimated 
pore sizes for the membranes (obtained from the correspondence with 
Millipore) are shown in Table 5.1. The Porex membrane (Porex Corperation) 
has a 4 cm migration time of 75 seconds and a reported pore size of 8 micron 
[153]. 
Table 5.1 Estimated pore sizes of different Millipore nitrocellulose membrane. 
Membrane Estimated pore size (Ilm) 
HF240 3-5 
HF180 5-8 
HF135 8 - 12 
HF120 10 - 14 
HF90 12 - 15 
HF75 13 - 17 
HF65 15 - 20 
The membranes were directly cast onto clear polyester (Mylar®). The direct 
casting process bonds the membrane to the backing without the use of 
adhesives that can migrate into the membrane substrate and interfere with 
assay performance. In addition, the membranes had a smooth surface with no 
powder on their surfaces that can interfere with the assay [154]. 
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The strips were assembled, deposited with capture antibodies and cut to size 
by the Newmarket Laboratories and posted to the author's lab. They were 
then stored in a desiccator at room temperature for use. 
5.3.2 Strip development procedures 
1. 10 III rabbit anti human albumin-Alexa Fluor 647 conjugate (protein 
concentration at 0.69 mg mrl, D/P=1.54) were applied on the conjugate 
pad of the strips. 
2. The strips were inserted in the 100 III of a series of human albumin (in 20 
mM bicarbonate buffer, pH 8.3, 150 mM NaCI, and 0.5% Tween 20) in 
small tubes. The solution started to migrate up the strips. 
3. The strips were left in the antigen until all the blue dye migrated to the 
absorbent pad. It took about 60 minutes (unless otherwise stated) for the 
complete migration on nitrocellulose membrane. 
4. The absorbent pad and the conjugate pad were cut off, the membrane was 
then stuck on a strip holder which is the same size and shape of a cell. 
5. The strip holder was insert into the prototype cell holder. 
6. The membrane was scanned from bottom to top. A profile was recorded 
with the fluorescent sandwich complex band shown as a peak (Figure 5.5). 
5.3.3 Study of strip development time 
The immunochromatography assay investigated was sandwich immunoassay. 
The method described in Section 5.3.2 was partially a pre-incubation method, 
which means that the antigens were first incubated with the antibody 
conjugate before incubated with the capture antibody. This needs the 
optimisation of the inCUbation time. This section describes the investigation of 
the effect of the incubation time on the completeness of the sandwich 
formation that affect the quality of the profile, therefore the sensitivity of the 
assay. 
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The following incubation time and sequencing were carried out before the 
detection, and the corresponding profiles are shown in Figure 5.5: 
1. The strip was incubated for 30 minutes. 
2. The strip was incubated for 60 minutes. 
3. The strip was incubated for 60 minutes, then dry for 60 minute laying flat. 
4. The strip was incubated for 60 minutes, dry for 30 minutes lying flat, then 
washed for 30 minutes. 
Conclusion: 
1. Incubation for 20 minutes resulted unsaturated sandwich peaks, 
2. Incubation for 60 minutes give the same good results as condition 3, and 4, 
and it is much simpler. 60 minutes incubation is good enough to resolve a 
saturated peak. 
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Figure 5.5. Optimisation of the incubation time of the strip 
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5.3.4 Comparison of amounts of capture antibodies and conjugate 
applied 
To optimise the concentration of the capture antibody that need to be 
deposited on the membrane and the conjugate antibody, anti human albumin 
IgGs at two different concentrations (1 mg ml"' and 4 mg ml"') were deposited 
on two separate strips, strip 1 with 1 mg ml"', and strip 2 with 4 mg ml"'. 
Conjugate antibodies at two dilutions were used on strip 1 at 1/80 dilution and 
strip 2 at 1/8 dilution, respectively. HF240 nitrocellulose membrane strips were 
used. A series of concentrations of human albumin was tested using the two 
conditions according to the procedures described in Section 5.3.2. The results 
are shown in Figure 5.6. 
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Figure 5.6. Comparison of the amount of the capture antibodies immobilized on the 
membrane and the amount of the conjugate applied 
Strip 1 has the anti human albumin IgGs deposited on it at 1 mg mr" while strip 2 had 
the anti human albumin IgGs deposited at 4 mg mr'. 
Conclusions: 
As expected, at the antigen concentration of 100 ng ml"' and above, the strips 
with 4 mg ml"' capture antibody and 1/8 dilution of conjugate antibody gave 
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higher fluorescent signal than the strips with 1 mg ml-' capture antibody and 
1/80 dilution conjugate antibody. But at antigen concentration of 50 ng mr' 
and lower, the two conditions made no difference for the fluorescence signals. 
These indicated that limit of detection should be over 50 ng mr'. 
5.3.5 Optimisation of signal gain of the portable fluorimeter 
This experiment was performed to compare the effect of the signal 
amplification of the portable fluorimeter. HF240 nitrocellulose membranes 
were used, with 4 mg mr' anti human albumin deposited as the capture 
antibody, and 1/8 dilution of the conjugate anti human albumin were applied 
as the labelled antibody. The strips were detected with the signal amplification 
from 1, 5, 15, 30 and 80 and back to 1 again, respectively. Results are shown 
in Figure 5.7 below. 
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Figure 5.7. Comparison of the effect of signal amplification of the portable fluorimeter. 
Conclusions: 
The signal amplification of the portable fluorimeter does not affect the 
sensitivity of the assay too much, although sensitivity increased slightly from 
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amplification 1 to amplification 30. However the baseline increased as well 
and the reading range decreased significantly from amplification 1 to 
amplification 30, so amplification 1 was still chosen for the following 
experiments unless otherwise stated. 
5.3.6 Comparison of five types of strip 
Five types of strips were tested to optimise the strip conditions. Each type was 
detected using amplification setting of 1 to 80. 500 ng mrl of human albumin 
was used as the analytes. The results of amplification 1 and 15 only are 
shown in Figure 5.8. 
1. Strips 01, 02----HF240, the antibody was applied at 1 micro litre per cm, 
at a specific antibody concentration of about 1.0 mg mrl. 
2. Strips 11, 12----HF240, new batches at the same condition of strip 01, 02. 
3. Strips 21, 22----HF240, same as 11, 12, but with anti rabbit IgG control 
4. Strips 31 , 32----HF240, same as 11 ,12, but 4 mg mrl concentration of the 
specific anti human albumin on capture line. 
5. Strips 41, 42----Porex membrane: Capture antibody was at 1 mg mrl. 
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Figure 5.8. Comparison of five types of strips (for explanation of strips see texts). 
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Conclusions: 
1. The 4 mg mr1 concentration of specific anti human albumin strips (strips 
31,32) certainly gave the highest intensity. This type of strip was thus used 
for the following experiments unless otherwise stated. 
2. The reason that the lots 0, 1, and 2 were different might be the variation of 
the operation of the striping machine that was used for immobilizing the 
capture antibody on the strip. 
3. The control lines for strips 21, 22 were very intense. At gain B and above, 
their signals saturated the detector reading scale. The lines could be seen 
easily with the naked eye, which meant that the conjugate levels were 
certainly more than enough. 
4. The signals on the porex membrane strips were weaker than on the 
nitrocellulose membrane at the same condition. The porex membrane 
strips were incubated for 1 hour, but the blue conjugate nearly ran out of 
the pad in this period. This membrane was a very fast membrane with 
bigger pore sizes, so some of the complex might have run out. 
5.3.7 Exclusion of higher wicking rate porex membrane strips. 
To examine the suitability of the porex membrane, the following experiments 
were carried out using 500 ngmr1 human albumins as analytes. 
1. Strips 01----HF240 nitrocellulose strips, 1 mg mrl specific anti human 
albumin applied as capture antibody. 
2. Strips 11----HF240 nitrocellulose strips as strips 01, new batch. 
3. Strips 31----HF240 nitrocellulose strips, 4 mg mrl specific anti human 
albumin applied as capture antibody. 
4. Strips 4----Porex membrane: sintered polyethylene, 4 mg mrl specific anti 
human albumin applied as capture antibody, incubated for different length 
of time. 
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The results are shown in Figure 5.9 below: 
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Figure 5.9. The comparison of different strips (for explanation of strips see text) 
Conclusion: 
1. From the above bar charts, it can be seen that the higher wicking rate 
membrane porex gave less signal than any of the other membranes, 
even in the best incubation conditions (20 minutes). So it was not suitable 
for this analysis. 
2. The 4 mg ml-1 anti human albumin concentration on the HF240 
nitrocellulose membrane was confirmed again as the best system. 
3. There was batch-to-batch variation as revealed by signal intensity of 
strips 01 and strips 11. This could be caused by the variation of the 
operation of the striping machine. 
5.3.8 Non-specific binding 
Non-specific binding (NSB) of conjugate antibody to the capture antibody, e.g. 
even when no antigen was present, was a big problem for this project. 
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The immunochemical detection of proteins bound to membrane matrices 
requires a blocking step prior to the detection step. Unoccupied binding sites 
on the membrane must be blocked to prevent non-specific binding in 
subsequent reaction steps. The blocking process is accomplished with 
detergent or protein solutions, via different mechanisms. Protein blocking on 
membrane binding sites may be relatively irreversible compared to detergent 
blocking. Furthermore, detergents may block by binding to the hydrophobic 
sites of proteins in solution that in turn prevents their hydrophobic interaction 
with membranes. The actual blocking procedure and content of the blocking 
solution depends on the type of membrane being used, as well as the nature 
of the blocking material. The choice of blocking procedure is critical to the 
success of the assay. 
Detergent solutions are the most economical blocking reagent and are fairly 
effective when working with nitrocellulose membrane. Ionic detergent such as 
SOS and some non-ionic detergents, e.g. Triton X-100, are not very useful as 
blocking reagents because they can cause losses of initial bound protein. 
Milder non-ionic detergent such as Tween 20 is the more commonly used 
blocking reagent [16]. 
Protein blocking solutions such as BSA, casein or gelatin tend to be much 
more effective at inhibiting non-specific reaction between the membrane and 
sandwich complex than detergent solutions. It is well known that protein 
solution (up to 5 to 10%) are necessary to effectively inhibit non-specific 
binding to nylon membranes, although the exact protein and its concentration 
should be determined experimentally for each application. Unfortunately, 
protein blocking solutions can also cause desorption of substantial amounts of 
immobilized capture proteins [16]. This desorption can lead to false negative 
results if the levels of these proteins are reduced below the sensitivity of the 
assay. 
This experiment tests the effect of 0.1 % Hammarsten casein in the conjugate 
buffer for the anti human albumin-Alexa Fluor 647 conjugate on the HF240 
128 
~---~---------
Chapter 5 - Experimental: Immunochromatography for human albumin 
strips (4 mg ml"' specific capture anti human albumin). Basically, 0.2% 
Hammarsten casein (boiled in 0.01m NaOH, pH adjusted to 8.5, and filtered) 
was mixed with the same volume of the 1/80 dilution of anti human albumin-
Alexa Fluor 647 conjugate. The sandwich immunochromatography assay was 
then carried out according to Section 5.3.2 with the concentration of human 
albumin as the analyte ranging from 0.5 ng mr' to 500 ng ml·1. Results are 
shown in Figure 5.10. 
Conclusion: 
In this particular system, 0.1 % Hammarsten did not help to get rid of the NSB, 
but increased it, also the higher concentration (0.5 Jlg mr' and above) of 
antigen gave less signal. No further investigation of the non-specific binding 
buffer solution was made for this was a preliminary experiment, as NSB buffer 
was specific for individual immunoassay systems. 
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(Strip 1 and 2 were at the same condition. Strip 3 were treated using 0.1% Hammarsten 
casein in the analyte buffer) 
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5.3.9 Effect of sucrose and comparison of pH of conjugate buffer 
As mentioned in Section 1.8.2, pre-treatment of the membrane with 
substances that will maintain a small distance between the microspheres 
(latex) and the membrane, yet which can easily be redehyd rated , is often 
helpful, and examples of substances commonly used are sucrose, various 
water soluble inert polymers, and surfactants. In this experiment, the effect of 
sucrose in the bicarbonate conjugate buffer at pH 8.75 and pH 9.6 was 
investigated for comparison. 
The human albumin-Alexa Fluor 647 conjugates dissolved in pH 8.75 and pH 
9.6 buffers with/without 20% sucrose were applied separately in different HF 
240 strips with 1 mg mr1 anti human albumin immobilized as the capture 
antibodies. Each strip was incubated in 500 ng mr1 human albumins for 60 
minutes. Results are shown in Figure 5.11. 
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Figure 5.11. Comparison of pH of conjugate buffer, and addition of sucrose (for 
explanation of strips see text) 
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Conclusion: 
1. The conjugate buffer at pH 8.75 was more efficient than at pH 9.6 for the 
antigen with or without sucrose in the conjugate buffer. 
2. The addition of 20% sucrose in the conjugate buffer gave a big background 
signal, especially in the case of pH 9.6, although it did help a little bit at pH 
8.75. This background was probably the detector reagent that stuck on the 
membrane caused by the viscosity of the sucrose. Therefore sucrose was 
not added in the following experiment unless otherwise stated. 
5.3.10 Comparison of pH of analyte buffer 
The main difference between conjugate buffer and analyte buffer is that 
analyte buffer must contain some detergent to enhance the migration of the 
analyte-detector reagent complex up the membrane, while the conjugate 
buffer does not have to. Experiences of Newmarket Laboratories showed that 
for some unknown reasons phosphate and tris buffer did not seem to be good 
buffer systems for running strip test with latex. Bicarbonate or ethanolamine 
buffered 150 mM NaCI at pH range from 8.6-9.6, with up to 2% Tween 20 
were said to be useful although the lower the Tween 20 concentration the 
better to avoid denaturing the antibodies. As shown in Section 5.3.9, pH of 
conjugate buffer affected the detection signal of 500 ng mr1 human albumins. 
This experiment was to investigate the effect of pH of bicarbonate buffer as 
the analyte buffer. 
Human albumin was dissolved in bicarbonate buffer (20 mM, 150 mM NaCl, 
2% Tween 20) at concentration of 0, 50, and 500ng mr1 at pH 7.5, 8.0, 8.3, 
8.5, 9.0, 9.6, and the immunochromatography assay were carried out 
following the procedure described in Section 5.3.2. Results are shown in 
Figure 5.12. 
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Analyte buffer pH optimisation 
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Figure 5.12. Comparison of pH of analyle buffer 
Conclusions: 
The best pH condition among the ones that were compared for the analyte 
buffer for human albumin immunochromatography system in the bicarbonate 
buffer (20 mM, 150 mM NaCI, 2% Tween 20) was at pH 8.3. No other buffer 
system was studied, as this was a preliminary experiment. 
5.3.11 Determination of lowest concentration of Alexa Fluor 647 that can 
be detected on membrane 
In order to have a rough idea of how low the Alexa Fluor 647 can be detected 
on the membrane, a series of concentration of the anti human albumin-Alexa 
Fluor 647 anti human albumin conjugate were applied onto the blank 
membrane using an electrophoresis applicator. The strips were left for 2 
minutes in a dark moisturised box, and then detected using the fluorimeter. 
The results are shown in Figure 5.13. 
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Conclusions: 
The lowest Alexa Fluor 647 that can be detected confidently was 62.5 nM of 
Alexa Fluor 647 as format of conjugate with anti human albumin. This result 
gave the rough idea of how much conjugate should be applied. 
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Figure 5.13. Determination of lowest concentration of Alexa Fluor 647 that can be 
detected on membrane 
5.4 Conclusions and discussions 
The preliminary investigation for the immunochromatography assay using 
human albumin has been done. These experiments using Alexa Fluor 647 
conjugated with anti human albumin as the detector reagent, and the in-house 
made portable laser fluorimeter as the detector worked to a good extent and 
were proved to be promising for further assay development for TB. 
The in-house made portable laser fluorimeter was proved to be capable of 
detecting the immunochromatography strip (Section 5.1). The long 
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wavelength laser light source of the fluorimeter shone on the strip with a spot 
sized around 1.5-2 mm in diameter, sharp enough to resolve two fluorescence 
conjugate lines on the membrane within 2 mm apart, while the length of the 
membrane on the strip for the detection was about 21 mm, which have 
enough space for the resolution of the capture and the control antibodies. The 
red PMT tube was capable of detecting long wavelength, in this case, 
emission wavelength at 668 nm. The application of the combination of a 
Schott RG 665 nm cut-off filter and a long edge pass filter 660 nm filtered 
most stray light and scattering light from the laser light source. 
The Alexa Fluor 647 conjugated with anti human albumin was proved to be a 
good detector reagent for the immunochromatography system for human 
albumin. At an estimated DIP ratio of 1.54, the conjugate could give a limit of 
detection at 62.5 nM of Alexa Fluor 647 (around 1 :800 dilution of the original 
conjugate). One drawback of the Alexa Fluor 647 would be its expense 
compared to latex labels that is a more common label for commercial kits. 
The immunochromatography assay for human albumin were proved working 
to a certain extent, although no complete optimisation was done for the 
preliminary experiment. The rough calibration curves were made at the 
present condition, and the limit of detection was determined so far at about 50 
ng mr1 (Section 5.3.4). With further optimisation of the conjugate buffer 
system, analyte buffer system, capture antibody system and membrane, and if 
the NSB problem were sorted out, the limit of detection could be improved 
further. The real system of TB was to be investigated at this point. 
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CHAPTER 6 
Experimental: Development 
of Immunochromatography 
Method for TB Diagnosis 
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INTRODUCTION 
The preliminary investigation of the immunochomatography has been 
described in Chapter 5. The development of the immunochromatography 
method for Tuberculosis (TB) diagnosis will be described in this chapter. 
Mycobacterium tuberculosis, the bacterium that causes TB disease, is 
protected from the host by a unique cell wall. One of the main components of 
this cell wall is lipoarabinomannan (LAM), a glycoconjugate that is involved in 
many interactions with the host's immune system and therefore likely to 
contribute to the pathogen's survival (see Section 1.9.2.7). LAM has been 
detected in the serum [122] and sputum [123] of patients with tuberculosis, but 
none of these tests to detect mycobacterial antigens has achieved widespread 
use for the diagnosis of active tuberculosis [124]. A test based on ELlSA using 
monoclonal IgMs against LAM as capture antibodies and rabbit antiserum 
against mycobacterium tuberculosis bacteria as a source of detector 
antibodies [124] was developed claiming to have a detection limit of 104 
mycobacterium tuberculosis bacteria per millilitre of sputum. Assuming that all 
LAM was extracted from the mycobacteria, and one mycobacterium 
tuberculosis bacterium contains approximately 100 fg of LAM, 104 
mycobacterium tuberculosis would contain 1 ng LAM (104 mycobacteria x 100 
fg = 106 fg = 1 ng) according to Pereira Arias-Bouda [124]. 
The use of the fluorescent microspheres instead of the commercial label 
Alexa Fluor 647 was a logical step as mentioned in Section 1.8.2.1, 
conventional lateral flow tests commonly employ dyed microspheres as their 
labels. Moreover, a good source of commercial fluorescence latex became 
available which was more photostable and more economic. It was then 
decided to pursue this assay development using fluorescence latex. 
This chapter describes the development of immunochromatographic assay for 
TB using LAM as antigen, long wavelength fluorescent microspheres as label, 
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and the portable laser fluorimeter as the detector. The intention was to 
develop a semi-quantitative test for TB for the preliminary diagnosis of TB. 
Basically, the fluorescent microspheres labelled antibody (conjugate) was 
applied on the sample pad adjacent to the cellulose nitrate membrane, the 
strip was then dipped in analyte antigen in solution, the conjugate was then 
forming complex with antigen, and the complex migrated up through the 
membrane by capillary flow forces, forming fluorescent 'sandwich' with 
capture antibodies previously deposited as a thin line on the membrane. The 
excess conjugate would then pass through and was absorbed into the 
absorbance pad adjacent on the other end of the membrane (see Figure 5.1). 
The strip was then inserted in the measuring compartment of the portable 
fluorimeter. The measuring compartment was then moved down through the 
measuring laser light, a fluorescent profile was collected by PC through a data 
logger interface, showing the fluorescent sandwich line as a peak like a 
chromatogram (details see Section 5.1). 
6.1 Reagents 
6.1.1 Antigen and antibody reagents 
The quality of antigen and antibody are crucial to the immunochromatography 
sandwich assay. Good quality antibody with good specificity to antigen gives 
less background and less non-specific binding. Purified Lipoarabinomannan 
(LAM) and monoclonal IgM against LAM were kindly provided by Newmarket 
Laboratories Ltd as the analyte antigen and antibody. They were stored in 
PBS buffer. 
6.1.2 Strips 
Whatman nitrocellulose membranes HF135 and HF120 have been used for 
this development. 
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6.1.3 Fluorescence latex 
The Dark Red Fluorescent Latex used here was aldehyde-modified 
polystyrene particles from Duke Scientific Corporation. This product was 
designed for lateral flow diagnostic test development, and for other research 
in diagnostics and biotechnology requiring detection and labelling of very low 
concentrations of substances [109]. The main characteristics of the particles 
latex are: 
Material: polystyrene microspheres (CsHs)x in deionised 
water 
Surface characteristics: aldehyde-modified 
Parking Area: 120-140 N I CHO 
Nominal Density: 1.06 g/cm3 
Appearance: blue 
Dye: dark red fluorophore (encapsulated throughout the 
polymer microspheres) 
Excitation maximum: 640 nm 
Emission maximum: 660 nm 
Nominal dye content: 1 % (w/v) 
Particle solids: 2% (by gravimetric analysis) 
Diameter: 0.39 micrometer (flm) (by light diffraction) 
Uniformity: <5% C.v. (by light diffraction as a known standard) 
Microbial growth: none (24 hour culture @ 37°C) 
6.2 Preliminary Experiments 
6.2.1 Conjugation procedures 
The aldehyde-modified latex are hydrophobic particles that adsorb and react 
with protein at neutral pH through the formation of a Schiff base between the 
aliphatic aldehyde surface groups and the amines on the protein (Figure 6.1). 
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The latex does not require any chemical pre-activation step for covalent 
binding to occur. Formation of a Schiff base is a reversible reaction. However, 
since several different amine groups on a protein are bound simultaneously to 
the latex surface aldehydes, thermodynamics are very unfavourable for 
dissociation of the protein. The Schiff bases can subsequently be reduced, if 
desired, to a stable alkylamine bond by addition of sodium cyanoborohydride. 
-< N~ H 
Schiff base 
1 Cyanoborohydride Buffer 
---<N;:( 
H 
Figure 6.1. Formation of Schiff base between aliphatic aldehyde surface groups and 
amines on antibody 
The conjugation procedure for linking anti LAM to the dark red fluorescent 
microspheres was modified from the manufacturer's instruction [155]: 
1. A solution of 10% L-77 in water was made, this was cloudy, 
2. A 10% solution of Tween 20 in water was made, 
3. The Tween 20 solution was added to the L-77 slowly with mixing until the 
L-77 went clear, 
4. A 2 III of the L-77fTween 20 mixture was added to every 100 III of latex (1 % 
solids), this step was to prevent the aggregation of the latex, 
5. A desired amount of antibody (in a buffer without amine groups) was added 
to the above latex suspension while vortex mixing, 
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6. The same volume of cyanoborohydride coupling buffer as the latex 
suspension used was also added to the suspension mixture while vortex 
mixing, 
7. The suspension mixture was allowed to couple for 2 hours at room 
temperature with frequent mixing, 
8. The suspension mixture was washed 3 times in tris-buffered saline pH 8.6, 
containing 0.2% BSA, using centrifugation and probe sonication, 
9. The antibody conjugated fluorescence latex suspension was checked to be 
able to migrate up a blank strip, using a high pH buffered saline containing 
Tween 20. 
6.2.2 Strip development procedures 
The immunochromatographic incubation procedures are modified as 
following: 
1. Monoclonal anti LAM-fluorescence latex conjugate (1 0 ~I) in conjugate 
buffer was applied on the conjugate pad of the strips (see Figure 5.1). 
2. The strips were inserted in 1 00 ~I of a series of analyte LAM solution 
(made up in analyte buffer) in small tubes. The solution started to migrate 
up the strips. 
3. The strips were left in the antigen in darkness for 60 minute, by then all the 
excess conjugate had migrated to the absorbent pad. 
4. The absorbent pad and the conjugate pad were cut off, the membrane was 
then stuck on a strip holder which was the same size and shape of a cell 
5. The strip holder was inserted into the portable fluorimeter cell holder. 
6. The membrane was scanned from bottom to top. A profile was recorded 
with the fluorescent sandwich complex band shown as a peak. 
6.2.3 Choosing filters for dark red fluorescence latex 
As the Stokes' shift of the fluorescence of the latex was small (20 nm, 
excitation wavelength 640 nm, and emission wavelength 660 m), appropriate 
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optical filter(s) or combinations need to be considered to fit in between the 
strip holder and the PMT detector. In order to do these, a long edge pass filter 
at COWL 660 nm, a Schott RG665 nm cut-off filter, and a combination of 
these two have been examined to measure the 0.001 % (w/v) suspension at 
different band width using the LS-50S fluorimeter. The resulted fluorescence 
plots are shown in Figure 6.2 (PS: The laser 635 nm light source's profile is 
imagined). 
--Slit 10/3 nm, no filter 
--Slit 10/5 nm, Schott RG 665 nm cut-offfilter 
Slit 1017.5 nm, long edge pass filter at 660 nm 
--Slit 1017.5 nm, Schott RG 665 nm cut-off filter and long edge pass filter at 660 nm 
Imagined Laser 635 nm light source's profile 
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Figure 6.2. Comparison of fluorescence spectrum of fluorescent latex with different 
filters in LS-508, 
Conclusions: 
From the spectra at different instrument band widths and filter conditions, it 
could be seen that: 
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1. With no filter in place, the measured emission wavelength (658 nm) was 
so close to the excitation wavelength (640 nm), that the signal detected by 
the portable fluorimeter PMT tube would have a very high background 
component due to the scattered exciting light (Rayleigh scattering). The 
excitation and emission bandwidth was chosen at 10/3 nm, as the 
emission intensity was too high. 
2. With only a Schott RG 665 nm cut-off filter in the emission beam, the 
observed fluorescence emission wavelength (670 nm) was still too close to 
the excitation wavelength (640 nm). The Rayleigh scattering contributed 
about 20% of the intensity passing through the filter. 
3. With only a long edge pass filter (660 nm) in the beam, the observed 
emission wavelength (-677 nm) was similar to the emission wavelength 
(675 nm) with both filters in the emission beam. But the Rayleigh 
scattering could still pass through which accounted for about 10% of the 
detected signal. 
4. The combination of the Schott RG 665 nm cut-off filter and the long edge 
pass filter at COWL 660 nm was chosen for the portable fluorimeter, as it 
greatly reduced the Rayleigh scattering and still retains the intensity. In 
addition, as the excitation wavelength of the laser source in the portable 
fluorimeter was 635 nm, which would be much sharper and stronger than 
the LS-50B Xenon light source, and also further away from the optimum 
emission wavelength (675nm), the fluorescence light collected by the PM 
tube after the filtration would be much more stable. In fact, the 
fluorescence signal obtained from the portable fluorimeter using the two 
filters was much more stable than any of the single filters. It was so stable 
that it would not alter even when the lid was open. 
6.2.4 Limit of detection in terms of number of particles on strips 
According to Bangslabs [104], the number of microspheres per ml could be 
calculated by the following equation: 
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N = 6x10 'O e S e PL 
neps ed 3 
number of microspheres per ml for suspensions in water 
weight % solids (e.g. for 10% solids suspension, S=1 0) 
density of solid sphere (g/cm3) 
density of microsphere suspension (g mr') 
100'pJ [S (1-ps) + (100 • Ps)) 
mean diameter (ftm) 
Where for the Dark Red Fluorescent Microspheres, Ps = 1.06 g/cm3 , d= 0.35 
flm, S = 2 (%). 
In order to estimate the limit of detection in terms of the number of particles on 
the strip, a series of dilutions of 2% fluorescence latex suspension were 
made. 10 ftl of the dilutions were added into a well of an electrophoresis 
applicator, then the latex suspension was applied onto the strip using the 
applicator. The fluorescence of the strips was then measured using the 
fluorimeter. The fluorescence plot of the 1/1000 suspension on the strip is 
shown in Figure 6.3. 
The plot ofthe fluorescence ofthe 1000 
dilution ofthe fluorescent latex conjugate 
made from 2% suspension applied on the strip 
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Figure 6.3. Determination of limit of detection in terms of number of fluorescence 
microspheres in strip membrane 
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Assume only 0.1 JlI of 1/1000 dilution of conjugate made from the 2% 
microsphere suspension were applied on the strip membrane, calculation 
using the above equation showed that the number of microspheres on the 
strip that could generate the fluorescence signal shown in Figure 6.3 was 
about 8.4x1 04 particles. 
Conclusions: 
About a quarter of the above signal would be at least 3xSD of the noise above 
the baseline signal, so the limit of detection in terms of the particle number 
was about 2x104 particles. This characteristic might be useful for the fine-
tuning of the final stage of the fluorimeter development. 
6.2.5 Anti LAM-fluorescent latex conjugate stability on the strips 
6.2.5.1 Photodecomposition by laser 
In order to check the photo stability of the latex conjugate on the strips, the 
following experiments were carried out. Basically, the Anti-LAM and 
fluorescent latex were applied on the membrane of a blank strip (no capture 
antibody were deposited). The strip was left dry for two minutes, then the 
fluorescence was measured 30 times by moving the cell holder down and up 
continuously. It took about 1000 seconds. The strip was then left in a dark 
moisturised box to recover for three hours. It was then detected again as 
above. Results are shown in Figure 6.4 (a) and (b). The standard errors in y 
direction of the polynomial lines were 44.63 and 32.87 [151], respectively. 
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Figure 6.4. Photodecomposition effect of laser 635 on fluorescent latex on strip. 
(a) Freshly prepared strip; (b) the same strip stored three hours in a dark moisturised 
box. 
Conclusions: 
1. From graph (a), it can be seen that the photodecomposition at the first 500 
seconds was not very serious. After that, the photo decomposition was 
steady. Within 1000 seconds, the fluorescence intensity has decreased 
about 20%. 
2. After three hours of recovery in the darkness at room temperature, the 
fluorescence of the strip did not recover, but still decreased steadily (graph 
b). This indicated that the fluorescence of the latex was photodecomposed 
by the laser, rather than photobleached. 
6.2.5.2 Photodecomposition by daylight 
Fluorescence latex-anti LAM conjugate was applied on the strip. The 
fluorescence on the strip was then measured with the portable fluorimeter for 
one cycle, then taken out to the daylight for about one second, then reinserted 
into the fluorimeter for measurement. This was carried out for 16 times in 
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1000 seconds (result shown in Figure 6.5 a). Then the strip was taken out and 
exposed in daylight for 20 minutes, then the same measurement was 
repeated as above for another 16 times (Figure 6.5 b). After 4 further hours 
exposure to daylight, the same strip was measured again for another 16 times 
following the same process as above (Figure 6.5 c). The standard error in y 
direction of the polynomial trend line were 25.49, 28.3, and 22.94, respectively 
[151], and the fluorescence intensity in (b) and (c) were 1211±59 and 
1158±46, respectively. 
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Figure 6.5. Photodecomposition effect of daylight on fluorescent latex conjugate. 
(for explanation of a,b,c, see text) 
Conclusions 
1. The fluorescence intensity of the fluorescence latex conjugate on the strip 
decreased by about 23.5% over 1000 seconds (Figure 6.5 a). 
2. Over the first 400 seconds, the decrease was small, only 5.2%. This 
confirmed the result in Section 6.2.5.1 (Figure 6.4 a). 
3. After 20 minutes exposure in daylight, the fluorescence intensity was very 
similar, and remained in the similar level over the 1000 seconds 
measurement, the average intensity was 1211±59 (Figure 6.5 b). 
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4. After further 4 hours exposure to the daylight, the fluorescence intensity of 
the conjugate on the strip was again similar, the average intensity was 
1158±46 (Figure 6.5 c), indicating the fluorescence of the latex was 
photodecomposed by daylight, and then remain stable at about 20 min 
onwards. 
6.2.5.3 Variation of positioning of strips on strip holder 
When the strip was detected by moving through the laser beam light, the 
position might be different every time. It was estimated that the laser beam 
spot was about 1.5 mm id, the conjugate line on the strip was about 3.5 mm 
wide and 1.5 mm thick. The cell holder-moving path may not be exactly 
straight. Moreover, the membrane of the strip was stuck on the strip holder 
simply by a piece of blue tack at this stage, so the angle to the laser light 
might be slightly different each time. This experiment investigated the 
positioning variation of the strip. 
The anti LAM IgM-fluorescent latex conjugate was applied on the strip the 
same way as above. The strip was scanned once, then the sample holder 
was taken out, the strip was repositioned, and was scanned again. The same 
process was carried out 24 times in about 1000 seconds. The results are 
shown in Figure 6.6. The standard error in the y direction of the polynomial 
line was 56.63 [151]. 
Conclusions 
1. The graph shown really is the result of the combination of the variation of 
the strip position, the photodecomposition effect of the laser and the 
daylight. The fluorescence intensity from the total effect has decreased 
about 45.0% in 1000 seconds, compared with 20% by laser only (Section 
6.2.5.1), and 23.5% by laser and day light (Section 6.2.5.2) 
2. The standard deviation in y direction is 56.63, which indicate higher 
repositioning error than by the laser (Section 6.2.5.1) and daylight (Section 
6.2.5.2) decomposition alone. 
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Figure S.S. Variation of strip positioning on strip holder plus photodecomposition. 
6.2.5.4 Conclusions and discussions 
The stability of the fluorescence latex conjugate has been determined. The 
decompositions were summarised in Table 6.1. It can be seen that both laser 
and daylight decompose fluorescence of the latex. The decomposition mainly 
took place within the first 1000 seconds. The fluorescence did not recover 
after four hours in the dark box (see Section 6.2.5.2.), but stayed much stable 
(Figure 6.5 C) which means the photodecomposition was permanent rather 
than photobleaching. These conclusions suggest that the strips need to be 
determined immediately after the development, and need to be stored in a 
dark moisturised box before fluorescence determination. The strip holder 
repositioning variance was quite significant at this stage, but it would not be as 
such in the final stage of the assay development, as the strip would be pre 
mounted in a pack for the end user. 
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Table 6.1. Comparison of the photo decomposition underdiferent condition. 
Laser Laser + Daylight Laser + daylight + 
strip positioning 
Decrease in 1000 
second 20% 23.5% 44% 
Decrease in 2000 
seconds 47% 35% 
6.3 Assay system development 
According to the experience of Newmarket Laboratories Ltd, the analyte 
buffers and conjugate buffers can be different for the optimisation of the 
assay. The main compositions of the buffers were really made according to 
experiences. Analyte buffer also act as the migration buffer, so it need to have 
some detergents, such as Tween 20, in it. It also needs some non-specific 
proteins, such as BSA or casein to be present either in the analyte buffer or in 
the conjugate buffer to help reduce the non-specific binding. There were lots 
of buffer systems and pH ranges to optimise, however this section mainly 
describes some comparison of the analyte and conjugate buffer due to 
shortage and preciousness of the antigen and antibody available. 
6.3.1 Rough calibration of anti LAM system on HF135 strips 
Five parallel measurements were carried out following the strip development 
procedures described in Section 6.2.2. The following conditions were used: 
Strips: HF135 
Capture antibody: monoclonal anti LAM IgM (in Bicine 10 nM, pH 7.8, 1% 
BSA), 1.5 mg mr1 
Conjugate buffer: 2 mM tris, pH 8.0, 20% sucrose, 10% byco 
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Conjugate: anti. LAM IgM and Dark Red Fluorescent Latex were 
conjugated in the conjugation buffer following the 
procedures in Section 6.2.1 
Analyte buffer A: 50 mM ethanolamine, pH 9.2, 1 % Tween 20 (v/v), 150 
mM NaCI 
Analytes: LAM 
The averages of the signals are shown in Figure 6.7. The error bars represent 
2xSDs. 
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Figure 6.7. LAM assay on HF 135 nitrocellulose membrane strips 
Conclusions: 
The limit of detection of the initial rough calibration, by the definition of blank 
signal plus two standard deviations of the blank (see dotted line), was 
between 24 ng mr1 and 240 ng mr1 [124). 
This initial calibration was very promising to a sensitive diagnosis kit with even 
lower limit of detection. In order to achieve this, optimisation of analyte buffer, 
conjugate buffer, strip membrane modification, etc, needed to be done. The 
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following two sections describe some works done on the analyte buffer and 
conjugate buffer system. 
6.3.2 Comparison of analyte and conjugate buffer 
6.3.2.1 Comparison of two analyte buffer system and repeatability of 
strips with anti LAM 
This section describes the comparison of two different analyte buffer systems. 
Analyte buffers were chosen as trial and error at this stage. Tris buffer is a 
popular biological buffer, so it was chosen as one to compare. Ethanolamine 
buffer was recommended by Newmarket Laboratories Ltd. 
Materials: 
Strips: HF135 (see Section 5.3.1) 
Capture antibody: monoclonal anti LAM IgM (in 10 nM bicine buffer, pH 7.8, 
1 % BSA), 1.5 mg mr1 
Control Line: goat anti mouse IgG 
Conjugate buffer: 2 mM tris buffer, pH 8.0, 20% sucrose (w/v) , 10% byco 
Conjugate: Anti LAM IgM and Dark Red Fluorescent Latex were 
conjugated in the conjugation buffer following the 
procedures in Section 6.2.1. 
Analyte buffer A: 50 mM ethanolamine, pH 9.0, 1% Tween 20 (v/v), 150 
mM NaCI 
Analyte buffer B: 20 mM tris buffer, pH 8.6, Tween 20 2% (v/v), 150 mM 
NaCI 
Analyte: 240 Ilg mr1 LAM. 
Two sets of seven strips were developed following the procedures described 
in Section 6.2.2 to detect 240 ng mr1 LAM using two different analyte buffer, 
respectively. The fluorescence signals were recorded and the relative 
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standard deviations (RSO) or coefficients of variation (CV) are shown in Table 
6.2. 
Table 6.2. Repeatability study of two buffer systems. 
Fluorescence Intensity I AU 
Buffer A Buffer B 
1 212 279 
2 206 343 
3 210 304 
4 221 367 
5 205 287 
6 242 335 
7 226 425 
Average 217 334 
SO 13 51 
CV(%) 6.12% 15.25% 
Conclusions: 
1. Ethanolamine buffer (A) was better than tris buffer (B), as it gives a smaller 
CV (6.12% vs 15.25%) for the same batch strips. This may be due to the 
different volatility or polarity of the two buffer systems. According to the 
experience of Newmarket Laboratories Ltd., tris was not a good buffer for 
the immunochromatography assay. 
2. The strip performance was quite repeatable as the CV was only 6.12% as 
in ethanolamine buffer (A). Obviously, other buffer systems, including 
concentration, ionic strength, pH, polarity, detergent, etc, need to be 
optimised for the further development of this assay, while at this stage, 
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ethanolamine buffer (A) was chosen as the analyte buffer system for the 
rest of the development described in this chapter. 
6.3.2.2 Effect of casein in conjugate buffer system 
Vast amount of efforts had been put in to try all sort of addition to the 
conjugate buffer to reduce non-specific bindings (NSB), such as BSA, 
Hammarsten casein, fish skin gelatin, type A gelatin, type B gelatin, 
polyethylene glycol (PEG) BODO, EDTA etc, at different concentrations and 
combinations. Among these, only Hammarsten casein was beneficial to 
reduce the NSB of the system. This section describes the benefit of the 
addition of Hammarsten casein in the conjugate buffer. 
The anti LAM IgM-Dark Red Fluorescent Latex conjugate prepared in Section 
6.2.2 was probe sonicated further and washed one more time. A comparison 
of the addition of 1 % Hammarsten casein in the conjugate buffer was made. 
The calibration graphs are shown in Figure 6.B 
Conclusions 
1. The addition of 1 % Hammarsten casein in the conjugate buffer helped to 
reduce the background signal from around 140 to 100. 
2. The addition of 1 % Hammarsten casein in the conjugate buffer made the 
slope of the calibration graph from 100 ng mrl and above steeper, 
indicating higher sensitivity. 
3. The limit of detection seemed lowered from 24-240 ng mrl (Section 6.3.1) 
to around 10-100 ng mr' although no replicate were made yet. This may 
be due to the treatment of further probe sonication and washing. 
So the conjugate with further sonication and washing, dilutes in ethanolamine 
buffer with 1 % Hammarsten casein were used in the further development of 
the immunochromatography assay for LAM. 
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Figure 6.8. Effect of addition of 1 % Hammarsten Casein in ethanolamine buffer. 
6.4 Development of immunochromatography assay 
6.4.1 Calibration of LAM with HF135 membrane strips 
A calibration chart from average of 3 sets of data was made (shown in Figure 
6.9. The errors were ±2xSD), using the following conditions according to the 
procedures described in Section 6.2.2: 
• Strip membrane: 
• Conjugate buffer: 
• Analyte buffer A: 
H135 
2 mM tris buffer. pH 8.0, 20% sucrose, 10% byco, 
1 % hammarsten casein 
50 mM ethanolamine buffer, pH 9.2, 1 % Tween 20 
(v/v), 150 mM NaCI 
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Figure 6.9. Calibration chart of LAM using HF 135 strips. 
Conclusions 
It can be seen that the limit of detection, by the definition of blank signal plus 
two standard deviations of the blank, was between 1-10 ng mr1 at this 
condition (see dotted line). According to Pereira Arias-Bouda [124], 1 ng mr1 
of LAM was equivalent to 104 mycobacteria mr1. So the LOO was about 104 to 
105 mycobacteria mr1. 
6.4.2 Calibration of LAM with HF120 membrane strips 
Four sets of calibrations were carried out following the same condition as in 
Section 6.4.1, except using the membrane HF120 due to unavailability of 
HF135, following the procedures described in Section 6.2.2. The average 
calibration chart is shown in Figure 6.10, the error bars show 2xSDs. 
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Figure 6.10. Calibration chart of LAM using HF 120 strips. 
Conclusions: 
1. The HF135 strips proved to give a better limit of detection (1-10 ng mrl) 
than the HF120 strips (10-100 ng mr1). 
2. Compare these results with the ones in Section 6.4.1, it can be seen that 
the slower wicking rate membrane has better limit of detection, although 
the throughput might be slower. It can be predicted that the HF240 
membrane should have better still limit of detection with the compensation 
of slower throughput. Unfortunately, HF240 was not available for this LAM 
. immunochromatography assay at this stage. 
6.4.3 Precision of the immunochromatography assays. 
The choice of immunoassay format (limited or excess reagent), label and 
instrumentation can all influence the characteristics of the assay with respect 
to detection limit, precision and the analytical range [17]. 
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Although the HF 135 was proved to have better sensitivity, as there were only 
HF120 strip available, the intra and inter assay CVs were done with HF120 
strips. 
Repeatability is the precision (or coefficient of variance or (CV) or relative 
standard deviation) measured within one group of replicate assays using the 
same condition including the reagents and instruments within a short period. It 
is also called within-run precision or intra assay CV [151]. 
Reproducibility is the precision measured between groups of replicate assays 
using the same conditions of the reagents and instruments, but different 
batches and different time. It is also called between-run precision or inter 
assay CV [151]. 
The summary of the repeatability and reproducibility of the assay are shown in 
Table 6.3. Four replicates were done using the same condition as in Section 
6.4.2 in day one. These data were analysed and the intra assay CVs were 
listed. Four replicates were done again in day two, and the intra assay CVs 
were listed in Table 6.3. A further two replicates were done in the second day 
afternoon. 
At this stage, the conjugates ran out. New batches of monoclonal anti LAM 
IgM were proved to have poor quality to carry out any conjugation with the 
fluorescent latex. So the above 10 replicates data were analysed for the 
reproducibility study (listed in Table 6.3). 
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Table S.3. Repeatibility and reproducibility of immunochromatographic assay 
Repeatability CV(%) Reproducibility CV(%) 
[LAM]/ngmr' Day one (n=4) Day two (n=4) Two days (n=10) 
1000 22.3% 22.5% 38.5% 
100 6.3% 19.7% 29.2% 
10 7.5% 23.0% 29.5% 
1 15.4% 11.2% 28.0% 
0.1 10.8% 13.7% 29.1% 
0 7.3% 10.8% 19.2% 
Conclusions: 
From Table 6.3, it can be seen that: 
I. The repeatability (intra CV) was small, half of the CVs were smaller than 
10%, most of them were within 15%, the highest concentration of LAM at 
1000 ng mr', exhibit highest CV, these indicate good repeatability for this 
semi quantitative assay. 
2. The inter assay CV for the blank was 19.2%, while from 0.1 ng mr' to 100 
ng mr', they were from 28.0% to 29.5%. For the highest concentration of 
antigen at 1000 ng mr\ the intra assay CV is 38.5%. 
3. The limit of detection, by the definition of blank signal plus two standard 
deviations of the blank, was between 10-100 ng mr', as shown in Section 
6.5.8. This means that the high CV at the high concentration of 1000 ng 
mr' would not affect the assay sensitivity. 
6.5 Conclusions and discussions 
The suitability of applying long-wavelength fluorescence as label of the lateral 
flow detection system for diagnosis had been investigated. The use of 
fluorescent latex was suitable for the TB diagnosis using LAM as the detection 
target. 
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The fluorescent latex was suitable for the TB diagnosis (Section 6.4). 
Investigation of this system revealed that limit of detection of 1-10 ng ml"' was 
possible, while 10-100 ng ml"' is easily achievable. It was also very useful for 
the semi-quantitative screening of TB disease. This was very promising to 
develop into commercial product. However, the batch-to-batch variance of the 
anti LAM IgM was unpredictable and was beyond the investigators' control. 
This directly affected the further investigation of the reproducibility of this 
system. Results of new batch of anti LAM IgM showed less sensitivity (data 
not shown) compared to the results shown above. 
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7.1 Conclusions 
The objective of this project was to develop a high throughput screening 
method for early stage diagnosis of tuberculosis using immunoassays with 
long wavelength fluorophores and an in-house made portable laser 
fluorimeter. The development has been directed into two different 
immunoassay formats, one using FIA as the vehicle including bead injection 
and micro-columns, while the other employed immunochromatography. 
To a large extent, the objective of this project has been fulfilled. For the FIA 
format with a micro column, the limit of detection was 1.79 I-Ig mrl for human 
albumin, while with the immunochromatography method, the limits of 
detection were 50 ng mrl for the human albumin and about 10 ng mrl for the 
TB antigen LAM. The performance of the portable fluorimeter has been 
satisfactory, though further improvements are envisaged (see below). 
The long wavelength fluorophores investigated were Cy5 (ex/em of 649/670 
nm) and Alexa Fluor 647 (ex/em of 650/665 nm). The latter was chosen as the 
fluorophore for the FIA work, as it was superior in terms of low self-quenching 
at DIP ratios as high as 8: 1 (vs. Cy5, 2: 1) and greater photo stability [156]. 
The FIA immunoassay bead injection (BI) method was studied (Chapter 3). 
The method involves immobilising capture antibodies on to beads. The target 
antigens (organisms) are then sandwiched in between the capture and 
labelled antibodies. A fluorescence signal, which is proportional to the amount 
of antigens, is then collected when the sandwich complex passes in front of 
the light beam in a flow cell. Antibody immobilisation on to four types of beads 
and the fluorophore labelling efficiency were investigated. The four types of 
beads were: CPG, UltraLink™ Biosupport Medium, MagnaBind™ Amine 
Derivatised Beads and UltraLink™ Protein A plus. However, the BI sandwich 
assay did not prove to be appropriate for this project because of the difficulties 
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discussed in Section 3.6. Fast sedimentation of the carrier beads made the 
reproducibility of the experiments poor. This was caused by the size of beads 
in the case of Ultra Link ™ Biosupport Medium and UltraLink ™ Protein A plus 
(50-80 microns), or the high density of the beads in the case of CPG (170 
microns) and MagnaBind™ Amine derivatised beads (0.5-1.5 microns). In the 
case of MagnaBind™ Biosupport Medium, the fluorescence of the label was 
either quenched or absorbed by the beads, so the fluorescence could not be 
detected. However, MagnaBind™ amine derivatised beads could be further 
investigated for use as an open immunomagnetic micro reactor. This will be 
discussed in Section 7.2.1. 
FIA methods with a micro column reactor were then studied as described in 
Chapter 4. This immunoassay method involved immobilising antibodies on to 
beads, either directly or through protein A based solid phases. The beads 
were then packed into a micro-column reactor to incorporate into the FIA 
system. Sandwich (reagent excess) assays have been investigated. In each 
case reactor-bound molecules were eluted from the system by a change of 
pH, thus limiting the available fluorophores to those that are reasonably 
fluorescent in acid solution. 
UltraLink™ Immobilised Protein A Plus was used (Section 4.2) initially, as the 
protein A can bind to the Fe regions of immunoglobulins and leave the Fab 
regions free for the antigen binding. Anti treponema pal/idum IgGs and their 
antigens were used as the model antibody and antigen. Dimethyl pimelidate 
(DMP) was used as a cross linker [94] in the hope of making the bond 
between the antibody and protein A stronger (see Section 1.7.3.2.4). , 
However, the immobilised antibody then showed reduced activity, leading to a 
poor response to the antigen. 
The UltraLink™ Biosupport Medium (Section 4.3) was then used with anti 
treponema pal/idum IgGs and its antigen as the model antibody and antigen. 
However, this column did not work as expected. It was concluded that either 
the affinity between the anti treponema pallidum IgGs and its antigen was not 
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strong enough, or the elution buffer (0.1 M citrate pH 2.0) was not strong 
enough to break the bond between the antigen and the immobilised antibody. 
Subsequent experiments using the UltraLink™ Biosupport Medium with 
commercial anti human albumin and its antigen worked well (Section 4.3), 
using a stronger elution buffer (0.1 M glycine hydrochloride pH 1.75 in 
ethylene glycol (1 :1/v:v). The limit of detection was 1.79 I1g mr1. Further 
optimisation could be attempted for this method. However, for commercial 
reasons, the project then moved on to the study of immunochromatography. 
The immunochromatographic method employed a lateral flow system and a 
sandwich (two-site) immunometric assay. Capture antibodies were 
immobilised on a coated membrane matrix at a pre-determined position and 
the antigen was analysed after binding to a fluorescence-labelled antibody. 
Both fluorescent latex and conventional fluorescent labels were used. The 
strips were simply immersed in a small volume of sample to start the analysis, 
and the chromatographic step was rapid and extremely simple. The in-house 
built portable laser fluorescence detector was fitted with a motor-driven 
sample holder to allow the length of the immunochromatographic strip to be 
scanned. The detector utilises a diode laser light source, optical filters in the 
emission beam and a miniaturised photomultiplier. 
Preliminary immunochromatography experiments had been done using anti 
human albumin antibodies and human albumin as the antibodies and 
antigens, and Alexa Fluor 647 as the label as described in Chapter 5. The 
immunochromatography assay for human albumin was shown to work to a 
certain extent, although no complete optimisation was attempted. 
Nitrocellulose membranes were chosen for the strips, the calibration of this 
system was studied and the limit of detection was determined to be ca. 50 ng 
mr1 (Section 5.3.4). No further optimisation of the conjugate buffer system, 
analyte buffer system, capture antibody system and the membrane was done, 
as the buffer systems and non-specific binding are criteria that depend on 
individual antibody/antigen system. 
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The immunochromatography method for TB screening used 
Lipoarabinomannan (LAM) as the antigen. Monoclonal anti LAM IgMs were 
immobilised on to the membrane as capture antibody and also used as the 
detector antibodies after labelling. The label investigated was fluorescence 
latex as these materials are conventionally used in immunochromatography. 
The system again used the portable laser fluorimeter as the detector. 
Comparisons of different conjugate and analyte buffer systems were made 
and the best limit of detection obtained was about 1-10 ng mr1, while 10-100 
ng mr1 was easily achievable. This method shows promise for developing into 
a commercial product. However, the batch-to-batch variations of anti LAM IgM 
and LAM were unpredictable, and beyond the author's control. With a batch of 
similar or better quality of anti LAM and LAM, the limit of detection could be 
pushed even further. 
The development of the portable laser fluorimeter had been an on-going 
process. It consists of two diode lasers at a nominal wavelengths of 635 nm 
and 650 nm (enabling to accommodate assays using different long 
wavelength fluorophores), a sample holder, filters which is changeable for 
using different fluorescence labels, a lens between the filters and the PMT, 
and a photo multiplier tube detector. All these components have been optically 
aligned as described in Section 2.1.3. The cell holder was motor-driven to 
allow the length of a immunochromatographic strip to be scanned. The 
instrument can also be easily adapted to allow FIA detection, and could 
readily be adapted to operate from batteries, so is suitable for field use. The 
portable laser fluorimeter was linked to a PC via an analogue to digital 
converter (ADC). The fluorimeter performed very well. The limit of detection of 
the system for solution measurements of pure Cy5 was 2.17x10-11 M 
compared with 3.51x10-9 M measured by LS-50B. The relative standard 
deviation for measuring Cy5 labelled anti LAM IgM immobilised strip was 
about 4% (n=13) which was good bearing in mind that it included the effects 
of photodecomposition (Section 2.1.3.7). Still further improvements could be 
made which will be discussed in the next section. 
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7.2 Future work 
7.2.1 Magnetic particles for micro-column for FilA 
Magnetic particles have been used to purify proteins and separate cells [83]. 
Once coated with specific ligand, the magnetic particle can be added to a 
heterogeneous target suspension to bind to the desired target molecules. The 
resulting complex can be removed form the suspension using a magnet. This 
format of purification is simple, rapid and reliable, requiring little more than an 
antibody and a magnet [83]. 
The possibility of using magnetic particles as the carrier bead in flow analysis 
has been investigated and described in Section 3.4. However, it was found 
that, the fluorescence of the label was either quenched or absorbed by the 
MagnaBind™ Biosupport Medium beads, so the fluorescence cannot be 
detected. Furthermore, the magnetic beads were quite dense, and sediment 
very fast, jamming the injection valve. They were obviously not a good choice 
for the bead injection format. However, as mentioned in Section 3.4., they 
could be further investigated for use in an open tubular or micro column 
format. 
An open tubular immunomagnetic bead reactor could be created within a 
flowing stream with an electromagnet as shown in Figure 7.1 [52, 145]. The 
advantages of this format are that 
• Spent beads may be discharged after each analysis. 
• It eliminates the problems of instability of reaction surfaces and 
• It eliminates the need for additional time traditionally required for 
regeneration of the solid-reaction phase 
The possible drawback of this approach is the cost of one analysis, as the 
magnetic particles and the antibody immobilised on them are only used once. 
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Figure 7.1. Illustration of the proposed open tubular immunomagnetic FIA format. 
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7.2.2 Zenon technology (Molecular Probes) 
Conventional fluorescence labelling of antibodies cannot determine the 
position of labelling. The fluorophores are usually attached to the antibodies 
randomly, possibly occupying the antigen recognition site, leading to reduced 
antibody activities. 
The lenon labelling method takes advantage of the immunoselectivity of the 
antibody binding reaction by forming a complex between an intact primary IgG 
antibody and a fluorophore-, biotin- or enzyme-labelled Fab fragment directed 
against the Fc portion of that IgG (Figure 6.1) [157]. Simple mixing of the 
labelled Fab fragment, which is supplied in the lenon Antibody Labelling Kits, 
with the corresponding primary antibody quantitatively produces the Fab-
antibody complex in under 10 minutes, with no pre- or post-labelling 
purification required. This labelled Fab-antibody complex can then be used to 
stain cells, tissues and other targets in the same manner as a covalently 
labelled primary antibody. 
lenon technology has the following benefits 
• Speed - It only takes 10 minutes for the labelling and the adsorption of 
residues, and no need to separate the nonspecific IgG. 
• Economy - It only requires 1 I-Ig of primary antibody compared with at least 
100 I-Ig of primary antibody for conventional direct labelling. 
• No preparation required - it does not require removal of exogenous 
proteins such as serum albumin from the antibody prior to complex 
formation. 
• Quantitative labelling - Nearly all of the primary antibody sample is labelled. 
The DIP ratio can be finely tuned. 
• Compatibility - lenon technology permits use of multiple antibodies in the 
same immunolabelling protocol. 
• Versatility - Essentially any dye, enzyme label or hapten can be prepared 
and used in the form of a lenon labelling reagent. 
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Figure 7.2. Illustration of zenon technology[157]. 
This technique has not been used in the present work as the currently 
available reagents are designed to be used with IgG, while anti LAM is an IgM 
antibody. However, in principle the same approach could be used if suitable 
reagents were available. 
7.2.3 Optimising immunochromatography performances 
The sensitivity and precIsion of bioanalytical systems and biosensors are 
currently limited by surface-protein non-specific binding (NSB), as this project 
has shown. Inhibition of NSB was thus a critical performance especially in the 
immunochromatography method development. Many factors could be 
optimised for this purpose. In Chapter 6, some of the factors have been 
considered, such as the conjugate buffer, analyte buffer, etc. With more 
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supplies of good quality antibody, these buffer systems could be optimised 
more thoroughly. 
Optimising performance by modifying the membrane component has been 
discussed in Section 1.8.3. However, the nitrocellulose membrane of the strip 
was a commercial product. This should be an area for future work. 
New technology in surface coating showed that it is possible to inhibit or 
reduce the NSB. OptiChem ™ surface coatings from Accelr8 Technology 
Corporation are formulated to inhibit NSB of protein. They are claimed to be 
superior to BSA blocking, for silicon (Si02/Si) wafers and tissue culture 
polystyrene (TCPS) surfaces [158], although nitrocellulose membranes have 
not apparently been directly compared with them. 
7.2.4 Reference beam for the portable fluorimeter 
The in-house built portable fluorimeter worked well as shown in Section 7.1. 
However, its stability could be improved further by putting in a beam splitter to 
make a reference beam. Nearly all commercial fluorescence instruments 
employ double-beam optics as shown in Figure 7.3 in order to compensate for 
fluctuations in the power of the source [159]. The figure only shows the 
reference beam for the laser 635 nm using a reference photodiode. The same 
photodiode could also serve laser 650 nm with proper arrangement. 
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Figure 7.3. Schematic diagram of the portable laser fluorimeter with reference beam. 
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APPENDIX A 
Appearance of the LS-50B fluorescence spectrophotometer (Perkin-
Elmer) located in our laboratory 
Figure A - Appearance of LS-50B 
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APPENDIX B 
Block diagram of the layout of the Perkin-Elmer LS-50B fluorescence 
spectrophotometer 
Figure B - Optical layout of the LS-50B fluorescence spectrophotometer 
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APPENDIX C 
Appearance of the model F-4500 fluorescence spectrophotometer (Hitachi) 
located in our laboratory 
Figure C - Appearance of the F-4500 in our laboratory 
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APPENDIX D 
Block diagram of the layout of the model F-4500 fluorescence 
spectrophotometer (Hitachi) 
Figure D - Internal block diagram of the F-4500 
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Figure E - Photograph of the in - house made portable fluorimeter 
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APPENDIX F 
Figure F - An illustration diagram [160) and 3D drawings of 
photomultiplier tube [161). 
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APPENDIX G 
Figure G - Photograph of 635 nm variable focus laser diode modules 
from Coherent [162]. 
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APPENDIX H 
Figure H - The picture of the ADC-16 data logger from Pico technology 
[163] 
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APPENDIX I. Supplier names and addresses 
SUPPIiIER. ADDRESS 
. > 
Amersham Pharmacia Biotech UK, Ltd. Amersham Place 
Little Chalfont 
Buckinghamshire 
HP7 9NA, UK 
Anachem, Ltd. 20 Charles Street 
Luton 
Bedfordshire 
LU2 OEBG, UK 
Cambio, Ltd. 34 Newnham Road 
Cambridge 
CB3 9EY, UK 
Coherent Greycaine Road 
Watford, 
Herts WD2 4PW, UK 
Duke Scientific Corporation 2463 Faber Place 
P.O. Box 50005 
Palo Alto, California 94303 USA 
Edmund Scientific Ltd 1 Tudor House 
Lysander Close 
Clifton Moor 
York Y030 4XB, UK 
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Elkay Laboratory Products (UK), Ltd. Unit 4, Marlborough Mews 
Crockford Lane 
Basingstoke, Hampshire 
RG24 8NA, UK 
Eppendorf Scientific, Inc. 1 Cantiague Road 
Westbury 
New York, USA 
Fisher Scientific UK Bishop Meadow Road 
Loughborough 
Leicestershire 
LE11 5RG, UK 
Gilson Company, Inc P.O. Box 200 
Lewis Center, 
Ohio 43035-0200 
USA 
Hamamatsu Photonics UK Limited 2 Howard Court, 10 Tewin Road 
Welwyn Garden City 
Hertfordshire, AL7 1 BW, 
UK 
Hellma (England), Ltd. Cumberland House 
24 - 28 Baxter Avenue 
Southend-on-Sea 
Essex 
SS2 6HZ, UK 
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Hitachi Scientific Instruments 
Molecular Probes, Inc. 
Newmarket Laboratories Limited 
Omnifit, Ltd. 
Perkin-Elmer, Ltd. 
Pico Technology Limited 
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7 Ivanhoe Road 
Hogwood Industrial Estate 
Finchampstead 
Berkshire 
RG404QQ, UK 
Cambridge Bioscience 
24 - 25 Signet Court 
Newmarket Road 
Cambridge 
CB5 BLA, UK 
Unit 1 B, Lanwades Businesspark 
Kentford 
Newmarket, Suffolk, CBB 7PN, 
UK 
2 College Park 
Cold hams Lane 
Cambridge 
CB1 3HD, UK 
Post Office Lane 
Beaconsfield 
Buckinghamshire 
HP9 1QA, UK 
The Mill House 
Cambridge Street 
St. Neots 
PE19 1QB, UK 
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Pierce (Perbio Science UK, Ltd.) Century House 
Tettenhall 
Cheshire 
CH39RG,UK 
Precisa Balances Ltd. 4 Vermont Place 
Tongwell 
Milton Keynes, Buckinghamshire 
MK15 8JA, UK 
RS Components Ltd Birchington Road, 
Corby, Northants, NN17 9RS, UK 
Sigma-Aldrich Company, Ltd. Fancy Road 
Poole 
Dorset 
BH12 4QH, UK 
USF Elga Ltd. High Street 
lane End 
High Wycombe 
Bucks. 
HP14 35H, UK 
Whatman International Ltd. St leonard's Road 
20 I 20 Maidstone 
Kent 
ME16 OlS, UK 
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